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Abstract 
 
Chronic low-grade inflammation in visceral adipose tissue (VAT) is a key feature 
of obesity and crucial in the development of insulin resistance (IR) and type 2 
diabetes mellitus (T2DM). VAT harbours resident immune cells including 
conventional dendritic cells (cDC), that work in cooperation to regulate metabolic 
homeostasis. Modulation of the immune system has the potential to ameliorate 
disease progression. VAT-cDCs are characterised by the activation of the Wnt/β-
catenin pathway, which is known to modulate cDC function and promote T cell 
immune tolerance. Impaired Wnt/β-catenin pathway activity in VAT-cDCs is 
observed during obesity. The aim of this thesis was to investigate the effect of 
sustained activation of Wnt/β-catenin signalling in cDCs in obese VAT, with the 
hypothesis that this could revert the development of VAT inflammation and IR. 
The immune and metabolic phenotype was characterised in mice with 
constitutively active β-catenin in cDCs, referred to as gain-of-function (GOF), in 
a model of diet-induced VAT inflammation. 
 
Increased tolerogenic responses of VAT-cDCs in the GOF mice was able to 
revert the development of VAT inflammation in part, altering T cell recruitment 
and inducing a more T cell immunosuppressive phenotype, but not sufficient to 
improve insulin sensitivity. Improvement of whole-body glucose homeostasis in 
the GOF mice was explained by increased insulin production from the islets. 
Reduced islet inflammation and expansion of islets, provided a greater insulin 
reserve in the GOF mice, improving β-cell insulin compensation in response to 
obesity-induced IR.  
 
Enhanced levels of adiponectin and reduced secretion of CCL17 in the GOF 
mice, prompted the investigation of atherogenic development in Ldlr-/- GOF 
chimera mice. Constitutive activation of β-catenin in cDCs was not sufficient to 
decrease aortic lesion density. 
 
Collectively these results indicate the significance of systemically modulating 
Wnt/β-catenin pathway in cDCs, with the potential to control the development of 
VAT inflammation and metabolic dysfunction in obesity. 
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Obesity is the accumulation of excess body fat which confers negative effects on 
human health. It is currently a global epidemic, with the number of adults 
classified with a body mass index (BMI) ≥ 30 kg/m2 increasing in prevalence every 
year (1). The obesity crisis is now the most serious public health problem 
worldwide causing a huge economic impact on healthcare providers (2). 
Increased BMI is associated with significantly higher risks of developing 
cardiovascular diseases, diabetes, cancers, osteoarthritis, depression and non-
alcoholic fatty liver disease, as well as an increased mortality rate. The World 
Health Organisation has established obesity as the leading preventable cause of 
death worldwide (3).  
 
1.1.1 Aetiology 
The aetiology of obesity is multifactorial, involving complex interactions between 
the environment and genetics. The principle cause of excessive fat deposition is 
an energy imbalance which has arisen from environmental and socioeconomic 
changes in diet and physical activity. A sedentary lifestyle and the over-
consumption of high-energy dense foods promotes a disequilibrium between 
energy intake and expenditure. The increased storage of excess energy 
predominately occurs in white adipose tissue, whereby fat mass expands over 
time. Specifically, the development of visceral adiposity results in obesity. In 
contrast to brown adipose tissue which is specialised in heat production 
(thermogenesis), the function of white adipose tissue is much broader and is the 
focus of this thesis, hence forth referred to as AT.  
 
Although societal and behavioural changes are fundamental in the development 
of obesity, biological factors are also known to regulate energy balance. A genetic 
component has been linked to obesity, with a high rate of heritability identified 
(4). Rare monogenic forms of obesity have been recognised, including mutations 
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involved in appetite regulation such as melanocortin receptor MC4R and Lep 
leptin genes (5). Genomewide association studies (GWAS) have identified over 
300 loci associated with common polygenic obesity. The most prominent 
discovery has been the cluster of variants at the FTO locus, which has 
demonstrated increased body weight with risk alleles (6). Epigenetic processes 
such as DNA methylation and histone modifications are emerging as risk factors 
for obesity (7). Interestingly, prenatal and postnatal exposures are suggested to 
influence metabolic health outcomes including the development of obesity. 
Physiological mechanisms that regulate energy balance through the brain-gut 
axis, cause excess fat deposition. Gastrointestinal hormones communicate with 
the central nervous system to control food intake and energy homeostasis. The 
role of microbiota has recently been implicated in the development of obesity (8). 
A number of acquired neuroendocrine conditions are also known to cause weight 
gain, including Cushing syndrome, hypothyroidism and polycystic ovary 
syndrome. In addition medication can have obesogenic effects, specifically 
psychoactive drugs which have a propensity to induce weight gain. These 
biological factors that contribute to the aetiology of obesity are exacerbated by 
environmental and behavioural influences which interplay to instigate excessive 
adiposity. 
    
1.1.2 Pathophysiology 
Chronic nutrition overload results in excessive adiposity and the dysregulation of 
lipid and glucose metabolism. The metabolic dysfunction in obesity is a central 
factor in metabolic syndrome and is involved in the pathophysiology of many 
obesity-associated diseases (9). In obesity the levels of lipids including 
triglycerides (TG) and cholesterol are elevated in the blood (dyslipidaemia), while 
free fatty acids (FFA) are released from adipocytes causing ectopic lipid 
deposition and lipotoxicity in other cell types. Blood glucose levels increase 
during obesity in the development of insulin resistance. Additionally, increased 
adiposity dysregulates adipokine release from AT which has significant 
implications in tissue dysfunction. Insulin resistance and adipocyte dysfunction 
are  further discussed in section 1.2.2 and 1.3.3 respectively.  
 
An important connection between obesity and chronic low-grade inflammation 
has been recognised over the last two decades. Inflammation develops as a 
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consequence of a complex network of cell and humoral responses, that defend 
the body from stimuli such as infection and tissue damage, in order to resolve 
homeostasis. Low-grade chronic inflammation in obesity exerts profound effects 
on whole-body lipid and glucose metabolism. A first key finding for the causal 
relationship was the increased expression of the pro-inflammatory cytokine 
tumour necrosis factor α (TNFα) in the AT of obese animals (10). Loss of TNFα 
improved glucose homeostasis resulting in increased insulin sensitivity, 
confirming the role of obesity-induced AT inflammation (11) (12). Other pro-
inflammatory cytokines, chemokines and cells have since been implicated in the 
pathogenesis of obesity. In view of this, obese AT and in particular visceral 
adipose tissue (VAT), have shown to mimic an active local inflammation site with 
detrimental effects on AT homeostasis. This is further discussed in section 1.4. 
 
1.1.3 Metabolic syndrome 
Metabolic abnormalities caused by visceral obesity and inflammation, have direct 
pathological consequences. It has been observed that endothelial dysfunction, 
oxidative stress, elevated blood pressure and pro-thrombotic state are, in part, 
the consequence of altered FFA metabolism and differential release of 
adipokines in obesity (13). The interaction between risk factors of metabolic 
susceptibility such as age and stress, and underlying metabolic changes 
including excess adiposity, insulin resistance and dyslipidaemia, perpetuates 
chronic vascular inflammation and ultimately results in atherogenic processes 
(14) (15). Metabolic dysfunction underlies the pathology of atherosclerosis and 
hypertension. This cluster of interconnected metabolic features is now diagnosed 
as metabolic syndrome, which develops over time into a multiple risk factor 
syndrome conferring a two-fold increase in the risk of developing atherosclerotic 
cardiovascular disease (ASCVD) and a five-fold increase in the risk of developing 
type 2 diabetes mellitus (T2DM) (Figure 1.1) (16). The core risk factors of the 
metabolic syndrome are atherogenic dyslipidaemia, elevated blood pressure, 
elevated plasma glucose, a pro-thrombotic state and a pro-inflammatory state 
which are exacerbated by the development of visceral obesity.  
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Figure 1.1 Development of Metabolic syndrome 
Atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular complications 
are the consequence of persistent atherogenesis. This is the result of metabolic risk 
factors which build up over time, exacerbated by visceral obesity. Metabolic syndrome 
results in type 2 diabetes mellitus (T2DM) and further increases the risk of ASCVD. 
Adapted from Grundy, 2006 (17). 
 
 
1.2 Type 2 diabetes mellitus 
 
The prevalence of type 2 diabetes mellitus (T2DM) is significantly increasing each 
year, becoming an expanding global health problem closely linked with the 
obesity epidemic (18). The diagnosis of T2DM is based on impaired glucose 
tolerance or elevated glycated haemoglobin A1c levels (19). As the most 
common form of diabetes, T2DM individuals have a high risk of developing 
vascular complications, such as retinopathy, nephropathy, neuropathy and 
cardiovascular disease. The chronic increase of blood glucose levels reduces 
vessel function and increases risk of cardiovascular morbidity and mortality (20) 
(21). As a multifactorial disorder involving the dysregulation of glucose, lipid and 
protein metabolism, T2DM is a complex chronic heterogeneous disease. Insulin 
resistance (IR) of peripheral tissues and impaired insulin secretion are critical in 
the development of T2DM. This pathophysiology results predominately from 
environmental factors such as obesity, however polygenic defects have 
additionally been identified by GWAS analysis in the T2DM population (22).    
  25 
1.2.1 Glucose homeostasis 
Glucose is critical for cellular function as it is required as fuel for glycolysis. The 
concentration of glucose circulating in the blood is carefully regulated in the body 
by negative feedback. There are many mechanisms which monitor blood glucose 
levels, however the response from the pancreas is the most well understood. The 
hormone insulin is produced from β-cells in the islets of the pancreas and 
released in response to high blood glucose levels (hyperglycaemia), whereas 
another hormone, glucagon, is secreted by α-cells in the islets of the pancreas 
when blood glucose levels are too low (hypoglycaemia). Insulin decreases blood 
glucose concentration by converting glucose into glycogen for storage 
(glycogenesis) (23), while glucagon exerts the opposite reaction releasing 
glucose from glycogen store (glycogenolysis), to increase blood glucose levels. 
Glycogenesis and glycogenolysis predominately occur in the muscle and liver. 
Another major metabolic effect of insulin is to increase the cellular glucose uptake 
primarily in muscle and AT, by upregulating glucose transporters (GLUT) which 
facilitate the diffusion of glucose into the cell. As soon as the glucose enters the 
cell, it is immediately phosphorylated into glucose-6-phosphate to preserve the 
concentration gradient, increasing glucose uptake and hence decreasing blood 
glucose levels. Insulin also inhibits the generation of glucose from non-
carbohydrate substrates such as lactate, glycerol and glucogenic amino acids in 
the cell (gluconeogenesis) (23). Although insulin and glucagon have been well 
characterised, many other hormones have been discovered which play roles in 
the regulation of glucose homeostasis, including amylin, somatostatin, 
epinephrine and glucagon-like peptide (GLP)-1 (24). Glucose homeostasis is 
critical for the body’s physiological function. However the metabolic control of 
glucose can become dysregulated. Diminished insulin production and sensitivity 
leads to subsequent hyperglycaemia, which have major systemic implications 
and promote the development of diabetes mellitus. Type 1 diabetes mellitus 
(T1DM) is a well characterised autoimmune disease, whereby β-cells are 
targeted for destruction by self-reactive immune cells, preventing the pancreas 
from producing insulin. T1DM is currently treated by administering exogenous 
insulin. While T2DM develops from IR and the insufficient production of insulin. 
The extent of IR and β-cell dysfunction varies amongst the T2DM population 
indicating a heterogeneous disorder. 
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1.2.2 Insulin resistance 
Insulin resistance (IR) is defined as the failure of cells to respond to insulin, which 
therefore prevents the lowering of blood glucose levels. Hyperglycaemia can 
result in vessel and organ damage. The absence of insulin sensitivity can be 
observed in most tissues in the body, predominantly in the muscle and liver, and 
precedes T2DM by many years (25). IR is caused by several factors that impair 
insulin signalling including excess lipids and other metabolic fuels, enhanced 
inflammatory signalling and activation of endoplasmic reticulum (ER) stress 
pathways. The phosphorylation of serine residues of insulin receptor substrate 
(IRS) inhibits insulin signalling through the phosphatidylinositol 3-kinase 
(PI3K)/Akt pathway (Figure 1.2) (26). Ectopic lipid accumulation during obesity 
results in increased FFA which can activate serine kinases such as c-Jun N-
terminal kinase (JNK) and IκB kinase (IKK) or through the generation of 
diacylglycerol (DAG) that activates protein kinase C (PKC) to induce serine 
phosphorylation of IRS (27). Obesity induces mitochondrial dysfunction 
increasing reactive oxygen species (ROS) and ER stress, which further activates 
PKC (19). Inflammation is a well established contributor to IR. The increased 
production of pro-inflammatory cytokines such as IL-6 and TNFα can activate 
JNK and IKK pathways and stimulate the production of suppressor of cytokine 
signalling (SOCS), which inhibits IRS action through ubiquination targeted 
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Figure 1.2 Disrupted insulin signalling causes insulin resistance 
Activation of the insulin receptor leads to tyrosine phosphorylation of insulin receptor 
substrate (IRS), initiating signal transduction through the PI3K/Akt pathway. Akt 
modulates glucose uptake by upregulating glucose transporters to the cell surface, 
increases glycogenesis and supresses gluconeogenesis. Akt inhibits the breakdown and 
promotes the synthesis of lipids and proteins. IRS can be alternatively phosphorylated 
on serine 307 reside, which diminishes its downstream signalling ability inhibiting the 
PI3K/ Akt pathway. Serine kinases such as c-Jun N-terminal kinase (JNK), IκB kinase 
(IKK) and protein kinase C (PKC) are activated by external stimuli such as cytokines and 
free fatty acids (FFA), which result in the serine phosphorylation of IRS. Inflammation 
induced suppressor of cytokine signalling (SOCS) promotes IRS degradation. 
 
1.2.3 β-cell dysfunction  
T2DM does not develop solely through IR; impairment of insulin secretion due to 
β-cell dysfunction must also occur. Pancreatic islets consist of endocrine cells 
that secrete specific hormones to regulate glucose metabolism, including insulin-
secreting β-cells (29). β-cells fill a predominant proportion of the islets and can 
situate in subclusters or hubs to form functional connectivity through gap 
junctions (30). The β-cell response to blood glucose levels by insulin synthesis 
and release, is critical to manage changes in nutrient load. Indeed, in obesity, 
there is a dramatic increase in compensatory β-cell mass. An acute expansion of 
β-cell mass occurs in response to the onset of diet-induced obesity to fulfil the 
systemic insulin requirement (31). However in T2DM, β-cells cannot secrete 
sufficient amounts of insulin to compensate for the increased IR of the peripheral 
tissues (32). This is represented by a reduction in β-cell mass and loss of β-cell 
function resulting in β-cell failure (Figure 1.3) (19). Although interventions have 
been developed to improve β-cell function, advances are being made to find 
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strategies to drive human β-cell proliferation and regeneration for the treatment 
of T2DM (33).  
 
Figure 1.3 Relationship between β-cell mass and function 
β-cell mass increases in obesity, while β-cell function remains unchanged. In T2DM, β-
cell mass and function significantly decreases leading to β-cell failure. Interventions 
such as weight loss or anti-diabetic drugs aim to improve β-cell function, although it is 
unclear how β-cell mass changes. Restoring β-cell mass in T2DM by interventions may 
revert to a compensatory phenotype observed in obesity. 
 
Multiple factors contribute to β-cell failure in T2DM, including ageing, genetic 
variants, resistance to GLP-1 and activation of ROS (32). Metabolic insults, such 
as glucotoxicity, lipotoxicity and ER stress, which are associated with the 
pathology of IR, are widely thought to be the main cause of damage to β-cells 
(34). However, it has recently emerged that activation of inflammatory pathways 
are also contributory factors in β-cell dysfunction (35). Characterisation of islet 
inflammation in T2DM has begun to reveal that immune cells affect β-cell insulin 
secretion. Increased numbers of leukocyte and pro-inflammatory mediators have 
been identified in islets of T2DM individuals (36). The roles of macrophage 
infiltration and interleukin (IL)-1β have been well described in promoting islet 
inflammation with deleterious effects on β-cell insulin secretion (37) (38). While 
the expression of cytokines and chemokines in transcriptomic analysis of islets 
has shown heterogeneity in T2DM individuals, it is widely accepted that they a 
play a role in exacerbating islet inflammation (39). Interestingly, β-cell hub 
structures which are necessary for insulin secretion, are adapted in response to 
inflammation and metabolic changes. Pro-inflammatory cytokines or exposure to 
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glucotoxicity or lipotoxicity results in β-cell dysfunction and impaired insulin 
production (40). Thus, it may be possible to envisage that immune cells play a 
role in maintaining proper connections in the islet hubs to prevent the disruption 
of β-cell function. 
 
1.2.4 Other pathophysiological mechanisms 
The dysfunction of glucose homeostasis in T2DM is mainly attributable to IR and 
impaired insulin secretion, leading to hyperglycaemia and dyslipidaemia. Other 
pathophysiological mechanisms in T2DM that contribute to hyperglycaemia have 
been identified (19). Increased glucagon levels in T2DM elevates glucose 
production by the liver (41). IR of adipocytes causes higher rates of the 
breakdown of lipids (lipolysis) and increased release of plasma FFA, which 
exacerbates IR (42). Additionally, increased intestinal and renal glucose 
absorption in T2DM promotes hyperglycaemia (43) (44). Furthermore, the 
dysregulation of neurotransmitters and resistance to appetite-suppressive factors 




Lifestyle modifications including changes to diet and physical activity can revert 
T2DM. Reducing excess adiposity has a significant impact on reducing IR and 
improving glucose tolerance (47) (48). However, interventions with 
pharmacological agents may be required to maintain normoglycaemia and 
reduce cardiovascular disease risk. Therapies summarised in Table 1.1, are often 
used in combination to treat multiple pathophysiological defects in T2DM. 
Although effective, many of these drugs have unwanted side effects and because 
of the heterogeneous nature of the T2DM population, can provide varying clinical 
response (49). Long-term normalisation of blood glucose levels in T2DM, 
depends on delaying or reversing β-cell failure to ensure appropriate insulin 
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Drug Mechanism of action 
Metformin Supresses hepatic glucose production 
Sulfonylureas Increases insulin secretion 
Meglitinides 
Short-acting insulin secretagogues (aiding insulin 
secretion) 
Thiazolidinediones Insulin-sensitising agents, increase β-cell function 
DPP4 inhibitors 
Prolongs half-life of GLP-1 in plasma, increasing 
insulin 
GLP-1 receptor agonist 
Increases in plasma GLP-1 levels, increasing 
insulin 
α-glucosidase inhibitors 
Reduces intestinal glucose absorption, increases 
GLP-1 
Sodium/ glucose co-
transporter 2 inhibitors 
Blocks renal glucose absorption 
 
Table 1.1 Therapeutics to treat T2DM 
Summary of anti-diabetic drugs and their mechanism of action. DPP4; Dipeptidyl 
peptidase-4, GLP-1; glucagon-like peptide 1.  
 
The deleterious effect of inflammation on β-cell function highlights the potential 
of immune modulation in the treatment of T2DM. Clinical studies have shown that 
modulation of the immune system, for example by IL-1 antagonism, can have 
beneficial effects on blood glucose levels, β-cell secretory function and insulin 
sensitivity (50) (51). In addition, supressing the pro-inflammatory transcription 
factor nuclear factor κB (NFκB), through administration of salicylates, improved 
glucose metabolism in patients with T2DM (52). A further strategy that has 
improved insulin secretion is the targeting of chemokines involved in macrophage 
infiltration, specifically CCR2 antagonism inhibiting monocyte chemoattractant 
protein (MCP)-1 (53). However, the possible benefits of modulating adaptive 
immune responses are less clear. These findings suggest that modulation of the 
immune system has the potential to ameliorate T2DM progression.  
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1.3 Adipose tissue 
 
White adipose tissue (AT) is one of the body’s connective tissues, comprised 
mainly of adipocytes but also contains pre-adipocytes, mesenchymal stem cells 
and immune cells. In contrast to brown adipose tissue, which is present at birth 
and decreases in ageing adult humans, AT is widely distributed over the body in 
specific adipose depots; subcutaneous AT (SAT) is located beneath the skin, 
visceral AT (VAT) surrounds the internal organs and AT is further found in the 
bone marrow and within muscles (54) (55). Physiologically AT acts as an 
insulating layer with a protective function, but most importantly, is a reserve of 
energy, providing metabolic support to the body. Excess energy is stored as TG 
in adipocytes and can be mobilised through lipolysis to be released as FFA into 
the circulation when required. AT is critical for maintaining lipid balance in 
response to changes in nutrition intake. However, despite being considered in 
the past as a passive inert energy store, AT has recently been recognised as a 
highly active metabolic and endocrine organ (56). 
 
1.3.1 Adipokines 
Mature adipocytes secrete cytokines, hormones and growth factors which are 
collectively known as adipokines. Adipokines act in an autocrine, paracrine, or 
endocrine manner to regulate food intake, AT homeostasis, immunity, 
vasculogenesis and energy metabolism (57). Differences in adipokine production 
have been reported from varying AT depots, with VAT generating a more active 
adipokine profile. The main adipokines secreted from VAT and their functions are 
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Table 1.2 Function of key adipokines 
Summary of main adipokines secreted from VAT, their effect on metabolism and 
cardiovascular disease and response to obesity. AMPK; 5' adenosine monophosphate-
activated protein kinase, VEGF; vascular endothelial growth factor, MCP1; monocyte 
chemoattractant protein, NAD; nicotinamide adenine dinucleotide. 
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1.3.2 Adipose tissue homeostasis 
During changes in nutrient intake, AT responds rapidly and dynamically through 
a tightly regulated process of adipocyte expansion (hypertrophy) and 
adipogenesis where pre-adipocytes differentiate into mature adipocytes 
(hyperplasia). This enables AT to increase storage requirements and conversely 
provide energy through lipolysis when necessary. Adipocytes uptake excess 
lipids, whereby esterification and synthesis of TG (lipogenesis) occurs for storage 
in the lipid droplet (LD). This results in AT expansion and prevents ectopic lipid 
deposition and lipotoxicity in other cell types. Lipid balance is central to AT 
response to metabolic demand, linking the cell biology of the adipocyte and AT 
physiology to whole-body metabolism. 
 
A number of adipogenic factors regulate healthy AT expansion, which are critical 
for maintaining tissue homeostasis (Figure 1.4). The nuclear receptor peroxisome 
proliferator-activated receptor-γ (PPARγ) is a master transcriptional regulator of 
adipogenic gene program. Activation of PPARγ promotes adipocyte lipid uptake, 
hypertrophy of mature adipocytes and induces adipogenesis, increasing the 
number of insulin sensitive adipocytes (58). Interestingly, reduced adipose mass 
was observed in PPARγ knockout mice (59) (60). PPARγ also maintains AT 
homeostasis by promoting beneficial adiponectin secretion from adipocytes, 
antagonizing pro-inflammatory transcription factors such as NFκB to halt 
inflammatory responses. Furthermore, PPARγ agonists are potent insulin 
sensitisers, preventing the development of IR (61). Another transcription factor 
family CCAAT/enhancer-binding proteins (C/EBP) also play a role in inducing 
adipocyte differentiation, confirmed by the absence of AT in C/EBPα−/− mice (62). 
C/EBPα and PPARγ cooperate to induce adipocyte differentiation through direct 
activation of multiple genes of terminally differentiated adipocytes (63). Their 
expression is sustained by a positive feedback loop which serves to maintain the 
phenotype of the mature adipocyte (63). Signalling proteins have also been 
implicated in regulating adipogenesis by activating C/EBPα and PPARγ. Wnt 
proteins which activate β-catenin signalling, are known to inhibit the differentiation 
of pre-adipocytes, specifically Wnt10b, to limit hyperplasia (64). Activation of the 
β-catenin pathway in transgenic mice over-expressing Wnt10b in adipocytes, 
prevents high-fat-diet-induced adipose tissue accumulation (65). ER signalling is 
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required for healthy AT function (66), including the X-box binding protein 1 (Xbp1) 
pathway which promotes adipogenesis and increases insulin sensitivity (67) (68).  
 
1.3.3 Adipose tissue dysfunction 
Chronic overnutrition results in aberrant adipocyte hypertrophy and impaired 
adipogenesis (Figure 1.4). Excess adiposity and subsequent AT dysfunction are 
central in the pathophysiology of obesity. AT dysfunction is characterised by 
oxidative stress, increased FFA release, dysregulation of adipokine release, ER 
and mitochondrial stress, hypoxia, extracellular matrix remodelling and the 
establishment of local pro-inflammatory environment (69). The dysfunction of AT 
contributes to metabolic dysregulation and the development of IR in obesity (42). 
 
 
Figure 1.4 Adipose tissue expansion 
Local factors regulate adipogenesis in positive energy balance, to induce adipocyte 
hyperplasia. Local signalling networks are impaired during chronic overnutrition which 
results in excessive adipocyte hyperplasia and aberrant adipocyte hypertrophy 
contributing to AT dysfunction. 
 
The unhealthy AT expansion in obesity is linked to the rapid induction of dense 
pro-fibrotic extracellular matrix (70). Interactions of adipocytes with the fibrous 
matrix have been identified as potential cues for driving AT dysfunction (66). 
Hypoxic conditions develop during aberrant AT expansion due to a decrease in 
interstitial oxygen tension and an increased need for tissue vascularisation. 
Hypoxia stabilises the transcription factor hypoxia inducible factor (HIF)-1α. 
Accumulation of HIF1α is observed in hypertrophic adipocytes, inducing a change 
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in gene expression and a cellular metabolic switch promoting glycolysis and 
supressing fatty acid oxidation (71). HIF1α plays an essential role in mediating 
adaptive changes of cell metabolism during hypoxia to balance oxygen demand 
and supply. Inhibition of adipocyte specific HIF1α activation attenuates AT 
expansion and inhibits diet-induced tissue inflammation and the development of 
IR (72) (73). Furthermore, hypoxia has been suggested to drive the dysregulation 
of adipokines in obesity (74).  
 
The modulation of adipokines released from adipocytes is well reported during 
obesity, detailed in Table 1.2. A decrease in the level of adiponectin and IL-10 
secreted from healthy adipocytes, perturbs the anti-inflammatory milieu and 
insulin sensitive state in healthy AT (75). However the majority of adipokines 
increase during obesity exacerbating AT dysfunction (76). Hypertrophic 
adipocytes produce increased levels of pro-inflammatory cytokines including IL-
6, IL-1β, TNFα and MCP1, to promote the development of AT inflammation and 
drive the initiation of IR. In addition, the adipocyte-derived hormones leptin and 
resistin become elevated in obesity (57). Leptin participates in the regulation of 
food intake and energy expenditure, involving pathways in the central nervous 
system. However during chronic overnutrition, peripheral leptin sensitivity 
decreases which results in the failure to control satiety. Additionally, leptin has 
pro-inflammatory actions, further increasing the production of IL-6 and TNFα and 
polarising T cell responses (77). Resistin also disrupts AT function by promoting 
aberrant inflammatory responses, such as increasing the expression of vascular 
adhesion molecule expression enhancing leukocyte entry into AT (78). The 
imbalance of pro- and anti-inflammatory adipokines in obesity alters tissue 
immune responses, promoting AT inflammation which contributes to tissue 
dysfunction (79).  
 
 
1.4 Immune cells in adipose tissue 
 
AT harbours a variety of immune cells in both healthy and pathological conditions, 
that work in cooperation with adipocytes to regulate metabolic homeostasis (80). 
Resident immune cells fulfil important house-keeping functions to maintain an 
anti-inflammatory milieu in the tissue. The tolerogenic state of lean AT provides 
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systemic metabolic control of glucose homeostasis and insulin sensitivity. 
However excess adiposity leads to substantial changes in the abundance and 
function of immune cells (81). The release of pro-inflammatory adipokines from 
hypertrophic adipocytes promotes immune cell infiltration, driving a pro-
inflammatory environment in obese AT (Figure 1.5). The role of immune cells in 
AT has gained considerable interest as they have been identified to influence 
systemic inflammation and metabolic pathways (82).  
 
 
Figure 1.5 Obesity-induced inflammation in adipose tissue 
Resident immune cells are critical to maintaining a healthy anti-inflammatory, insulin 
sensitive phenotype, generating cytokines that prevent inflammation. However, in 
obesity-induced inflammation, the immune cell composition is altered and reflects a pro-
inflammatory state which consequently results in an insulin resistant phenotype. 
 
1.4.1 Myeloid immune populations  
Adipose tissue macrophages (ATM) are the most well characterised immune 
population in the tissue. Derived from circulating monocytes, macrophages are 
heterogeneous cells widely distributed in peripheral tissues (83). They play key 
roles in pathogen defence and tissue homeostasis, through their phagocytic 
capacity. In lean conditions, resident ATM are essential for normal AT function 
through the clearance of apoptotic adipocytes and cell debris, the control of lipid 
cytotoxicity by lipid buffering and the production of anti-inflammatory IL-10 (84).  
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Despite their protecting function in lean tissue, ATM are known to be central 
players in AT obesity-induced inflammation. A seminal report revealed that the 
macrophage population significantly increased in AT during obesity (85). The 
accumulation of ATM is driven by processes such as tissue hypoxia, fibrosis, lipid 
spillover, adipokine release and ER stress, all of which increases the survival and 
proliferation of resident ATM, inhibits their emigration from tissue and increases 
monocyte trafficking to AT. The proportion of ATM increases to 50% of total VAT 
cells in obesity, accompanied by a recruitment of F4/80+CD11c+ inflammatory 
macrophages (86). Disruption of this macrophage recruitment or their 
inflammatory activation pathways protects mice from diet-induced IR (87). In 
addition, obesity promotes a switch in macrophage phenotype, inducing 
polarisation towards a more pro-inflammatory state (88). PPARγ has 
demonstrated an important role in this phenotypic shift, modulating lipid 
accumulation which affects macrophage polarisation (89). These inflammatory 
ATM are considered the primary source of TNFα, exacerbating AT inflammation 
(90). 
 
AT dysfunction is defined by adipocyte death from the stress of excessive AT 
remodelling in obesity (91). Dying adipocytes release cytosolic constituents 
including damage-associated molecular patterns (DAMPs) which are sensed by 
pattern recognition receptors (PRRs) such as toll-like receptors (TLRs) on ATM 
inducing the activation and production of TNFα and IL-1β, exacerbating tissue 
inflammatory responses (92). The morphology and location of ATM changes 
during the onset of obesity, often ATM aggregate into crown-like structures 
surrounding large lipid droplets resulting from apoptotic adipocytes (93).  
 
Other myeloid immune cells populate AT, including neutrophils, mast cells and 
eosinophils. Neutrophils are short-lived, highly mobile immune cells which 
comprise of a large number of granules containing diverse, biologically active 
substances. They are considered the primary effectors of acute inflammatory 
response and secrete high levels of cytokines and chemokines, recruiting other 
immune cells. Neutrophils have been observed in lean AT of mice, although in 
low abundance contributing less than 1 percent of total AT immune cells. They 
were the first immune population to be recruited after the induction of high fat diet 
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(HFD) tissue inflammation, suggesting a role during the initial stages (94). 
Another granulocyte population is the eosinophil, which participates in anti-
inflammatory immune responses. Resident eosinophils have been identified in 
AT and are potent IL-4 producers, however their numbers decrease in obesity 
(95). IL-4 is known to have insulin-sensitising effects and modulate macrophage 
polarisation towards anti-inflammatory phenotype. The third granulocyte 
identified in AT are mast cells, which rapidly degranulate in response to 
pathogens. Activated mast cells release inflammatory mediators, including 
prostaglandin PGE2, leukotriene LTB4 and several cytokines. Mast cells are 
elevated in obese AT of mice and humans, with important roles in ATM infiltration 
and development of IR (96). Although myeloid populations are fundamental in 
innate immune responses, they also play roles in the development of adaptive 
immunity effector cells and cytokine production by macrophages, mast cells and 
neutrophils are critical for the activation of lymphocytes.  
 
1.4.2 Lymphoid immune populations 
T cells are bone-marrow derived lymphocytes that mature in the thymus, which 
possess vital roles in adaptive immune responses. T cells exist in a naïve state 
until they encounter antigens recognised by their highly variable T cell receptor 
(TCR), when they become activated and primed to carry out their effector 
functions (Figure 1.6). A diverse repertoire of TCR is determined by VDJ gene 
recombination in the complementary determining region of the antigen 
recognition site. The T cell population is divided into subtypes by their cell surface 
markers and roles in immunity. CD8+ cytotoxic T cells produce cytokines and 
cytotoxic granules and activate caspase cascades through Fas/FasL interactions, 
to kill tumour cells and cells infected by intracellular pathogens such as viruses. 
CD4+ T helper (Th) cells are essential for shaping the immune response. They 
participate in a broad range of functions including assisting B lymphocytes in 
antibody generation, the activation of innate immune functions and the 
recruitment of other immune cells. These roles are orchestrated through the 
production of various cytokines and chemokines from Th cells, which are further 
categorised by their signature cytokine release; Th1 cells produce IFNγ, IL-2 
while Th2 cells release IL-4, IL-5, IL-10, IL-13, IL-25, and the most recently 
identified Th17 cells produce IL-17A, IL-21, IL-22 (97). These subsets have 
distinct functions and are involved in specific responses to pathogens. Aberrant 
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Th cell responses are associated with inflammatory, autoimmune and allergic 
diseases. Differentiation of Th subsets is dependent on the environment of T cell 
priming, by the upregulation of specific transcription factors. Another CD4+ T cell 
subset is regulatory T cells (T regs), which are critical for regulating immune 
responses and play an important role in immune tolerance. Natural T regs 
emerge from the thymus, while inducible T regs arise from differentiation of naïve 
T cells in the periphery. T regs cells exert their suppressive functions through the 
production of anti-inflammatory cytokine IL-10 and transforming growth factor β 
(TGF-β). Interestingly, IL-10 production by all Th cells serves as a negative 
regulatory mechanism for limiting immune responses to prevent tissue damage. 
Natural killer T (NKT) cells, T follicular helper cells (Tfh) and γδ T cells are other 
distinct CD4+ T cell populations. 
 
T cells constitute the second largest immune cell population in AT and become 
increasingly abundant as obesity-induced tissue inflammation develops in mouse 
and man (98) (99). In lean AT, a unique resident T reg population participates in 
the maintenance of tissue homeostasis by suppressing immune responses and 
preserving insulin sensitivity (100) (101). However during AT dysfunction, the 
number of T regs decreases while Th1, Th17 and cytotoxic effector T cell 
populations increase generating pro-inflammatory signals in the AT (102) (81). 
AT-T cells can influence adipokine secretion from adipocytes through 
CD40/CD40L interactions, and the production of IFNγ drives ATM accumulation 
(103) (104). A unique feature of T cell populations in AT is their limited TCR 
repertoire, suggesting that a specific set of antigens drives T cell function during 
obesity (105). Interestingly, it has been identified in homeostatic conditions that 
VAT harbours a large population of memory T cells (106). Upon infection these 
VAT resident memory T cells are sufficient to protect naïve mice from intestinal 
pathogen re-challenge, indicating VAT as an important site for memory 
responses with long-term protective functions.  
 
B cells participate in humoral adaptive immunity, producing antigen-specific 
antibodies. The number of B cells increases in obese AT and B cells are known 
to mediate tissue inflammation (107) (108). TLRs expressed on AT-resident B 
cells recognise DAMPs released from dying adipocytes and trigger antibody 
release during AT dysfunction. Immunoglobulin (Ig)G antibodies induce IR during 
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diet-induced obesity, with suggested roles in the clearance of apoptotic 
adipocytes and ATM polarisation (107) (109).  
 
1.4.3 Fat-associated lymphoid clusters 
AT contains organised structures referred to as fat-associated lymphoid clusters 
(FALCs) which expand during inflammation (110). FALCs are considered 
inducible non-classical lymphoid tissues in direct contact to surrounding 
adipocytes. The highly vascularised structures are comprised mainly of B cells, 
with CD4+ T cell and CD11b+ myeloid cell populations also identified (111). It is 
proposed that FALCs collect peritoneal antigens from AT, contributing to the 
immune surveillance of the tissue. They are present in heterogeneous size and 
number within different AT depots (112). Although there is limited understanding 
of FALCs, it has been suggested that the structures provide immunological 
niches facilitating adaptive B and T cell immune responses in AT (113). FALCs 
have also been shown to mediate the recruitment of myeloid cells and express 
increased levels of Th2 cytokines (110) (111). However much of this work has 
focused on CD11c+ F4/80+ cells in the FALCs, which is likely to be a mixed 




1.5 Dendritic cells 
 
Dendritic cells (DCs) are often referred to as ‘sentinels’ for the body, as they 
sense and respond to their environment and are considered a central component 
of the immune system. DCs were initially characterised as key antigen presenting 
cells by Steinman and Cohn in 1973 and have since revealed important functions 
in innate and adaptive immunity (115). DCs are critical for initiating and 
modulating immune responses but also for inducing immune tolerance, in order 
to orchestrate the immune system. 
 
1.5.1 Function of dendritic cells 
Migrating from the bone marrow, DC precursors are found in peripheral blood 
and enter every non-lymphoid tissue where they reside in an immature state. 
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They are especially abundant in tissues that are exposed to the external stimuli, 
for example in the skin and gut. These cells are specialised to sample the 
extracellular milieu for surveillance. They express a repertoire of PRRs, including 
TLRs on their cell surface to detect and capture antigens including pathogen-
associated molecular patterns (PAMPs). Upon PAMP engagement, PRRs trigger 
signalling cascades in the immature DC that leads to their maturation towards an 
immunogenic DC phenotype. DCs undergo a complex phenotypical and 
functional maturation, which involves the stabilisation of the major 
histocompatibility complex (MHC), the upregulation of cell surface molecules 
CD86, CD80, CD40 and the secretion of cytokines required for T cell activation. 
Simultaneously, the chemotactic receptor CCR7 is upregulated, enabling DC 
migration through the lymphatic system to the draining lymph node. The foreign 
antigen is processed and presented by the immunogenic DCs to naïve T cells in 
the lymph nodes through MHC molecules, which in combination with cytokine 
stimulation and costimulatory signals, induces effector T cell activation and 
proliferation (Figure 1.6). Different environmental signals to which DCs are 
exposed to, influence the type of the immune responses initiated, including Th 
cell polarisation and tolerance induction.  
 
Figure 1.6 Dendritic cell activation of T cell response 
Initiation of effector T cell requires three signals from DC. Firstly the stimulation of T cell 
receptor (TCR) by the major histocompatibility complex (MHC)/peptide complex 
presented by DC, secondly interactions between costimulatory ligands such as CD80/86 
and CD28 and thirdly the secretion of cytokines from DC polarises the T cell response. 
 
Immune tolerance is fundamental for regulating immune homeostasis and 
depends on two distinct processes; central tolerance occurs in the thymus to 
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eliminate T cells that detect self-antigens, while peripheral tolerance avoids over-
reactivity of the immune system, preventing responses to non-pathogenic 
organisms or environmental antigens in the tissue and lymph nodes. Tolerogenic 
DCs are central players in establishing immune tolerance, contributing to both 
central and peripheral tolerance (116). The tolerogenic DC population is formed 
of naturally occurring and induced cells, which are viewed together as a subtype 
of immature-polarised DCs. They are maintained in a tolerogenic state by anti-
inflammatory cytokines present in the environment, and only weakly express 
costimulatory molecules. However, this anti-inflammatory phenotype can be 
reverted in the presence of pro-inflammatory stimuli. In peripheral and lymphoid 
tissues, tolerogenic DCs establish T cell tolerance by the induction of anergy, 
deletion of antigen-specific T cells and stimulation of T reg differentiation and 
expansion, which collectively suppresses immune responses and is fundamental 
to the maintenance of tissue immune homeostasis (117). Subsequently, 
immunogenic and tolerogenic DCs have contrasting effects on T cell responses 
(Figure 1.7).  
 
Figure 1.7 Type of dendritic cell affects T cell response 
DC sense and respond to their environment. Pro-inflammatory stimuli e.g. PAMPs and 
DAMPs are recognised by pattern recognition receptors e.g. TLRs on DC cell surface, 
which leads to the maturation of immunogenic DCs. In the lymph nodes, immunogenic 
DCs present antigens to naïve T cells and secrete high levels of inflammatory cytokines 
such as IL-12 and IL-6 which induces effector T cell differentiation and proliferation to 
shape the adaptive immune response. Under a tolerogenic environment DCs acquire 
regulatory functions providing signals that enable T reg differentiation and expansion. 
Tolerogenic DCs are viewed as a subtype of immature-polarised DCs. 
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1.5.2 Dendritic cell ontogeny and subsets 
DCs are a diverse heterogeneous population, characterised by cell surface 
markers and localisation. DC subsets follow different migratory pathways and 
provide varied immunological functions (118). Classically DCs are subdivided into 
two main lineages; myeloid/conventional DCs (cDCs) and plasmacytoid DCs 
(pDCs). Much research has determined that these cells originate from precursor 
DC (pre-DCs) progenitors in the bone marrow, in the presence of tyrosine kinase 
receptor fms-like tyrosine kinase 3 ligand (Flt3L). Tracing back to common 
myeloid progenitors in the bone marrow, a committed DC progenitor has been 
identified which gives rise to pre-DC population (119). Before leaving the bone 
marrow and entering the peripheral blood and lymphoid organs, the development 
of pDC lineage is committed by the upregulation of transcription factor E2-2 
although the mechanism has yet to be fully understood (120) (121). While cDCs 
differentiate in the periphery from pre-DCs that have migrated from bone marrow 
into lymphoid and non-lymphoid tissue. cDCs differentiate into two main subsets, 
cDC1 and cDC2, categorised by their cell surface molecule expression. This 
differentiation process is controlled by expression of transcription factors 
including interferon regulatory factor (IRF)-8 and IRF4, which distinguish between 
cDC1 and cDC2 respectively (118). A recent study has newly identified several 
other distinct DC subsets using single-cell transcriptome profiling, highlighting DC 
heterogeneity (122). 
 
DCs have distinct functions that differentially regulate adaptive and innate 
immune responses. pDCs have decreased antigen presenting capacity due to 
their lower expression levels of MHCII and CD11c and limited expression of 
PRRs in steady-state. Yet pDCs play a major role in anti-viral immune responses 
characterised by the rapid production of type 1 IFN production (123). cDCs 
populate most lymphoid and non-lymphoid tissues and are identified by high 
expression levels of MHCII and CD11c (124), hence they have enhanced 
capability to sense tissue damage, capture and present antigens or to enforce 
tolerance. The cDC subsets have different transcriptome profiles and lineage 
markers, with IRF8 and IRF4 required for their development and function (118). 
IRF8+ cDC1 in lymphoid tissues express CD8 and in non-lymphoid tissue they 
are characterised by the expression of CD103, while IRF4+ cDC2 express CD11b 
regardless of tissue (125). In addition to serving as potent antigen presenting 
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cells, cDC subsets possess distinct roles in innate immune responses against 
specific type of pathogens (126). cDC1 can efficiently recognise viral and 
intracellular antigens and have an intrinsic capacity to crosspresent antigens to 
CD8+ T cells (127). Their non-redundant production of IL-12 is critical to inducing 
type 1 immune cell responses, including NK cell activation for IFNγ production 
(128) (129). cDC2 preferentially promote CD4+ T cell responses, such as Th17 
cell responses against extracellular bacteria and fungi, through the production of 
IL-23, IL-6 and TGFβ (130) (131). cDCs are involved in type 2 immune cell 
responses against parasites, but the exact mechanism by which they regulate 
Th2 immunity is unclear (126). During inflammation, a distinct population of 
monocyte derived DCs (moDC) have also been identified in tissues which 
originate from infiltrating monocytes. These cells can also be differentiated from 
monocytes in vitro using granulocyte-macrophage colony-stimulating factor (GM-
CSF) and IL-4.  
 
1.5.3 Dendritic cells in adipose tissue 
The distinct contribution of VAT-cDCs in tissue inflammation and tissue immune 
homeostasis has to date, been poorly understood. Studies have investigated DC 
populations in VAT, as outlined in Table 1.3. However the phenotypic overlap 
with other myeloid cells has hampered accurate studies of VAT-cDCs. Although 
high expression of MHCII and CD11c defines the cDC population, CD11c has 
also been used to identify inflammatory ATMs (132), thus this promiscuous 
expression in myeloid cells has rendered the role of VAT-cDCs elusive. For 
clarity, in studies where the distinction between moDC and cDCs is unclear or 
contamination with monocytes or macrophages is likely, cells will be referred to 
as DCs.  
 
1.5.3.1 Adipose tissue dendritic cells in tissue inflammation 
A number of studies have demonstrated that the MHCII+ CD11c+ population 
accumulates in VAT of mouse and man during obesity, although it is unclear if 
these cells were activated macrophages, moDCs or cDCs (133) (134). The 
presence of MHCII+ CD11c+ cells has shown to be critical for the recruitment of 
macrophages into the tissue during diet-induced tissue inflammation. The 
injection of moDC derived from bone marrow, into mice, boosted immune cell 
recruitment into VAT, indicating that DCs play a part in regulating immune cell 
  45 
tissue infiltration (133). A subset of DCs termed ‘inflammatory DC’ with low 
expression of F4/80 have been observed in VAT and display enhanced antigen 
presenting capacity in vitro, inducing T cell activation specifically Th17 responses 
(134). These observations were confirmed by an independent study, which 
further demonstrated DCs infiltrating VAT secreted higher levels of IL-6 and IL-
23 to promote Th17 differentiation (135). Ablating CD11c+ cells, including 
macrophages, monocytes and DCs, attenuates VAT inflammation in obese mice 
(132). Although inconclusive, these findings collectively suggest that DCs adopt 
an activated pro-inflammatory state in obesity and play an important role in the 
initiation of tissue inflammation. However due to the phenotypic overlap in these 
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Table 1.3 Key findings on adipose tissue dendritic cells 
  46 
1.5.3.2  Antigen sampling 
In physiological conditions, VAT-cDCs are proposed to participate in antigen 
sampling, to modulate immune responses. cDCs in VAT surrounding lymph 
nodes, known as perinodal AT (PAT), are found close to collecting lymphatic 
vessels (CLVs). This strategic location is suggested in order to ‘sense’ the tissue 
environment and contribute to the immune surveillance of neighbouring tissue 
(138). CLVs have an inherent permeability where the lymph components are 
released and distributed within the surrounding PAT areas. cDCs closely 
associate with CLVs to uptake soluble antigens released from leaky CLVs and 
migrate to the lymph node for antigen presentation to T cells. Vessel permeability 
can be compromised in obesity, diabetes and infections, facilitating antigen 
leakage into tissue and VAT-cDC uptake. In addition it has been suggested that 
the interaction between cDCs and CLVs, a process that is controlled by the 
chemokine receptor CCR7, contributes to the maintenance of vessel integrity 
(139).  
 
1.5.3.3  Crosstalk with adipocytes 
Pre-adipocytes are predominately adjacent to adipose vasculature where they 
differentiate to mature adipocytes (140) (141). Interestingly, cDCs are also found 
in close proximity to AT vessels suggesting a possible interaction with pre-
adipocytes. It has been proposed that this crosstalk may be important for tissue 
homeostasis. A recent study suggested moDCs may play a role in regulating 
adipocyte expansion and differentiation (136). Interestingly, GM-CSF knockout 
mice (Csf2-/-) exhibited greater adipocyte volume and differentiation under 
physiological conditions compared to control mice, which was accompanied by 
reduced F4/80+ CD11b+ CD11c+ AT-DCs. However GM-CSF is a growth factor 
for many myeloid cells including neutrophils, macrophages and moDCs (142). In 
addition, pre-adipocyte differentiation was inhibited upon incubation with moDC 
conditioned medium, but not bone marrow-derived macrophage supernatant, 
through a mechanism mediated by matrix metalloproteinase (MMP)-12 and 
fibronectin-1 secretion (136).   
 
The interaction between AT-cDCs and adipocytes has the potential to modulate 
both cell functions. For instance, pathways activated in the adipocyte have been 
linked with the regulation of cDC function. Such pathways include Xbp1 pathway, 
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which is upregulated in response to endoplasmic reticulum (ER) stress. It has 
been suggested that during differentiation, adipocytes upregulate the Xbp1 
pathway to counteract the stress associated with protein and lipid biosynthesis. 
During obesity, increased ER stress leads to pathway upregulation (67). 
Overexpression of Xbp1 in adipocytes promotes adiponectin multimerisation 
improving systemic glucose homeostasis in vivo (143). Additionally, Xbp1 
pathway has been found to be upregulated in tumour-infiltrated DCs resulting in 
the loss of immunostimulatory activity and inhibition of anti-tumour T cell 
responses (144). Hypoxia is another pathway associated with adipocyte and cDC 
dysfunction. Hypoxia is observed in hypertrophic adipocytes, with an 
accumulation of adipocyte HIF1α detected during chronic over-nutrition. In DCs, 
HIF1α has been reported to play a crucial role in the activation of inflammation 
(145) (146). Hypoxic conditions in combination with lipopolysaccharide (LPS) 
stimulus, modulate the maturation, activation and antigen-presenting capacity of 
moDCs. Furthermore, CCR7 expression is upregulated on DCs in response to 
HIF1α, facilitating migration to lymph nodes (147). These results indicate that 
simultaneous activation of the HIF1α pathway in adipocytes and AT-cDCs during 
obesity, may exacerbate tissue expansion and inflammation. Collectively these 
findings open up the possibility that AT immune homeostasis could be modulated 
by the upregulation of adipocyte-related pathways in cDCs. 
 
1.5.3.4  Lipolysis of adipocytes 
Triglycerides (TG) in AT are the major energy reserve in the body. During energy 
deprivation, adipocytes undergo a switch towards lipolysis resulting in the 
breakdown of TG into FFA and glycerol. Lipolysis can be initiated not only during 
starvation but also as a result of infections. This is particularly true for PAT. 
Adipocytes in PAT exhibit distinct site-specific properties that enable local 
interactions with the lymph node (148). These local interactions modulate the 
lipolysis of adipocytes, which is exacerbated by immune stimuli such as TNFα, 
IL-4 and IL-6 resulting in higher levels of lipolysis in PAT (149). These findings 
suggest that PAT adipocytes interact directly with lymph nodes, responding to 
and supporting immunological processes (150). Interestingly, DCs were located 
preferentially in PAT compared to other AT depots (151). It has been proposed 
that AT-DCs directly stimulate perinodal adipocyte lipolysis in vitro (152). 
Furthermore, Sadler et al. observed that PAT adipocytes elicit higher rates of 
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lipolysis during low-grade inflammation (152). Therefore, local interactions 
between VAT-cDCs and PAT may play an important role in maintaining lipid 
balance and immune responses in AT. 
 
DCs can uptake the fatty acids released from adipocytes, either for use as fuel or 
to be incorporated into the cell membranes. Alternatively, fatty acids are stored 
as TGs in lipid droplets (LDs) within the cell, which are increasingly recognised 
to play important roles in immune regulation. LDs have been shown to facilitate 
metabolic processes and support immune responses, including antigen 
crosspresentation, activation of IFN and pathogen clearance (153). LDs are 
associated with increased DC immunogenicity, in which high levels of LD 
promote DC activation and enhanced effector T cell stimulation (154). However, 
the effect of LD accumulation in cDCs is determined by the environmental 
context. In tumours where there is an increased cellular demand for energy, the 
accumulation of LDs in DCs induces a dysfunctional phenotype, resulting in 
defective T cell stimulation and presentation of tumour-associated antigens (155). 
In addition, oxidised lipids generated in tumour environment were shown to 
directly abrogate DC crosspresentation of antigens, while in physiological 
conditions only low levels of oxidised lipids accumulate in DCs (156). Thus, the 
lipid content of LDs further determines DC function. The lipid-rich environment of 
AT may increase the lipid uptake of AT-cDCs with higher levels of TG stored in 
LDs, however the functional consequences of this remains unclear in the context 
of AT.  
 
1.5.4 Dendritic cell involvement in insulin resistance  
Inflammatory immune responses are well recognised to impact metabolic 
processes. Studies have indicated that the contribution of DCs in AT inflammation 
affects the development of IR. Depletion of CD11c+ cells in obese mice 
normalises insulin sensitivity restoring glucose homeostasis (132), although 
these results are difficult to interpret as CD11c is also expressed on other myeloid 
cells. Additionally, it has been observed that CD11c+ CD64- cells in AT contribute 
to the development of IR in diet-induced obesity (137). Inhibition of dipeptidyl 
peptidase-4 (DPP4), also known as CD26, on AT moDC has been suggested as 
a mechanism to attenuate IR (157). Furthermore, it has been proposed that 
moDC participate in AT mitochondrial metabolism during obesity dysregulating 
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insulin sensitivity, by a mechanism involving the lysine metabolite 2-aminoadipate 
(2-AA) (158). These findings collectively suggest that AT-DCs have the capacity 
to directly or indirectly affect systemic metabolism, by modulating insulin 
sensitivity during tissue inflammation. 
 
Interestingly, the expression of CD1c, a marker of human cDCs, in SAT has 
shown to be correlated with homeostasis model assessment-estimated insulin 
resistance (HOMA-IR) in obese patients (134). Clinical observations remain 
unclear on the role of DCs in the development of IR. It has been reported that the 
numbers of circulating cDC1 and pDCs are diminished in T2DM patients with 
poor metabolic control (159) (160). However in a separate T2DM population 
study, the number of moDCs were increased in the circulation (161). In the 
pancreas, the role of cDCs in T1DM autoimmune pathophysiology has been well 
established. Subsets of cDCs have been identified and demonstrate distinct roles 
in T1DM islet immunity, such as the cDC1 population which is essential for the 
recruitment of autoreactive T cells (162) (163). However it is yet to be understood 
if and how cDCs can directly affect islet inflammation and β-cell insulin secretion 
in T2DM.  
 
 
1.6 Wnt/β-catenin signalling 
 
Wnt proteins are secreted signalling molecules that are important during 
embryonic development and regulate adult tissue homeostasis and remodelling 
(164). They are fundamental in the control of cell proliferation and differentiation 
by activating numerous signalling pathways, including the canonical Wnt/β-
catenin pathway (165). Although Wnt/β-catenin signalling is required for basic 
developmental processes, it has recently emerged to play a role in immunity, and 
in particular in the control of cDC function (166) (167). Additionally, links between 
the Wnt/β-catenin pathway, adipogenesis and insulin sensitivity are beginning to 
be identified.  
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1.6.1 Canonical pathway 
β-catenin is constitutively expressed in cells, however in the absence of Wnt 
ligands it is rendered inactive. Cytoplasmic β-catenin is recruited to a degradation 
complex containing Axin, adenomatous polyposis coli (APC) and casein kinase I 
(CKI) and glycogen synthase kinase (GSK)-3β. The kinases phosphorylate β-
catenin, targeting it for ubiquination and proteasomal degradation. The Wnt 
ligand family comprises of 19 Wnt proteins in mammals, which typically act in an 
autocrine or paracrine manner. Specific Wnt proteins preferentially activate the 
canonical pathway, including Wnt1, Wnt3a and Wnt10b (168). When Wnt ligands 
bind to the N-terminal of frizzled receptors (FZD) with the assistance of co-
receptor transmembrane low-density lipoprotein receptor-related protein (LRP)-
5/6, this leads to the inactivation of the degradation complex. Dishevelled (Dsh) 
protein is recruited to the cell membrane providing a site for Axin and GSK3β to 
phosphorylate and bind to the cytoplasmic tail of LRP5/6, rendering them 
inactive. This results in accumulation of β-catenin in the cytoplasm. After 
translocation to the nucleus, β-catenin binds to transcription factors lymphoid 




Figure 1.8 Schematic of canonical Wnt/β-catenin signalling pathway 
FZD; frizzled receptor, LRP; low-density lipoprotein receptor-related protein, APC; 
adenomatous polyposis coli, CKI; casein kinase I, GSK3β; glycogen synthase kinase 3β, 
Dsh; dishevelled; LEF; lymphoid enhancing factor, TCF; T cell factor. 
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1.6.2 Wnt/β-catenin regulation of gene transcription 
β-catenin is an evolutionary conserved protein, with a primary role in cell-cell 
adhesion but is also critical for gene transcription. β-catenin is the key effector 
protein in the pathway responsible for signal transduction to the nucleus, where 
it triggers transcription of Wnt-specific genes mediated by TCF/LEF transcription 
factors (169). In the absence of β-catenin, TCF/LEF act as transcriptional 
repressors enabling histone deacetylation however, upon β-catenin binding, co-
repressors are displaced, promoting the activation of gene transcription. There is 
a vast number of diverse Wnt/TCF/β-catenin target genes, which are 
continuously being discovered. These genes are subject to complex, context-
dependent regulation and expressed in a tissue-specific or temporally restricted 
manner (170). The broad range of processes that Wnt/β-catenin signalling 
regulates indicates the plethora of target genes. Notably the expression of anti-
inflammatory cytokines, IL-10 and IL-27, are the result of Wnt/TCF/β-catenin 
target gene transcription. Aberrant pathway activation and repression are 
involved in tumorigenesis. 
 
Relevant to this project, Wnt/β-catenin signalling has been shown to regulate 
adipogenesis and is associated with insulin sensitivity. Activation of the pathway 
by glycogen synthase kinase (GSK)-3β inhibitor or Wnt10b ligands, blocks pre-
adipocyte differentiation (171) (65). Dysregulation of Wnt/β-catenin signalling has 
been associated with T2DM susceptibility in mouse and man (172). This was first 
suggested by the loss of Wnt5b function in humans, which was associated with 
increased T2DM susceptibility in the absence of obesity (173) (174). Variants of 
Tcf7l2, involved in β-catenin gene transcription, confer higher risk of β-cell 
dysfunction and the development of T2DM (175). In mice, activation of the 
pathway in vivo by overexpression of Wnt10b in adipocytes showed a significant 
decrease in total body fat and resistance to developing high-fat diet induced IR 
(176) (177). 
 
1.6.3 Activation of β-catenin in immune tolerance 
Recent studies have shown a further link of the Wnt/β-catenin pathway with the 
regulation of inflammation, particularly in cDCs where activation of the pathway 
has emerged to be important for immune tolerance (167). Exposure to Wnt 
ligands induces a regulatory state of cDCs, producing high levels of IL-10 and 
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limiting the expression of inflammatory cytokines and in addition Wnt-conditioned 
DCs promote T reg responses, despite not affecting cDC maturation or 
expression of costimulatory molecules in response to TLR ligands (178) (179) 
(180) (181). Activation of β-catenin through various other Wnt-independent 
mechanisms has also demonstrated a tolerogenic phenotype of cDCs. Disruption 
of E-cadherin-E-cadherin interactions promotes the activation of β-catenin in 
DCs, stimulating a high level of IL-10 production in vitro and protection against 
the experimental model of autoimmune encephalomyelitis (EAE) (182). 
Furthermore, TLR2-mediated signals induce β-catenin activation in DCs through 
PI3K/Akt pathway, promoting IL-10 production and T reg differentiation to 
supress chronic inflammation and protection from Th17/Th1 mediated 
autoimmune neuroinflammation (179). Other pathways activate β-catenin in DCs 
to promote immune tolerance, including TLR9 (179), Fas signalling (183) and 
TGF-β (184).  
 
Immune tolerance has shown to be abrogated in a number of mouse models with 
depletion of β-catenin in the DC population. Using CD11c specific β-catenin 
knockout mice, intestinal DCs exacerbated inflammatory responses disrupting 
gut tissue homeostasis (185). The depletion of β-catenin in CD11c+ population 
decreased production of IL-10, resulting in reduced T reg population and an 
increased Th17 responses which subsequently rendered mice more susceptible 
to colitis (185). Similarly, loss of Wnt/β-catenin signalling through deletion of 
LRP5/6 or β-catenin in CD11c+ population, resulted in increased Th1/Th17 
differentiation and reduced T reg response by regulating the expression of pro- 
and anti-inflammatory cytokines (178). This effect was sufficient to exacerbate 
the development of EAE, while conversely constitutive activation of β-catenin in 
CD11c+ cells delayed EAE onset (178). However in another autoimmune model 
of collagen-induced arthritis (CIA), CD11c specific β-catenin knockout mice 
exhibited no changes in splenic Th T cell populations but displayed a reduced T 
reg frequency, although this was not sufficient to alter CIA onset and severity 
(186). It is proposed that the contrasting results in disease models may in part be 
explained by tissue-dependent Wnt expression, therefore dependence on Wnt/β-
catenin for tolerogenic signalling may be tissue specific.  
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1.7 Hypothesis and aims 
 
With chronic inflammation playing a key pathogenic role in obesity and the 
associated development of T2DM, investigating potential immunomodulation 
mechanisms may provide alternative therapeutic targets. Recent studies have 
established that activation of the Wnt/β-catenin pathway is important for the 
tolerogenic activity of cDCs (185) (178). Available transcriptome data indicates 
that Wnt/β-catenin pathway is upregulated in cDC1 subset present in VAT. 
Interestingly during obesity, the levels of Wnt10b are known to be supressed 
implying that the activity of the Wnt/β-catenin pathway is impaired in AT (65). In 
this thesis, the role of the Wnt/β-catenin pathway in cDCs in VAT and potential 
therapeutic implications will be investigated. Using cDC-specific mouse models 
for β-catenin deletion or gain-of-function, this work will explore the effect on VAT-
cDC phenotype and VAT homeostasis under steady-state conditions and during 
diet-induced tissue inflammation. We hypothesise that activation of Wnt/β-
catenin pathway in cDCs sustains a tolerogenic phenotype, critical for the 
maintenance of VAT immune homeostasis. The following aims will be addressed: 
 
• To determine the role of β-catenin in VAT-cDCs, with the use of a mouse 
model with depletion of β-catenin in cDCs, referred to as β-catenin 
knockdown 
- Investigate the effect on tissue inflammation  
- Assess the activity of the pathway 
 
• To characterise a mouse model with constitutively active β-catenin in 
cDCs, referred to as gain-of-function (GOF) in physiological conditions and 
in a model of diet-induced tissue inflammation 
- Analyse the immune phenotype of the VAT, spleen and lymph nodes 
- Examine the maturation and functional response of the cDC population 
in VAT 
- Understand the impact on whole-body glucose homeostasis, insulin 
sensitivity and investigate effects on islet and β-cell biology 
- Explore other metabolic measures, including adipokine and cytokine 
levels 
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• To explore targeting the Wnt/β-catenin pathway in cDCs for therapeutic 
potential 
- Investigate the atherogenic development in Ldlr-/- GOF chimera model 
- Test micelle polymer structures for targeted delivery, examine the 
specificity and affinity of the route 
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C57BL/6 and BALB/c were purchased from Charles River laboratories. 
Ctnnb1tmKem (Ctnnb1Fl/Fl), Zbtb46tm1Kmm/J (Zbtb46GFP), B6.Cg-Tg(TcraTcrb) 
425Cbn/J (OT-II) and B6.129S7-Ldlrtm1Her/J (Ldlr -/-) were purchased from 
Jackson laboratories. Zbtb46-Cre mice were kindly provided by M. Nussenzweig 
(Rockefeller University, USA), Ctnnb1lox(ex3) mice were kindly provided by M. M. 
Taketo (Kyoto University, Japan) (187). Ctnnb1Fl/Fl Zbtb46-Cre (β-catenin 
knockdown) mice were generated by crossing Ctnnb1Fl/+ Zbtb46-Cre with 
Ctnnb1Fl/Fl. Littermates Ctnnb1Fl/+ Zbtb46-Cre were used as wild type (WT) 
controls. Ctnnb1lox(ex3)/+ Zbtb46-Cre/+ (gain-of-function, GOF) mice were 
generated by crossing Ctnnb1lox(ex3)/+ with Zbtb46-Cre/+. Littermates 
Ctnnb1lox(ex3)/+ Zbtb46+/+ were used as wild type (WT) controls. Mice were housed 
in temperature- and humidity-controlled rooms at 22°C and 55% humidity, with a 
12 hour light/12 hour dark cycle. Mice were fed normal chow diet or AIN-76A 
Western diet or 58Y1 High fat diet (Test Diet IPS Ltd) and given water ad libitum; 
animals were rehoused in clean cages weekly. Diet composition is detailed in 
Table 2.1. 15 g of Z-NEST (IPS Ltd) was used as nesting material to help regulate 
temperature and light levels. Body weight was recorded weekly. All animal work 
was carried out in accordance with UK government Home Office licensing 





Normal diet (ND) 
Energy: 4.07 kcal/g 
Western diet (WD) 
Energy: 4.49 kcal/g 
High fat diet (HFD) 









Carbohydrate 62.1% 44.4% 20.3% 
Protein 24.7% 15.5% 18.1% 
Additional 
ingredients  
Sucrose - 3.18% Sucrose - 34.1% 
Sucrose - 8.8% 
Lard - 31.7% 
 
Table 2.1 Diet composition 
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2.1.1 Genotyping 
Genomic DNA was extracted from ear clips and the genotype was determined by 
PCR. The ear clips were digested using 200 µl DirectPCR lysis buffer (Viagen 
Biotech) with 0.4 mg/ml proteinase K (Life Technologies) and incubated more 
than 6 hours at 55°C and then for 1 hour at 85°C. Polymerase chain reaction 
(PCR) reaction mixes were prepared containing DEPC H2O, 10 mM dNTP, 10 x 
PCR buffer (Qiagen), HotStart Taq DNA polyermase (Qiagen), forward and 
reverse primers (Table 2.2) and DNA template diluted 1:100. PCR reactions were 
carried out using the thermal cycler (Applied Biosystems) using the following 
steps; initial activation step at 95°C for 15 min, 35 cycles of denaturation at 94°C 
for 45 sec, annealing at either 62°C for Ctnnb1lox(ex3) or 59°C for Zbtb46-Cre or 
60°C for Ctnnb1Fl/Fl for 45 sec and extension at 72°C for 1 min, after 35 cycles 
final extension step at 72°C for 10 min. The end products were diluted with 5 x 
loading dye buffer (BioLine) and analysed on 2% agarose gel run at 60V. Agarose 
(Sigma) was dissolved into TBE buffer containing 1M Tris base (Sigma), 1M Boric 
acid (Sigma) and 0.02M EDTA (Sigma) to form a gel including Gel Red 
(Bioscience) for imaging by UV transilluminator. The presence of a single band 
at 493 base pairs (bp) was identified as Zbtb46-Cre/+ or at 300 bp as Ctnnb1Fl/Fl 
and two bands at 600 bp and 700 bp were identified as Ctnnb1lox(ex3)/+.  
 
 
Table 2.2 Primer sequences for genotyping 
 
2.1.2 Generation of chimeric mice 
Recipient C57BL/6 male or Ldlr-/- male or female mice were γ-irradiated twice 
with a dose of 5 Gγ 3 hours apart. One day later, mice were reconstituted by 
intravenous (i.v.) injection with either 3 x 106 bone marrow cells from GOF or WT 
mice, or 1 x 106 fetal liver cells from β-catenin knockdown mice or relevant WT 
Ctnnb1lox(ex3) 
Forward sequence: AGAATCACGGTGACCTGGGTTAAA 
Reverse sequence: CATTCATAAAGGACTTGGGAGGTGT 
Zbtb46-Cre 
Forward sequence: GGAGGTGGCGAGGGCTCCCCTGAGG 
Reverse sequence: CCTCACATTGCCAAAAGACGG 
Ctnnb1Fl/Fl 
Forward sequence: AAGGTAGAGTGATGAAAGTTGTT 
Reverse sequence: CACCATGTCCTCTGTCTATTC 
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control. Recipient mice were maintained on acidified water 1 week before 
irradiation and during the critical 4 week reconstitution period. Figure 2.1, 2.2 & 
2.3 detail the generation of the mouse models. 
 
Figure 2.1 Generation of the chimeric β-catenin knockdown model 
               
Figure 2.2 Generation of the chimeric GOF model 
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Figure 2.3 Generation of the chimeric Ldlr-/- GOF model 
 
 
2.2 Primary cell culture and isolation 
 
2.2.1 Extraction of mouse bone marrow cells 
The femurs and tibias of mice were removed from euthanized animals. The bones 
were cleaned and sterilised in 70% ethanol. Using MACS buffer containing PBS 
(Gibco), 2% heat inactivated fetal bovine serum (FBS) (Seralab), 2mM EDTA, the 
bones were flushed through with 5 ml syringe and 23 G needle (BD Microlance) 
to liberate the marrow cells. The harvested bone marrow cells were filtered 
through a 70 µm cell strainer (Fisher) to remove any debris and further washed 
with MACS buffer, centrifuged at 1600 rpm for 5 min. The supernatant was 
discarded and cell pellet resuspended in an appropriate volume for counting. To 
count viable cells, cell suspension was diluted 1:1 ratio with trypan blue (Sigma) 
for dead cell exclusion and counted using a haemocytometer, visualised by light 
microscope. The value obtained from one primary 1 mm2 square was equal to 
the number of cells x 104 in 1 ml. After counting, the cells were resuspended at 3 
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x 107 /ml in sterile PBS for i.v. injections for the generation of chimeras or used 
for culturing bone marrow dendritic cells.  
 
2.2.2 Culture of bone marrow dendritic cells (BMDC) 
The cells harvested from bone marrow were counted as previously described and 
resuspended to 2.5 x 106 /ml in complete R10 media and 0.2 µl/ml Flt3 ligand 
recombinant protein (Invitrogen). Complete R10 media contained RPMI 1640 
(Gibco), 10% FBS, 1% Pen/Strep (Gibco), 1% Glutamine (Gibco), 1% HEPES 
(Gibco), 1% Sodium Pyruvate (Gibco), 0.1% 2-Mercaptoethanol (Gibco). Cells 
were seeded at 1 ml/well in a 24 well plate (Costar) and incubated for 9 - 10 days 
at 37°C, 5% CO2. On day 5 of culture the media was changed, removing existing 
media and replacing with fresh complete R10 media and Flt3 ligand. 
 
2.2.3 Immune cell isolation from visceral adipose tissue  
Visceral adipose tissue (VAT) was collected from euthanised mice, from the 
gonadal, epididymal, mesenteric and peri-renal fat depot sites, with care to first 
remove the lymph nodes. The tissue was weighed and placed into tissue wash 
buffer containing PBS and 2% FBS and the tissue was diced. The weight was 
recorded for cell number calculations and to determine the percentage of body 
weight. To digest the tissue, 5688 U Collagenase II (Sigma) and 0.32 U DNase 
(Sigma) was added per gram of VAT in 2 ml wash buffer and incubated at 37°C 
with agitation 220 rpm for 30 min. The digested tissue was passed through 100 
µm cell strainer (Fisher) and centrifuged at 2000 rpm for 10 min. If a fatty layer 
was observed after spinning, the AT was under digested and the layer was 
collected and re-digested. The supernatant was discarded and the combined 
pellets of immune cells present in the vascular fraction were isolated. The pellet 
was lysed for red blood cells using ACK lysis buffer, containing 150mM NH4Cl 
(Sigma), 10mM KHCO3 (Sigma), 0.1mM Na2EDTA (Sigma) dissolved in H2O and 
pH adjusted to 7.2 - 7.4. The cells were resuspended in 1 ml ACK lysis buffer for 
2 min, and washed with tissue wash buffer and centrifuged at 1800 rpm for 5 min. 
The resulting cell suspension was filtered through a 70 µm cell strainer and 
centrifuged at 2000 rpm for 10 min. The supernatant was discarded and the cell 
pellet was washed with PBS. The immune cell pellet was stained for analysis by 
flow cytometry or placed in Trizol (Invitrogen) for mRNA analysis. 
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2.2.4 Immune cell isolation from spleen and lymph nodes 
Spleen and mesenteric, inguinal, cervical, axillary, brachial or mediastinal lymph 
nodes were collected from euthanised mice. The spleen or lymph nodes were 
placed in serum free DMEM (Gibco) and digested with 400 U/ml Collagenase D 
(Roche) using 5 ml syringe and 25 G needle (BD Microlance) to balloon the tissue 
to expel cells, followed by fine dicing of the tissue. The spleen or lymph nodes 
were incubated with the Collagenase D for 18 min at 37°C and digestion was 
stopped by adding EDTA. The digested spleen or lymph nodes were passed 
through 70 µm cell strainer and centrifuged at 1600 rpm for 5 min. The 
supernatant was discarded and red blood cells in the pellet were lysed using ACK 
lysis buffer and washed with PBS. The immune cell pellet was stained for analysis 
by flow cytometry or for further cell isolation.  
 
2.2.5 CD11c+ cell and CD4+ T cell isolation 
CD11c+ cells and CD4+ T cells were isolated from spleen or VAT by positive 
selection using microbeads and LS columns (MACS Miltenyi Biotec). The isolated 
immune cells were counted and resuspended at 1 x 108 /400µl in MACS buffer. 
The cells were incubated with 40 µl CD11c+ or CD4+ microbeads (MACS Miltenyi 
Biotec) for 20 min at 4°C. The cells were washed with MACS buffer, centrifuged 
at 1800 rpm for 5 min and the supernatant was discarded. The cells were then 
resuspended in 800 µl of MACS buffer and loaded into a pre-washed LS column 
while being placed in the magnetic field of a MACS separator. The column was 
washed three times with MACS buffer and the flow through collected was 
discarded. After the final wash the LS column was removed from the magnet and 
5ml MACS buffer was loaded into the column and the cells bound with 
microbeads within the column were flushed out using the plunger into a new tube. 
The cells were centrifuged at 1800 rpm for 5 min and the supernatant was 
discarded. The cells were counted and resuspended in complete R10 media to 
an appropriate cell concentration for plating. 
 
2.2.6 CD3+ T cell isolation  
CD3+ T cells were isolated from spleen and lymph nodes of BALB/c mice by 
negative selection using Dynabead (Invitrogen). The isolated immune cells were 
counted and resuspended at 1 x 108 /ml in MACS buffer. For an initial blocking 
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step FBS was added to the cells in a 15 ml tube, followed by the antibody mix. 
After 20 min incubation at 4°C, the cells were washed twice with MACS buffer, 
centrifuged at 350 g for 5 min and the supernatant was discarded. The cells were 
resuspended in MACS buffer and incubated with pre-washed Dynabeads for 15 
min at room temperature with agitation. After mixing, the tube was placed in the 
DynaMag magnet for 2 min to allow for separation and while the tube remained 
in the magnet the unbound CD3+ T cells were transferred into a new tube. The 
new tube was placed back into the magnet and the separation was repeated. The 
CD3+ T cells were washed in MACS buffer, centrifuged at 1800 rpm for 5 min and 




2.3 Flow cytometry staining 
 
2.3.1 Extracellular staining 
The cells were resuspended in FACS buffer containing PBS, 2% FBS and 2mM 
EDTA and placed in wells of 96 V-bottom plate (Costar). The cells were stained 
for surface markers with fluorescently conjugated primary antibodies, see Table 
2.3. All the samples were stained with fixable Aqua Dead cell stain (Invitrogen) 
diluted 1:1000 in PBS, to exclude dead cells from analysis. The samples were 
stained at 4°C for 30 min and then washed twice with FACS buffer where the 
plate was centrifuged at 1800 rpm for 5 min and the supernatant discarded. The 
samples were fixed at 4°C for 30 min with 1% PFA (Sigma) and washed twice 
with FACS buffer. After staining and fixing the samples were resuspended in 
FACS buffer and analysed by flow cytometry using a LSR Fortessa (BD 
Biosciences) and FlowJo version 10 software. A gating strategy was used to 
identify immune populations through expression of cell surface markers (Figure 
2.4). 
 
2.3.2 Intracellular staining 
After staining cell surface markers as described previously, the samples were 
incubated in permeabilization/fixation buffer from intracellular staining kits 
(eBioscience or BD Bioscience) at 4°C for 30 min. The samples were washed in 
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permeabilization buffer before staining with fluorescently conjugated primary 
antibodies (BioLegend), see Table 2.3, at 4°C for 30 min in permeabilization 
buffer and washed twice with FACS buffer. After staining and fixing the samples 
were resuspended in FACS buffer and analysed by flow cytometry using a LSR 
Fortessa and FlowJo version 10 software. A gating strategy was used to identify 
immune populations through expression of intracellular markers (Figure 2.4). 
 
 
Figure 2.4 Gating strategy for flow cytometry analysis 
 
2.3.3 Fluorescence activated cell sorting of live cells 
The cells were stained as previously described with fluorescently conjugated 
primary antibodies, see Table 2.3 and fixable Aqua Dead cell stain. The cells 
were counted and resuspended at 2 x 107 /ml in FACS buffer in 5 ml 
polypropylene tube (Falcon). Live sorting was carried out using either an Aria II 
or Aria Fusion (BD Biosciences) with 85 µm nozzle. CD11c+ MHCII+ CD103+ 
CD11b+ conventional dendritic cells were collected into pre-coated polypropylene 
tubes containing 500 µl FBS. Once resuspended in FACS buffer, the cells were 
centrifuged at 2000 rpm for 10 min and the supernatant was discarded. This wash 
step was repeated twice. The sorted cells were resuspended in the appropriate 
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Table 2.3 Antibodies used for flow cytometry staining 
Specificity Clone Fluorochrome Supplier Dilution 
CD16/32 93 FITC BioLegend 1:200 
F4/80 BM8 PerCP BioLegend 1:200 
CD206 C068C2 Brilliant Violet 421™ BioLegend 1:200 
CD11c HL3 Brilliant Violet 605™ BD Biosciences 1:200 
CD11c N418 Brilliant Violet 605™ BioLegend 1:200 
CD103 2E7 APC eBioscience 1:200 
MHCII M5/114.15.2 AlexaFluor®700 BioLegend 1:200 
CD11b M1/70 APC-eFluor®780 eBioscience 1:200 
MertK  PE R&D Systems 1:200 
CD45 30-F11 PE-CF594 BioLegend 1:800 
CD64 X54-5/7.1 PE-Cy7 BioLegend 1:200 
CD8 53-6.7 FITC eBioscience 1:200 
CD8 53-6.7 APC-eFluor®780 eBioscience 1:200 
LY6G IA8 Brilliant Violet 421™ BioLegend 1:200 
NK1.1 PK136 Brilliant Violet 605™ BioLegend 1:200 
CD3 17A2 AlexaFluor®700 eBioscience 1:200 
SiglecF E50-2440 PE-CF594 BD Biosciences 1:200 
CD4 RM4-5 PE-Cy7 BioLegend 1:200 
CD4 RM4-5 PerCP BioLegend 1:200 
B220 RA3-6B2 PerCP BioLegend 1:200 
FOXP3 150D/E4 PE eBioscience 1:200 
FOXP3 FJK-16s PE-Cy7 eBioscience 1:200 
CD69 H1.2F3 FITC BioLegend 1.200 
CD44 IM7 eFluor®450 BioLegend 1:200 
CD44 IM7 PerCP BioLegend 1:200 
CD62L MEL-14 Brilliant Violet 605™ BioLegend 1:200 
Nkx6.1 R11-560 PE BD Biosciences 1:50 
Nkx6.1 R11-560 AlexaFluor®647 BD Biosciences 1:50 
Ki67 16A8 AlexaFluor®700 BioLegend 1:50 
TNFα MP6-XT22 PE-Cy7 BD Biosciences 1:200 
IL-17A eBio17B7 PE eBioscience 1:200 
IFNγ  APC BD Biosciences 1:200 
CCR4 2G12 PE BioLegend 1:200 
TCRVα2 B20.1 PE BioLegend 1:200 
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2.4 Antigen presentation assays 
 
2.4.1 CFSE labelling of T cells 
Isolated CD3+ and CD4+ T cells were labelled with CFSE (Invitrogen). The cells 
were resuspended at 1 x 107 /ml in PBS and incubated with 3 µM CFSE for 9 min 
at room temperature. Immediately the excess CFSE was quenched by adding an 
equal volume of FBS and incubating for 1 min before washing with PBS. The cells 
were centrifuged at 2000 rpm for 10 min and the supernatant was discarded. The 
cells were washed further once more in PBS and counted. The CFSE labelled 
CD3+ or CD4+ T cells were resuspended in complete R10 media to an appropriate 
cell concentration for plating. 
 
2.4.2 Ex vivo mixed leukocyte reaction (MLR) 
CD11c+ cells or sorted dendritic cells isolated from the spleen or VAT of 
experimental chimera mice were cultured with CFSE labelled CD3+ T cells, 
harvested from the spleen and lymph nodes of BALB/c mice. Cells were isolated 
as previously described and resuspended in complete R5 media. Complete R5 
media contained RPMI 1640, 5% FBS, 1% Pen/Strep, 1% Glutamine, 1% 
HEPES, 1% Sodium Pyruvate, 0.1% 2-Mercaptoethanol. DCs were resuspended 
at 5 x 105 /ml and 100 µl was seeded into a 96 well U-bottom plate (Costar). CFSE 
labelled CD3+ T cells were resuspended at 2.5 x 106 /ml and 100 µl was added 
into the wells with the DCs. The cells were mixed at a ratio of 1:5 (5 x 104 DC: 
2.5 x 105 CD3+ T cells per well) and incubated for 5 days, after which cells were 
harvested and CFSE dilution was assessed by flow cytometry. Supernatant was 
harvested to measure cytokine release from T cells. 
 
2.4.3 In vivo antigen presentation  
Mice were injected i.v. with ovalbumin (OVA)-specific OT-II CD4+ T cells purified 
from spleen and lymph nodes of OT-II mice by CD4+ bead positive selection 
(MACS Miltenyi Biotec) and labelled with 3 µM CFSE (Invitrogen). The next day, 
mice were immunized with 200 µg of OVA (Sigma) by intraperitoneal (i.p.) 
injection. Three days later, immune cells were isolated from spleen, lymph nodes 
and VAT and stained, as described above, for analysis by flow cytometry. The 
dilution of CFSE in the T cell population was used as an indicator of cell division.  
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2.5 T cell responses 
 
2.5.1 Ex vivo stimulation of cytokines 
Immune cells from spleen, lymph nodes and VAT were isolated as previously 
described. Samples were resuspended in FACS buffer in 5 ml polypropylene 
tubes and centrifuged at 1800 rpm for 5 min. The supernatant was discarded and 
the cell pellet was resuspended in 500 µl of complete R5 media containing 20 
ng/ml Phorbol 12-myristate 13-acetate (PMA) (Sigma) and 1 µg/ml Ionomycin 
(Sigma). Unstimulated cells were included as a negative control. After 1 hour 
incubation at 37°C, 10 µg/ml Brefeldin A (Sigma) was added into all of the tubes 
+/- stimulation and incubated for a further 4 hours at 37°C. Cells were stained as 
previously described, to analyse cytokine production by flow cytometry.  
 
 
2.6 Islets assays 
 
2.6.1 Isolation of islets 
Immediately after mice were euthanised, the pancreas was inflated with 1 µg/ml 
Collagenase V (Sigma) by injecting into the hepatic duct using 30 G needle (BD 
Microlance), after clamping the ampulla. The inflated pancreas was removed, 
placed into a tube with 1 ml of 1 µg/ml Collagenase V diluted into additive-free 
RPMI (Sigma) and incubated in a water bath at 37 °C for 10 min. Cold additive-
free RPMI was added followed by centrifugation at 1000 rpm for 1 min. The 
supernatant was removed before adding about 15 ml of cold additive-free RPMI 
and the pancreas was resuspended in the media. This pellet was washed three 
more times. The islets were resuspended in 3 ml of Histopaque 119 (Sigma). A 
sucrose gradient was made by adding dropwise 3 ml of Histopaque 1083 and 
1077 (Sigma) and RPMI was added dropwise up to 12 ml. The gradient was 
centrifuged at 2500 rpm for 20 min. The islets found just below the RPMI layer 
were collected and centrifuged at 1000 rpm for 1 min after addition of up to 12 ml 
RPMI. The supernatant was removed; islets were resuspended and placed in a 
petri dish containing 15 ml complete R10 media. After a few hours of recovery at 
37 °C islets were handpicked. Islets were placed into culture overnight to 
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measure insulin release or used for co-cultures to measure β-cell proliferation or 
further processed to isolate immune cells from the islets.  
 
2.6.2 Immune cell isolation from islets 
Islets were harvested as previously described and 20 handpicked islets were 
resuspended in 1 ml of islet digestion buffer containing HBSS (Sigma), 10% FBS 
and 0.2 mg/ml Collagenase IV (Sigma). Islets were incubated for 30 min at 37°C 
with agitation 120 rpm and passed through a 30 G needle. The digested islets 
were passed through 70 µm cell strainer and centrifuged at 1600 rpm for 5 min. 
The supernatant was discarded and the cell pellet was washed with PBS. The 
immune cell pellet was stained for analysis by flow cytometry or placed in Trizol 
for mRNA analysis. 
 
2.6.3 Dendritic cell and islet co-cultures 
Islets were harvested as previously described from donor C57BL/6 mice and 
seeded into a 12 well plate (Costar), 5 handpicked islets were placed into 2 ml 
complete R10 media per well. The cDC population was sorted from cultured 
BMDC as previously described and resuspended at 5 x 105 /ml and 100 µl was 
added per well. Islets and DCs were cultured together overnight and treated with 
or without 1 µg/ml anti-IL-10 (BioLegend). The supernatant was harvested the 
next day and insulin and IL-10 was measured in the supernatant by ELISA. To 
measure β-cell proliferation, islets and DCs were cultured together for 5 days. In 
this set up, 8 islets were seeded into a 48 well plate (Costar) in 500 µl complete 
R10 media per well. The DC population was resuspended at 1 x 105 /ml and 100 
µl was added per well. The islets were harvested after 5 day culture and digested 
as previously described. The cell pellet obtained from the islets was stained for 




Figure 2.5 Dendritic cell and islet co-culture 
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2.7 Transcript analysis 
 
2.7.1 Expression profiling 
Expression profiling was performed using publicly available raw data (ImmGen 
GEO: GSE37448) in R (188). Between-array RNA quantile normalization was 
performed and unmapped or multi-mapping probes removed prior to differential 
expression analysis with limma (189). Fold change rankings were used in GSEA 
to identify differentially regulated pathways (FDR < 0.25). Processed data are 
available at ImmGen data browsers (http://www.immgen.org/). 
 
2.7.2 RNA extraction from visceral adipose tissue and islet 
immune cells 
RNA from 100 mg diced VAT or 20-30 islets was isolated by phase separation 
and using RNeasy lipid tissue mini kit (Qiagen). The harvested tissue was 
incubated in Trizol for 5 min at room temperature to allow dissociation of the 
nucleoprotein complex. The samples were centrifuged at 12,000 g for 10 min at 
4°C and the supernatant under the fatty layer was transferred into a new tube. 
For phase separation, chloroform (Fisher Chemical) was added to the samples 
and vortexed for 15 sec. After incubation for 2 min at room temperature, the 
samples were centrifuged at 12,000 g for 15 min at 4°C to separate into layers. 
Carefully the upper aqueous phase was removed and transferred into a new tube, 
with care not to disturb the interphase and organic layer. The RNeasy lipid tissue 
mini kit was used to isolate the RNA, performed to the manufacturer’s 
instructions. An equal volume of 70% ethanol was added to the sample, 
transferred into spin column placed in 2 ml collection tube and centrifuged at 
12,000 g for 15 sec. The flow-through was discarded and the column was washed 
with buffer RW1, repeating the centrifugation step and discarding the flow-
through. The wash step was repeated twice more with buffer RPE. The 
membrane in the spin column was dried by centrifugation at full speed for 1 min. 
The column was placed into a new collection tube and RNase-free water was 
added and centrifuged at 12,000 g for 1 min. The RNA collected in the tube was 
quantified by LVIS measurement using Spectrostar Omega reader (BMG 
Labtech). 
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2.7.3 RNA extraction from immune cells from visceral 
adipose tissue 
RNA from the immune cell pellet from VAT was isolated by phase separation, 
further precipitated and washed. The pellet was collected in Trizol and processed 
as previously described. Once the upper aqueous phase was harvested, the RNA 
was precipitated using 100% Isopropanol (Fisher Chemical). Glyco blue (Life 
Technologies) was added during this step as a carrier to the aqueous phase. 
After overnight incubation at 4°C, the sample was centrifuged at 12,000 g for 10 
min at 4°C. The supernatant was discarded and the RNA pellet was washed with 
75% ethanol, repeating the centrifugation step and carefully discarding all of the 
supernatant. The pellet was dried by 5 min in the air and resuspended in RNase-
free water. The RNA was incubated at 55 - 60°C for 10 min for denaturation. The 
RNA was quantified by LVIS measurement using Spectrostar Omega reader. In 
some cases, the RNA purity was improved using RNeasy MinElute cleanup kit 
(Qiagen), performed to the manufacturer’s instructions. 
 
2.7.4 cDNA synthesis 
Reverse transcription of RNA to cDNA was performed using High-Capacity RNA-
to-cDNA kit (Applied Biosystems). The measured RNA concentration was 
normalised to the sample with the lowest concentration, the kit can convert up to 
2 µg of RNA per reaction. The RT reaction mix was prepared containing; 10 µl of 
2 x RT Buffer mix, 1 µl of 20 x RT Enzyme mix and relevant volume of RNA and 
nuclease- free H2O to give a total volume of 20 µl per reaction. The RT reaction 
mixes were added into PCR tubes (Applied Biosystems) and vortexed and 
centrifuged to spin down the contents and eliminate air bubbles. The RT reactions 
were carried out using the thermal cycler (Applied Biosystems) with an incubation 
at 37°C for 60 min and heating to 95°C for 5 min before cooling to 4°C. The cDNA 
was used for performing quantitative real-time PCR reactions. 
 
2.7.5 Primer design 
Forward and reverse primers were either used from the literature, from primer 
bank or were designed using Primer3 software using NCBI blast generated 
sequences of mRNA (National Centre for Biotechnology Information). Primers 
were designed with an amplicon size of 100 - 150 base pairs, the primer size of 
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18 - 23 base pairs in length, with 40 - 60% GC nucleotide content, a maximum 3’ 
complementarity of 1, a maximum self-complementarity of 2 and a melting 
temperature between 59.5 and 61°C. Forward and reverse primers were 
purchased from Invitrogen, see Table 2.4. 
 
2.7.6 Quantitative real-time polymerase chain reactions 
(qRT-PCR)  
Transcripts were analysed by qRT-PCR in 96 well PCR plates (Bio-Rad) by 
adding to each well 2 µl cDNA, 0.5 µl forward and reverse 10 µM primer stock, 
5µl iTaq™ Universal SYBR® green (Bio-Rad) and 2.5 µl nuclease free water 
(Qiagen). Plates were sealed using adhesive plate sealers (Bio-Rad), gently 
vortexed and centrifuged at 1800 rpm for 1 min. qRT-PCR was analysed using a 
CFX connect light cycler (Bio-Rad) with 95°C start for 3 min, then 40 cycles of 
95°C for 10 sec and 55°C for 30 sec. Gene-relative expression was calculated 
using the ΔΔCT method to demonstrate fold-change and normalised to a 
reference control (GAPDH) with control sample set as 1. The geometric mean 
was used as a more appropriate representation of ΔΔCT, which does not have a 
normal data distribution. Data is represented in ΔΔCT format, however statistical 
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Table 2.4 Forward and reverse primer sequences 
 
 
 Forward sequence  Reverse sequence 
Gapdh GGCTCATGACCACAGTCCA CACATTGGGGGTAGGAACAC 
IL-10 AAACAAAGGACCAGCTGGAC TTCCGATAAGGCTTGGCAAC 
TNFα TCGTAGCAAACCACCAAGTG  TTTGAGATCCATGCCGTTGG  
IL-6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 
IL-1 AACCTGCTGGTGTGTGACGTTC CAGCACGAGGCTTTTTTGTTGT 
IFNγ CAGCAACAGCAAGGCGAAA   CTGGACCTGTGGGTTGTTGAC 
IL-17A AAAGCTCAGCGTGTCCAAAC TTCTGGAGCTCACTTTTGCG  
CCL2 GCTGGAGCATCCACGTGTT ATCTTGCTGGTGAATGAGTAGCA 
CCL17 GGATGCCATCGTGTTTCTGA GCCTTCTTCACATGTTTGTCTTTG 
Adipoq GACGTTACTACAACTGAAGAGC CATTCTTTTCCTGATACTGGTC 
Leptin TGAGTTTGTCCAAGATGGACC GCCATCCAGGCTCTCTGG  
Tgfβ CCCGAAGCGGACTACTATGC ATAGATGGCGTTGTTGCGGT 
Wnt1 ATTTTGCGCTGTGACCTCTT AGCAACCTCCTTTCCCACTT 
Wnt2 GGTCAGCTCTTCATGGTGGT GGAACTGGTGTTGGCACTCT 
Wnt3a TCGGAGATGGTGGTAGAGAAA CGC AGA AGT TGG GTG AGG 
Wnt4 AAGAGGAGACGTGCGAGAAA CACCACCTTCCCAAAGAACAG 
Wnt5a CTCTCCGAAGTCCATGTCGT GGACGATACTCCAGGCAGAG 
Wnt5b TCTCCGCCTCACAAAAGTCT CACAGACACTCTCAAGCCCA 
Wnt6 GCGGAGACGATGTGGACTTC ATGCACGGATATCTCCACGC 
Wnt7a GACAAATACAACGAGGCCGT GGCTGTCTTATTGCAGGCTC 
Wnt8b CCAGAGTCCCGGGAGGTAG GAGATGGAGCGGAAGGTGT 
Wnt9a GGACAACCTCAAGTACAGCAG TCCACTCCAGCCTTTATCACC 
Wnt10a CCACTCCGACCTGGTCTACTTTG TGCTGCTCTTATTGCACAGGC 
Wnt10b AATGCGGATCCACAACAACA TTCCATGGCATTTGCACTTC 
Wnt11 TGCTTGACCTGGAGAGAGGT AGCCCGTAGCTGAGGTTGT 
Ccr4 ATCGTGCACGCGGTATTCTCC GACGGGGTTAAGGCAGCAGTGA 
Foxp3 GGCCCTTCTCCAGGACAGA GCTGATCATGGCTGGGTTGT 
Myc GCCACGTCTCCACACATCAG TCTTGGCAGCAGGATAGTCCTT 
Cyclin D1 GCGTACCCTGACACCCCTCTC CTCCTCTTCGCCTGATCC 
Cyclin A GCCTTCACCATTCATGTGGAT TTGCTGCGGGTAAAGAGACAG 
Cdk4 ACCCTGTCATCTGTTTATGC AGGTGTTAGTGGGAGATCCT 
Fzd1 TGCCCAGTGTCTTTCTCCTT TCTCTTTAGCCTCTCCCAACC 
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2.8 Metabolic assays 
 
2.8.1 Glucose tolerance test (GTT) 
Mice were fasted overnight for approximately 16 hours or 6 hours as stated, in 
cages with the absence of nesting material. Fasted blood glucose levels were 
collected from the initial tail bleed using blood glucose meter and test strips 
(FreeStyle Optium Neo, Abbott). Mice were administered with 1.5 mg D-Glucose 
/g of body weight (Sigma) by intraperitoneal (i.p.) injection and blood glucose was 
measured from tail vein blood at 15, 30, 60, 90 and 120 min after injection. 
 
2.8.2 Insulin tolerance test (ITT) 
Mice were fasted for 3 hours or 6 hours as stated, in cages with the absence of 
nesting material. Fasted blood glucose levels were collected from the initial tail 
bleed using blood glucose meter and test strips. Mice were administered with 0.5 
U Insulin /kg of body weight (Actrapid) by i.p. injection with and blood glucose 
was measured from tails vein bleed at 15, 30, 60, 120 and 180 min after injection. 
 
2.8.3 Collection of plasma 
Blood was collected from tail bleed of fasted mice or from terminal cardiac 
puncture into EDTA-coated capillary blood collection tubes (Sarstedt). The 
samples were centrifuged at 2000 rpm for 10 min, the cell pellet was discarded 
and supernatant, the plasma was collected for further analysis.  
 
 
2.9 Enzyme-linked immunosorbent assay (ELISA) 
 
2.9.1 Cytokine and chemokine ELISA 
The concentration of cytokines including TNFα, IL-10, IL-6, IL-12, IL-4, IL-17A, 
IFNγ and chemokine CCL17, were quantified using ELISA kits (Invitrogen) 
performed to the manufacturer’s instructions. CD11c+ cells were purified from 
spleen and VAT as described previously, and plated at 1 x 105 cells/ well. Cells 
were cultured overnight in complete R10 media and supernatant was collected 
the next day. IL-10, IL-6, IL-12, CCL17 was measured in the harvested CD11c+ 
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supernatant. IL-4, IL-17A, IFNγ was measured in the harvested supernatant from 
ex vivo mixed leukocyte reaction. TNFα was measured in plasma collected from 
terminal bleed. The wells of a 96 flat-bottom high affinity protein-binding plate 
(Costar) were coated with purified capture antibody diluted in coating buffer 
overnight at 4°C. The wells were washed 3 times with PBS + 0.05% Tween-20 
(Sigma) (PBS-T) and blocked in assay buffer for 1 hour at room temperature to 
prevent non-specific antibody binding. The block was aspirated and the 
standards and samples were added into the wells and incubated for 2 hours at 
room temperature. Standards were prepared in assay buffer, with a serial 1:2 
dilutions performed to generate an 8-point standard curve. Samples were used 
neat or diluted in assay buffer dependent on the analyte. The wells were washed 
3 times with PBS-T and biotin-conjugated detection antibody diluted in assay 
buffer, was added for 1 hour at room temperature. The wells were washed 3 times 
with PBS-T and Avidin-HRP enzyme diluted in assay buffer, was added for 30 
min at room temperature. The wells were washed 5 times with PBS-T and 
Tetramethylbenzidine (TMB) substrate solution was added until the standard 
curve had developed, which ranged between 5 and 20 min depending on the 
analyte. Once developed, 1M hydrochloric acid was used to stop the reaction, 
and the plate was read at 450 nm absorbance using Spectrostar Omega reader. 
The concentrations of the cytokines in the samples were interpolated from the 
standard curve using Prism 7 (GraphPad software). 
 
2.9.2 Metabolic ELISA 
Adiponectin, leptin and insulin from fasted or non-fasted plasma samples were 
measured using ELISA kits (Merck Millipore) performed to the manufacturer’s 
instructions. The wells of pre-coated plates were washed 3 times with wash buffer 
and the standards, quality controls and samples were added and incubated for 2 
hours at room temperature with agitation with detection antibody. The standards 
and samples were diluted in assay buffer, dependent on the kit and analyte. The 
wells were washed 3 times with wash buffer and the enzyme solution was added 
for 30 min at room temperature with agitation. The wells were washed 5 times 
with wash buffer and substrate solution was added for 15 min to develop until the 
stop solution was added. The plate was read at 450nm absorbance using 
Spectrostar Omega reader and concentrations of analytes in the samples were 
interpolated from the standard curve using Prism 7. 
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2.9.3 Cholesterol and free fatty acid quantification 
Levels of total cholesterol, HDL and VLDL/LDL from plasma samples were 
determined using a quantification kit (Abcam) performed to the manufacturer’s 
instructions. HDL and VLDL/LDL fractions were separated from the plasma by 
mixing with precipitation buffer and incubating for 10 min at room temperature. 
The sample was centrifuged for 10 min at 2000 g and the HDL fraction 
supernatant was harvested. The cell pellet was further precipitated to remove all 
the supernatant and the precipitate was resuspended in PBS to generate the 
VLDL/ LDL fraction. Total cholesterol was determined from the plasma directly. 
Standards were prepared in assay buffer to generate a 6-point standard curve 
from 5 - 0 µg/well. Samples were used neat or diluted in assay buffer dependent 
on the fraction. The standards and samples were added into a 96 well flat-bottom 
plate and diluted 1:2 with cholesterol reaction mix containing cholesterol probe, 
enzyme mix, cholesterol esterase and assay buffer. To measure free cholesterol, 
cholesterol esterase was absent from the reaction mix. After incubating for 1 hour 
at 37°C in the dark, the plate was read at 570 nm absorbance using Spectrostar 
Omega reader and the cholesterol concentration in the samples were 
interpolated from the standard curve using Prism 7. 
 
 
2.10 Image staining and analysis 
 
2.10.1 Immunohistochemistry 
VAT, heart and pancreas tissue was fixed in 4% PFA and embedded in paraffin 
by Histopathology core services, QMUL. Sections were mounted onto slides and 
stained with haematoxylin and eosin. Pancreas sections were immunostained 
with rabbit polyclonal antibodies for CD3 (Dako), insulin (ICN), Ki67 (Abcam, 
clone SP6) or cleaved caspase-3 (Cell Signalling Technologies) using Ventana 
OmniMap DAB- HRP staining system (Discovery XT) performed by 
Histopathology core services, QMUL. Heart sections were stained with Sirus red 
for the identification of the aortic sinus. Stained slides were scanned using 
Pannoramic 250 High Throughput scanner to gain digital images for analysis. 
Adipocyte size was calculated from H&E stained VAT sections using ImageJ 
Adiposoft software (190), three fields of view from each image per tissue were 
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analysed. Islet size was determined from H&E stained pancreas sections using 
ImageJ software, all islets from five levelled sections per tissue were analysed 
where the level was set at 25 µm. Ki67+ cells were counted in the islets of Ki67 
stained pancreas sections, all islets from three levelled sections per tissue were 
analysed. All analysis was performed blinded. 
 
2.10.2 Immunofluorescence 
Unstained sections from paraffin embedded pancreas tissue were mounted onto 
slides by Histopathology core services, QMUL. An initial antigen retrieval step 
was performed before immunofluorescence staining. Slides were incubated in 
Xylene (Fisher Chemical) for 5 min twice, 100% ethanol for 2 min twice, 90%, 
70%, 50% ethanol for 2 min and distilled water for 5 min. Slides were boiled in 
10mM Sodium citrate buffer containing 0.05% Tween-20, pH 6, at 100°C for 30 
min. After cooling, the slides were washed in PBS-T and blocked with 10% goat 
serum, 0.3% Triton X-100 (Sigma), 1% BSA buffer for 1 hour at room 
temperature. Slides were washed three times with PBS-T for 5 min and incubated 
overnight at 4°C with rabbit anti-mouse Ki67 antibody (Abcam, clone SP6) diluted 
1:100 in 10% goat serum, 0.3% Triton X-100, 1% BSA buffer. Slides were washed 
three times with PBS-T for 5 min and incubated for 1 hour at room temperature 
with goat anti-rabbit IgG antibody conjugated with AlexaFluor®555 (Life 
Technologies) diluted 1:1000 in 0.1% goat serum, 0.3% Triton X-100, 0.1% BSA 
buffer. Slides were washed three times with PBS-T for 5 min and incubated for 1 
hour at room temperature with anti-mouse Nkx6.1 antibody conjugated with 
AlexaFluor®647 (BD Bioscience, clone R11-560) diluted 1:200 and DAPI (Sigma) 
diluted 1:2000 in 0.1% goat serum, 0.3% Triton X-100, 0.1% BSA buffer. Slides 
were washed three times with PBS-T for 5 min and covered with mounting media 
(Vector Laboratories) and coverslip before analysis on Axio Observer Z1 
microscope (Zeiss) using AxioVision software (Zeiss). Ki67+ Nkx6.1+ cells were 
counted in the islets of the stained pancreas sections, all islets from three levelled 
sections per tissue were analysed. Analysis was performed blinded. Unstained 
sections from paraffin embedded pancreas tissue from Zbtb46GFP were mounted 
onto slides by Histopathology core services, QMUL. Slides were covered with 
mounting media containing DAPI (Vector Laboratories) and coverslip, before 
visualisation on Axio Observer Z1 microscope using AxioVision software to 
observe GFP signal.  
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2.10.3 Whole mount aorta staining 
Immediately after mice were euthanised, the vasculature was flushed with cold 
PBS. The aorta was excised, carefully removing the fat deposited on the vessel 
and aortic arch. The aorta was cut from the heart above the aortic sinus valves 
and branching vessels were removed in the arch, thorax and abdomen sections. 
Isolated aortas were placed in a petri dish with PBS and cleaned to remove all 
external deposits of fat using a dissecting microscope. The aorta were fixed 
overnight in 4% PFA and stored in 70% ethanol. Carefully the aortas were cut 
open longitudinally for en face Oil Red O staining. For staining, the aortas were 
placed into distilled H2O and transferred into freshly prepared 3 mg/ml Oil Red O 
solution and incubated for 15 min at room temperature with agitation. The aortas 
were washed in 60% isopropanol for 5 min, repeated twice more and further 
transferred into distilled H2O. Glycerol gelatin (Sigma) was used to mount the 
aortas onto the slides with coverslips before visualised using M205 FA 
microscope (Leica). Images of the aortas were analysed blindly using ImageJ to 
quantify the percentage lesion density. 
 
2.10.4 Ex vivo confocal microscopy 
Zbtb46GFP mice were injected i.p. with fluorescently conjugated primary 
antibodies against LYVE-1 (eBioscience) and PECAM-1 (eBioscience) 4 hours 
prior to surgery.  Mice were euthanised and the mesenteric organs including the 
associated VAT was exteriorised and fixed in 4% PFA for 10 min. The tissue was 
mounted on a home-built perplex stage and viewed using SP8 confocal 
microscope (Leica) with 20 x objective. Images were attained with the use of 
sequential scanning of different channels at every 0.52 µm of tissue depth at a 
resolution of 1024 x 470 pixels in the x & y plane, respectively and imaged at a 
zoom factor of x 2. Acquired confocal images were analysed using the 3D 
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2.11 Western blotting 
 
2.11.1 Cell lysis 
Cell lysates were generated from CD11c+ isolated cells from spleen, pancreas, 
VAT and bone marrow using CelLytic M cell lysis reagent (Sigma) and combined 
phosphatase and proteinase inhibitors (Pierce). The cell pellet was resuspended 
in lysis buffer and sonicated for 10 sec before incubating on ice for 15 min. The 
lysed cells were centrifuged at 12,000 g for 15 min and the supernatant containing 
protein was transferred to a new tube. The protein concentration of the samples 
were quantified using the Bradford assay. 
 
2.11.2 Bradford assay and sample preparation 
The concentration of protein in the cell lysate samples were determined using 
Bradford reagent (Bio-Rad). BSA standards were prepared in PBS, with a serial 
1:2 dilutions performed to generate a 7-point standard curve from 8 - 0.125 
mg/ml. The standards and samples were added into a 96 well flat-bottom plate, 
diluted 1:200 with Bradford reagent. The plate was read at 595 nm absorbance 
using Spectrostar Omega reader and the protein concentration in the samples 
were interpolated from the standard curve using Prism 7. The measured cell 
lysates were normalised to the sample with the lowest protein concentration, to 
load 10 - 50 µg of protein. The loading mix was prepared containing; 3.75 µl of 4 
x NuPAGE™ LDS sample buffer (Invitrogen), 1.5 µl of 10 x NuPAGE™ sample 
reducing agent (Invitrogen) and relevant volume of cell lysate and nuclease-free 
H2O to give a total volume of 15 µl to load per well. The sample mix was heated 
at 70°C for 10 min. 
 
2.11.3 Gel electrophoresis separation and transfer 
The proteins were separated by SDS-PAGE using a mini protean precast gel 
(Bio-Rad). The gel was assembled into the running tank and a proper seal was 
ensured. The tank was filled with 1 x running buffer, containing 2.5 mM Tris base, 
25 mM Glycine (Sigma) and 0.01% (w/v) SDS (Sigma). The comb from the gel 
was removed and 15 µl of denatured sample mix and pre-stained ladder (Bio-
Rad) were loaded per well. The gel was run at 120V for approximately 1 hour at 
room temperature, until the blue dye front reached the bottom of the gel cassette. 
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The nitrocellulose membrane (GE Healthcare) and gel were equilibrated in 1 x 
transfer buffer, containing 2.5 mM Tris base, 25 mM Glycine and 1% (w/v) 
Methanol (Fisher). The transfer apparatus was assembled into the running tank 
and filled with 1 x transfer buffer. The transfer was run at 100V for 1.5 hours at 
room temperature.  
 
2.11.4 Immunoblotting and visualisation 
The membrane was washed in PBS-T for 5 min and blocked for 1 hour at room 
temperature. The blocking buffer contained PBS-T with 5% (w/v) blotting milk 
blocker (Bio-Rad). After the blocking step, the buffer was removed and the 
membrane was incubated with rabbit anti-mouse β-catenin antibody (Cell 
Signalling Technologies), rabbit anti-mouse non-phospho β-catenin (active) 
antibody (Cell Signalling Technologies) or rabbit anti-mouse p65 antibody 
(SantaCruz) overnight at 4°C. The primary antibody was diluted in PBS-T with 
5% (w/v) milk, 1:1000 for β-catenin antibody or 1:200 for p65 antibody. After the 
incubation, the membrane was washed with PBS-T for 10 min and this was 
repeated twice more. The membrane was incubated with HRP-conjugated 
donkey anti-rabbit IgG antibody (GE Healthcare) for 1 hour at room temperature. 
The secondary antibody was diluted 1:2000 in PBS-T with 5% (w/v) milk. After 
the incubation, the membrane was washed with PBS-T for 10 min and repeated 
twice more. Blotted proteins were detected using Luminata™ Forte Western HRP 
substrate (Millipore) and exposed on to Hyperfilm™ photo film (Amersham) for 
visualisation. The membrane was subsequently probed for β-actin as a loading 
control following the same method, using rabbit anti-mouse β-actin antibody (Cell 
Signalling Technologies) diluted 1:1000. Density of the β-catenin or p65 bands 
was calculated relative to β-actin by ImageJ software. 
 
 
2.12 Power calculations 
The number of mice (sample size) required to obtain statistical difference with 
90% of power depended on the assay performed; 5 mice were required for flow 
cytometry, qRT-PCR and ELISA experiments, 10 mice were required for 
metabolic assessments by GTT and ITT. 
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2.13 Statistical analysis 
Statistical significance was determined by Student’s two-tailed t-test with p values 
of 0.05 or less. For qRT-PCR, Student’s t-test established statistical significance 
from normally distributed ΔCT data values, although data is represented in ΔΔCT 
format. For GTT, ITT and paired insulin measurements, statistical significance 
was evaluated with 2-way ANOVA followed by Bonferroni post-test. Data were 
analysed and charts were generated using Prism 7. Significant differences were 
denoted as *p<0.05, **p<0.01, ***p<0.001 and n.s. not significant.  
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 Constitutive β-catenin pathway 
activation in conventional Dendritic 






The presence of the MHCII+ CD11c+ DC population in VAT has previously been 
reported, however a distinct role of cDCs in the tissue has yet to be fully defined. 
Collectively studies have suggested that MHCII+ CD11c+ DCs adopt an activated 
pro-inflammatory state in obesity (133) (134) (135). Interestingly, ablating all 
CD11c+ cells attenuates VAT inflammation and promotes the recovery of glucose 
homeostasis in obese mice (132). However CD11c is expressed on various 
myeloid cells including tissue infiltrated macrophages and monocytes. Therefore 
with this phenotypic overlap the distinct contribution of cDCs in VAT inflammation 
has been poorly understood. Furthermore, there is limited understanding about 
the role of cDCs in tissue homeostasis in steady-state conditions. It has been 
suggested that AT-cDCs participate in antigen sampling to modulate immune 
responses and have the potential to control adipogenesis and lipogenesis of 
adipocytes through direct or indirect mechanisms, although this is yet to be clearly 
established (138) (136) (152). Although these initial findings indicate that cDCs 
are important in maintaining VAT function, the mechanisms regulating this 
process have yet to been identified in cDCs. 
 
The Wnt/β-catenin pathway has emerged as an important regulator of 
adipogenesis and insulin sensitivity (65) (176) (177). Recent studies have shown 
a further link of Wnt/β-catenin pathway with the regulation of inflammation, 
particularly in cDCs where activation of the pathway is important for immune 
tolerance (185) (178). However it has yet to be examined if this dependence on 
Wnt/β-catenin for tolerogenic signalling is tissue specific. Interestingly, 
transcriptome data indicates that the Wnt/β-catenin is upregulated in cDC1 
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subset present in VAT. Transcriptome raw data files are publicly available at 
http://www.immgen.org/ GEO: GSE37448. Thus we hypothesised that Wnt/β-
catenin pathway in cDCs would play role in maintaining VAT homeostasis. 
Additionally during obesity, the levels of Wnt10b are known to be supressed 
implying that the activity of the Wnt/β-catenin pathway may be impaired in obese 
VAT (65). Consequently we further proposed that sustaining Wnt/β-catenin 
pathway activation in VAT-cDCs could ameliorate the development of obesity-
induced tissue inflammation and revert the associated insulin resistance (IR). 
 
In this chapter the role of Wnt/β-catenin signalling in cDCs is investigated to 
explore the effect on cDC phenotype, immune responses and implications on 
VAT metabolism during tissue homeostasis and in diet-induced tissue 
inflammation. Furthermore systemic effects on whole-body glucose homeostasis 





3.2.1 cDCs are present in VAT in close proximity to vessels 
 
Overlap of cell surface marker expression has hindered the study of cDCs in VAT. 
Although high expression of MHCII and CD11c defines the cDC population, 
CD11c has also been used to identify inflammatory ATMs (132) thus this 
promiscuous expression in myeloid cells has rendered the role of VAT-cDCs 
elusive. To understand the distinct contribution of cDCs in vivo, new reporter mice 
have recently been generated based on the expression of the highly cDC-specific 
Zbtb46 promoter (191). Zbtb46 is a transcription factor which is selectively 
expressed by cDCs and their committed progenitors, but not expressed in pDCs 
or other myeloid lineages (192). Zbtb46GFP and Zbtb46-Cre mice have been used 
to characterise the role of VAT-cDCs in homeostatic conditions and explore the 
mechanisms that control their immune function (193). 
 
Mesenteric VAT and vessels from Zbtb46GFP mice were imaged by ex vivo 
confocal microscopy, showing the close proximity of GFP+ cDCs to PECAM-1+ 
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capillary vessels and LYVE-1+ initial lymphatic vessel in VAT (Figure 3.1A). This 
strategic location is consistent with a proposed role of cDCs to sample antigens 
in VAT (138). Kuan et al. observed that collecting lymphatic vessels had an 
inherent permeability and that cDCs in the surrounding VAT are closely 
associated with these vessels in order to uptake soluble antigens released from 
the lymph. These findings support a role for VAT-cDCs for the immune 
surveillance of neighbouring tissue in homeostatic conditions. 
 
3.2.2 The Wnt/β-catenin pathway is upregulated in VAT-
cDC1 
 
cDCs are present in two main subsets in VAT, cDC1 (CD103+) and cDC2 
(CD11b+), which vary in function, transcriptome profile and lineage markers 
(118). Following gene set enrichment pathway analysis (GSEA) it was observed 
that these populations selectively upregulate distinct adipocyte-specific pathways 
in VAT, specifically Wnt/β-catenin pathway in cDC1 and PPARγ pathway in cDC2 
(193). The protein expression of active β-catenin was increased in Zbtb46GFP+ 
sorted VAT-cDC1, while higher levels of PPARγ expression was observed in 
Zbtb46GFP+ sorted VAT-cDC2 population (Figure 3.1B). PPARγ is known to 
regulate lipid accumulation during hypertrophy controlling adipocyte expansion, 
while the Wnt/β-catenin pathway controls adipocyte hyperplasia (58) (64). Thus, 
the upregulation of these pathways in cDCs is proposed in order to “sense” 
changes in tissue homeostasis.  
 
To investigate if, similar to other tissues, activation of the Wnt/β-catenin pathway 
in cDC1 is important for controlling inflammation, cell-sorted cDC1 isolated from 
spleen and VAT of Zbtb46GFP mice were incubated overnight with TLR4 agonist 
Glucopyranosyl Lipid A (GLA) in the presence of Wnt/β-catenin pathway agonist 
SB216763 (SB) (194). Activation of the pathway in cDC1 population suppressed 
TLR4-induced inflammatory responses, demonstrated by the significant 
reduction of pro-inflammatory IL-6 release and significant increase in production 
of anti-inflammatory IL-10 (Figure 3.1C&D). This effect was observed in cDC1 
from VAT, but not spleen. Therefore in steady-state, this data supports the 
hypothesis that activation of the β-catenin pathway in cDC1 sustains a 
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tolerogenic phenotype in VAT, inhibiting local inflammation and contributing to 
the maintenance of tissue immune-homeostasis. 
 
Figure 3.1 VAT-cDCs acquire a tolerogenic phenotype to suppress inflammation 
(A) Mesenteric VAT and vessels from Zbtb46GFP mice were imaged by ex vivo confocal 
microscopy and visualized using a Leica SP8 confocal microscope. GFP+ cDCs (green) 
located in close proximity (black arrows) to PECAM-1+ capillary vessels (blue) in VAT 
(left and central image) but also close to mesenteric afferent lymphatics (LV, middle 
picture) and LYVE-1+ initial lymphatic vessels (red) near the gut (right image). (B) cDC1 
and cDC2 populations were sorted from VAT of Zbtb46GFP mice. Expression of active β-
catenin and PPARγ was detected by western blot, shown as a representative of three 
independent experiments. (C) cDC1 cells sorted from VAT and spleen of Zbtb46GFP mice, 
were incubated overnight with 5 µg TLR4 agonist GLA  with or without 20 µM β-catenin 
pathway agonist (SB). Levels of IL-6 (C) and IL-10 (D) in the supernatant were measured 
by ELISA. Bars represent the mean ± SEM and graphs shown are representative of three 
independent experiments (n=9). Statistical significance was determined by Student’s 
two-tailed t-test, results not significant unless otherwise denoted as *p<0.05, **p<0.01, 
***p<0.001,  
 
3.2.3 Wnt/β-catenin pathway in VAT-cDC1 controls tissue 
inflammation in vivo 
 
To assess the role of Wnt/β-catenin pathway in cDC1 in vivo, floxed β-catenin 
Ctnnb1Fl/Fl mice were crossed with transgenic Zbtb46-Cre mice to generate a 
knockdown model. Unexpectedly, β-catenin deletion was lethal due to Zbtb46 off-
target expression in non-hematopoietic cells. To bypass this issue, chimeric mice 
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were generated using fetal liver cells from conditional cDC-specific β-catenin 
knockdown mice or littermate control mice, hence forth referred to as β-catenin 
knockdown mice or WT control mice respectively (Figure 2.1). Thus, in this model 
only cDCs express Zbtb46 and therefore β-catenin was only knocked down in 
cDCs. To understand the effect on VAT immune homeostasis, mRNA expression 
in VAT from β-catenin knockdown mice and WT control mice was measured by 
qRT-PCR. In steady state conditions where mice were fed normal chow diet (ND) 
and in the absence of tissue inflammation, the levels of IL-10 were significantly 
decreased in β-catenin knockdown mice compared to the WT (Figure 3.2A). This 
suggests that deletion of β-catenin in cDCs decreases anti-inflammatory 
phenotype in homeostatic conditions, supporting previous data that β-catenin 
prevents the onset of inflammation through IL-10 production. Interestingly, IL-10 
is known to supress cDC maturation (195).  
 
The association between obesity and low-grade chronic inflammation has been 
well described. Inflammatory responses in VAT are known to play a causal role 
in obesity-induced IR (35). To understand the effect the β-catenin in cDCs in the 
control of obesity-induced VAT inflammation, β-catenin knockdown mice and WT 
control mice were fed western diet (WD) for 12 weeks. WD is formulated to 
represent typical Western nutrition, including increased levels of cholesterol, 
saturated fats, salt and sugar (Table 2.1). This enables the translation of mouse 
models for diet-induced obesity research. qRT-PCR analysis of VAT from mice 
fed WD, demonstrated a significant decrease in IL-10 mRNA levels in β-catenin 
knockdown mice compared to WT mice (Figure 3.2B). This was accompanied by 
a significant increase in the T cell chemoattractant CCL17 production, reduction 
in IFNγ and a switch to IL-17A T cell responses in VAT of β-catenin knockdown 
mice. This suggests that cDC-specific deletion of β-catenin alters T cell 
responses in VAT, which is associated with increased inflammation. Furthermore 
levels of the pro-inflammatory cytokine IL-6 was increased in line with previous 
data, suggesting that β-catenin pathway activation in cDCs is important for 
delaying the onset of pro-inflammatory responses in obesity. In addition, the 
mRNA expression of adiponectin, which is expressed by adipocytes, was 
significantly reduced, indicating some degree of adipocyte dysfunction in VAT of 
β-catenin knockdown mice. These findings were replicated in the mRNA analysis 
of the stromal vascular fraction (SVF), the compartment of VAT where immune 
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cells reside (Figure 3.2C). These observations strongly support that β-catenin 
abrogation in cDC population exacerbates obesity-induced VAT inflammation. 
  
 
Figure 3.2 Deletion of β-catenin in cDCs modulates the inflammatory state of VAT 
qRT-PCR analysis for the mRNA expression in VAT of β-catenin knockdown and WT 
mice fed ND (A) or 12 weeks of WD (B). Similarly mRNA expression was analysed in 
SVF of β-catenin knockdown and WT mice fed 12 weeks of WD (C). Expression levels 
of all mRNA were normalised to GAPDH expression. Bars represent ΔΔCT data values, 
the expression in β-catenin knockdown mice compared to WT, set at 1 indicated by the 
dotted line. Error bars show the geometric mean of ten biological replicates for VAT and 
five for SVF. Statistical significance of ΔCT data values was determined by Student’s 
two-tailed t-test, results not significant unless otherwise denoted as *p<0.05, **p<0.01, 
***p<0.001. 
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3.2.4 Impaired Wnt/β-catenin pathway in cDC1 in obese VAT 
 
A single nucleotide polymorphism in the human Wnt10b gene has been 
associated with early-onset familial obesity (196). During obesity it is proposed 
that Wnt ligand availability diminishes in VAT, specifically Wnt10b levels are 
suppressed in obesity, which inhibits preadipocyte differentiation enabling 
adipocyte hyperplasia  (65). Significant reduction of Wnt10b was confirmed at the 
transcriptional level in VAT from mice fed WD (Figure 3.3A). This suggests that 
the activity of the Wnt/β-catenin pathway could be impaired in cDC1, in part 
contributing to the development of VAT inflammation after long-term chronic 
nutrition. Indeed, reduced active β-catenin protein expression was observed in 
Zbtb46GFP+ sorted VAT-cDC1 from WD compared to ND fed mice (Figure 3.3B). 
This was not due to a defective pathway, as VAT-cDC1 were still able to respond 
to β-catenin pathway agonist SB when cultured ex vivo, albeit at lower levels 
reflecting the activated-state of cDCs in VAT. A significant reduction of IL-6 and 
increase in IL-10 levels were measured from the supernatants of incubated VAT-
cDC1 (Figure 3.3C&D). Hence during obesity, activation of the β-catenin pathway 
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Figure 3.3 Chronic over-nutrition reduces Wnt/β-catenin pathway activation in 
VAT-cDCs 
Zbtb46GFP mice were fed ND or WD for 12 weeks. (A) qRT-PCR analysis for the mRNA 
expression of Wnt ligands in VAT of mice fed ND compared to WD. Expression levels of 
all mRNA were normalised to GAPDH expression. Bars represent ΔΔCT data values, 
the expression in WD fed mice compared to mice fed ND, set at 1 indicated by the dotted 
line. Error bars show the geometric mean of five biological replicates. Statistical 
significance of ΔCT data values was determined by Student’s two-tailed t-test, results 
not significant unless otherwise denoted as *p<0.05, **p<0.01, ***p<0.001. (B) cDC1 
cells were sorted from VAT of Zbtb46GFP mice fed ND or WD. Expression of active β-
catenin was detected by western blot, shown as a representative of three independent 
experiments. (C) cDC sorted from VAT and spleen of Zbtb46GFP mice fed ND or WD, 
were incubated overnight with 5 µg TLR4 agonist GLA with or without 20 µM β-catenin 
pathway agonist (SB) or DMSO control (Unstim). Levels of IL-6 (C) and IL-10 (D) in the 
supernatant were measured by ELISA. Bars represent the mean ± SEM and graphs 
shown are representative of three independent experiments (n=9). Statistical 
significance was determined by Student’s two-tailed t-test, results not significant unless 
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3.2.5 Generation of a mouse model with constitutive 
activation of the β-catenin pathway in cDCs 
 
The previous data suggests that sustained activation of β-catenin signalling in 
cDCs could ameliorate the development of tissue inflammation and IR during 
obesity. To investigate this, a mouse model was generated with constitutive 
expression of degradable resistant form of active β-catenin (Ctnnb1lox(ex3)/+) (187) 
in the cDCs (Zbtb46-Cre+) (191). Zbtb46-Cre/+ mice were crossed with 
Ctnnb1lox(ex3)/+ mice, where Lox/Cre-dependent deletion of exon 3 prevents the 
phosphorylation and degradation of β-catenin, rendering the Wnt/β-catenin 
pathway constitutively active. Due to expression of Zbtb46 in non-hematopoietic 
cells, mice died between 3-4 weeks of birth. Thus bone marrow chimeras were 
generated, where bone marrow cells from Ctnnb1lox(ex3)/+ Zbtb46-Cre/+ (gain-of-
function, GOF) or littermate controls Ctnnb1lox(ex3)/+ Zbtb46+/+ (wild type, WT) were 
transferred into irradiated C57BL/6 recipient mice, hence forth referred to as GOF 
mice or WT mice respectively (Figure 2.2). In the GOF mice, only cDCs express 
Zbtb46 and hence specifically express constitutively active β-catenin. Increased 
expression of β-catenin in cDCs was confirmed in VAT and bone marrow of the 
GOF mice by western blot and densitometry analysis (Figure 3.4A&B). 
 
 
Figure 3.4 Overexpression of β-catenin in the GOF model 
CD11c+ DCs were isolated from VAT (A) and from Flt3L-bone marrow cultures (B) of WT 
and GOF mice. Expression of β-catenin was detected by western blot, shown as a 
representative of three independent experiments. Expression of β-catenin was 
normalised to β-actin expression by densitometry analysis, mean ± SEM (n=3). 
Statistical significance was determined by Student’s two-tailed t-test, results not 
significant. 
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3.2.6 Constitutive β-catenin activation in cDCs modulates 
the immune phenotype in homeostatic conditions   
 
Activation of β-catenin signalling has emerged as a mechanism for inducing 
tolerogenic DCs. To understand the effects of constitutive β-catenin activation in 
cDCs in homeostatic conditions, chimeric GOF and WT control mice were fed 
ND. Both groups of mice increased in body weight at the same rate over time 
(Figure 3.5A). Similarly, there was no difference observed in total (Figure 3.5B) 
or percentage (Figure 3.5C) of VAT weight between GOF and WT mice fed ND. 
Constitutive activation of β-catenin in cDCs does not impact body and VAT weight 
in steady state, which is not surprising as VAT inflammation would be minimal 
and locally restrained by the resident anti-inflammatory immune network. 
 
 
Figure 3.5 Body and VAT weight measures in the GOF model in homeostatic 
conditions 
GOF and WT mice were fed ND. (A) Body weight was measured over the duration of 10 
weeks, mean ± SEM (n=6/7). (B) Total VAT from GOF and WT mice was harvested and 
weighed, mean ± SEM (n=6/7). (C) VAT content was calculated as percentage of body 
weight, mean ± SEM (n=6/7). Statistical significance was determined by Student’s two-
tailed t-test, results not significant. 
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To examine the impact of constitutive β-catenin activation in cDCs on the steady 
state immune phenotype, flow cytometry staining was used to quantify immune 
cell numbers in the VAT, spleen, mesenteric draining lymph nodes and inguinal 
non-draining lymph nodes of GOF and WT mice. The gating strategy detailed 
previously was used to analyse the immune populations (Figure 2.4). In addition, 
the mRNA expression of cytokines, chemokines and adipokines were measured 
in VAT and SVF by qRT-PCR.  
 
The spleen is an important lymphoid organ, it is the site for the initiation of the 
immune responses by lymphocytes in response to DCs presenting antigens 
found circulating in the blood. By measuring immune populations in the spleen 
this provides an understanding of systemic immune health of the whole organism. 
Furthermore a caveat of the GOF model is that constitutively active β-catenin in 
cDCs is expressed systemically, not exclusively in VAT where it was initially 
observed to maintain tissue inflammation. Similar systemic effects would be 
observed during therapeutic drug treatments. Constitutive activation of β-catenin 
in cDCs induced a significant increase in total number of NK cells and a decrease 
in total macrophage numbers, albeit not significant, in the spleen (Figure 3.6A). 
Interestingly the ratio of T reg cells in CD4+ T cell population was significantly 
increased in the GOF mice compared to WT mice, implicating a wider change in 
T reg cell homeostasis (Figure 3.6A). However, there were no changes in the 
cytokine expression of CD4+ T cell population, indicative of helper T cell subsets, 
nor in the production of T cell chemoattractant CCL17 from cDCs ex vivo between 
the GOF and WT mice in steady state (Figure 3.6B&C). The production of IL-6 
from splenic cDCs cultured ex vivo was decreased and the levels of IL-10 
secreted were marginally elevated in the GOF mice indicating a potential 
tolerogenic phenotype of cDC, although these observations were not significant 
(Figure 3.6D&E). The numbers of immune populations in the mesenteric draining 
lymph nodes and inguinal lymph nodes were not significantly altered between the 
GOF and WT mice in steady state (Figure 3.7 & Figure 3.8).  
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Figure 3.6 Immune phenotype in the spleen of the GOF model in homeostatic 
conditions 
Spleens from GOF and WT mice fed ND, were digested. (A) Total numbers of immune 
populations in the spleen were quantified by flow cytometry, mean  SEM (n=4). (B) 
Percentage of IFNγ, IL-17A, TNFα -expressing CD4+ T cells were quantified by flow 
cytometry, mean  SEM (n=5). CD11c+ DCs were isolated from the spleen of GOF and 
WT mice and cultured overnight. (C) CCL17, (D) IL-6 and (E) IL-10 were measured in 
supernatant by ELISA, mean  SEM (n=3). Statistical significance was determined by 
Student’s two-tailed t-test, results not significant unless otherwise denoted as *p<0.05.  
 
A 
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Figure 3.7 Immune phenotype in the draining lymph nodes of the GOF model in 
homeostatic conditions 
Mesenteric draining lymph nodes from GOF and WT mice fed ND, were digested. (A) 
Total numbers of immune populations in the draining lymph nodes were quantified by 
flow cytometry, mean  SEM (n=3). (B) Percentage of IFNγ, IL-17A, TNFα -expressing 
CD4+ T cells were quantified by flow cytometry, mean  SEM (n=3). Statistical 
significance was determined by Student’s two-tailed t-test, results not significant. 
 
A 
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Figure 3.8 Immune phenotype in the non-draining lymph nodes of the GOF model 
in homeostatic conditions 
Inguinal non-draining lymph nodes from GOF and WT mice fed ND, were digested. (A) 
Total numbers of immune populations in the non-draining lymph nodes were quantified 
by flow cytometry, mean  SEM (n=4). (B) Percentage of IFNγ, IL-17A, TNFα -expressing 
CD4+ T cells were quantified by flow cytometry, mean  SEM (n=3). Statistical 
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Interestingly there is a suggestion that constitutive β-catenin activation in cDCs 
modulates the T cell composition in VAT during homeostatic conditions. The total 
numbers of CD4+ T cells and T reg cells were significantly increased in GOF mice 
compared to WT, despite no difference in the ratio (Figure 3.9A-C). Furthermore, 
in the GOF mice there was a significant decrease in T cell chemoattractant 
CCL17 production in VAT and increase in FOXP3 expression in SVF, as 
measured by qRT-PCR analysis (Figure 3.9D&E). The chemokine CCL17 is 
known to recruit CCR4+ inflammatory T cells and restrict the recruitment of T reg 
cells (197) (198) (199). This suggests an altered recruitment of T cell populations 
in VAT of GOF mice at steady state. In addition mRNA levels of IL-17A, but not 
IFNγ, were also significantly increased in the SVF of GOF mice (Figure 3.9E), 
which has been recently linked with the accumulation of T reg cells in AT by 
tissue-resident population of γ T cells (200). Overall these findings suggest that 
constitutive β-catenin activation in cDCs enables a T cell driven 
immunosuppressive phenotype in VAT in homeostatic conditions. 
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Figure 3.9 Immune phenotype in the VAT of the GOF model in homeostatic 
conditions 
VAT was digested from GOF and WT mice fed ND. (A) Total numbers of immune 
populations in the VAT were quantified by flow cytometry, mean  SEM (n=4). 
Representative dot plots of CD3+ T cell population with gates on CD8+ and CD4+ T cells 
(B) and T reg cells (C), from VAT of GOF and WT mice. Statistical significance was 
determined by Student’s two-tailed t-test, results not significant unless otherwise 
denoted as *p<0.05. qRT-PCR analysis for mRNA expression in VAT (D) and SVF (E) 
of GOF and WT mice. Expression levels of all mRNA were normalised to GAPDH 
expression. Bars represent ΔΔCT data values, the expression in GOF mice compared 
to WT, set at 1 indicated by the dotted line. Error bars show the geometric mean of six 
biological replicates. Statistical significance of ΔCT data values was determined by 
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3.2.7 Constitutive β-catenin activation in cDCs modulates 
the immune phenotype in Western diet-induced tissue 
inflammation   
 
To investigate the hypothesis that constitutive β-catenin pathway activation in 
cDCs could revert the development of tissue inflammation during obesity, GOF 
and WT mice were fed WD for 16 weeks. WD induces chronic inflammation in 
VAT and enables translation of mouse models for diet-induced obesity research. 
Body weight of both groups of mice increased at the same rate over time (Figure 
3.10A). The VAT harvested from mice fed 16 weeks of WD demonstrated no 
difference in weight between the GOF and WT (Figure 3.10B), additionally this 




Figure 3.10 Body and VAT weight measure of the GOF model in inflammation 
GOF and WT mice were fed WD. (A) Body weight was measured over the duration of 16 
weeks, mean ± SEM (n=8). (B) Total VAT from GOF and WT mice was harvested and 
weighed, mean ± SEM (n=8). (C) VAT content was calculated as percentage of body 
weight, mean ± SEM (n=8). Statistical significance was determined by Student’s two-
tailed t-test, results not significant.  
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To assess the effect of constitutive β-catenin activation in cDCs on the immune 
phenotype during inflammation, the mRNA expression of cytokines, chemokines 
and adipokines were measured in VAT and SVF by qRT-PCR. During obesity, a 
shift in CD4+ T cell subsets has been well described, with the expansion of 
activated Th1, Th17 populations and a reduction of Th2 cells and T reg cells 
(201). The expression of FOXP3 was significantly increased in the SVF of GOF 
mice, as measured by qRT-PCR analysis (Figure 3.11A) indicating a greater T 
reg population. This was accompanied by a significant decrease in the T cell 
chemoattractant CCL17 production in VAT of GOF mice (Figure 3.11B). 
Interestingly, cDC-derived CCL17 has been shown to promote tissue 
inflammation by restricting T reg cell recruitment (198). A significant reduction in 
IFNγ mRNA expression in VAT of GOF mice further confirmed a modulation of 
VAT-T cell responses by constitutive β-catenin activation in cDCs (Figure 3.11B). 
In the GOF model, an immunosuppressive environment in the tissue is clearly 
induced as evidenced by the significant increase in IL-10 and adiponectin 
expression in the SVF and VAT of the GOF mice respectively (Figure 3.11A&B). 
These results echo the observations in steady state that constitutive β-catenin 
activation in cDCs promotes a trend towards a T cell driven immunosuppressive 
phenotype, to restore the anti-inflammatory immune network in VAT in GOF mice. 
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Figure 3.11 mRNA expression in the VAT of the GOF model in inflammation  
VAT was digested from GOF and WT mice fed 16 weeks of WD, to induce chronic low-
grade tissue inflammation. qRT-PCR analysis for mRNA expression in SVF (A) and VAT 
(B) of GOF and WT mice. Expression levels of all mRNA were normalised to GAPDH 
expression. Bars represent ΔΔCT data values, the expression in GOF mice compared 
to WT, set at 1 indicated by the dotted line. Error bars show the geometric mean of six 
biological replicates. Statistical significance of ΔCT data values was determined by 
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The previous data indicates at the mRNA level the T cell phenotype is modulated 
in the GOF model. Immune cell populations in the VAT, spleen, mesenteric 
draining lymph nodes, inguinal non-draining lymph nodes and blood of GOF and 
WT mice, were analysed by flow cytometry staining. The gating strategy detailed 
previously was used to analyse the immune populations (Figure 2.4). In VAT, 
there is a suggestion that cDCs with constitutively activated β-catenin drives a T 
cell driven immunosuppressive phenotype. The ratio of T reg cells in the CD4+ T 
cell population showed a trend towards an increase in the GOF mice compared 
to the WT, although there were no significant changes in the abundance of CD4+ 
T cells or T reg cells (Figure 3.12A). Trends towards an increase in naïve T cell 
population and decrease in the percentage of IFNγ, IL-17A, TNFα -expressing 
CD4+ T cells were also observed in the GOF mice compared to WT (Figure 
3.12A&B). Furthermore, there was a suggestion that the population of central 
memory T cells was increased in VAT of the GOF mice (Figure 3.12A). In fact 
this population may simply be maintained in the GOF model, as it has recently 
been reported that VAT harbours a large population of memory T cells with long-
term protective functions during homeostasis (106). While in VAT of WT mice the 
numbers of memory T cells may potentially decrease during the development of 
tissue inflammation. Modulation of the innate immune populations were also 
observed in VAT of the GOF mice. Constitutive activation of β-catenin in cDCs 
reduced the infiltration of macrophages, neutrophils and monocytes, albeit not 
significantly (Figure 3.12A). Interestingly there was a trend towards an increase 
of total numbers of the cDC1 population in VAT of GOF mice, despite no 
differences in total numbers of cDCs or the cDC2 population (Figure 3.12A). 
These observations were in concordance with previous models of constitutive 
expression of active β-catenin in CD11c+ populations, where β-catenin has 
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Figure 3.12 Immune phenotype of the VAT in the GOF model in inflammation 
VAT was digested from GOF and WT mice fed 16 weeks of WD, to induce chronic low-
grade tissue inflammation. (A) Total numbers of immune populations in the VAT were 
quantified by flow cytometry, mean  SEM (n=4). (B) Percentage of IFNγ, IL-17A, TNFα 
-expressing CD4+ T cells were quantified by flow cytometry, mean  SEM (n=5). 
Statistical significance was determined by Student’s two-tailed t-test, results not 
significant. 
A 
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The spleen of GOF mice fed WD reflected similar modulations of immune cell 
populations as observed in VAT. Total numbers of neutrophils were significantly 
reduced, indicating a decrease in systemic inflammation in the GOF mice (Figure 
3.13A&C). A significant increase in the total number of cDC1 cells was observed 
in the spleen of GOF mice (Figure 3.13A&B), confirming previous observations 
in similar models (202). In addition the splenic T reg population was significantly 
expanded in the GOF mice compared to WT (Figure 3.13A&D). Although there 
was no difference in the ratio of T reg cells in the CD4+ T cell population between 
GOF and WT mice, nor in the abundance of other T cell populations (Figure 
3.13A&B). Interestingly, the production of IL-12 from splenic DCs derived from 
GOF mice was significantly decreased, in the presence or absence of LPS 
indicating that constitutive activation of β-catenin in cDCs promotes a potential 
tolerogenic responses upon an inflammatory challenge (Figure 3.13F).  
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Figure 3.13 Immune phenotype of the spleen in the GOF model in inflammation 
Spleen from GOF and WT mice fed WD, were digested. (A) Total numbers of immune 
populations in the spleen were quantified by flow cytometry, mean  SEM (n=4). 
Representative dot plots of cDC populations (B), Ly6G+ neutrophils (C), and T reg cells 
(D) from the spleen of GOF and WT mice. (E) Percentage of IFNγ, IL-17A, TNFα -
expressing CD4+ T cells were quantified by flow cytometry, mean  SEM (n=6). (F) 
CD11c+ DCs were isolated from the spleen of GOF and WT mice and cultured overnight 
with and without 1 g/ml LPS. Levels of IL-12 were measured in supernatant by ELISA, 
mean  SEM (n=3). Statistical significance was determined by Student’s two-tailed t-test, 
results not significant unless otherwise denoted as *p<0.05, **p<0.01.  
 
A+ 
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Lymphatic vessels in VAT drain into the mesenteric lymph nodes, with the primary 
function to filter lymph collected from the tissue. Antigens collected by cDCs or 
other antigen presenting cells, initiate adaptive immune responses in the lymph 
nodes. It has been shown during obesity, CLVs encased in VAT are remodelled 
and develop increased permeability which exacerbates tissue inflammation due 
to antigen infiltration in VAT (138). Thus, investigating the immune cell 
populations of the draining lymph nodes and control non-draining lymph nodes, 
was important to understand the immune responses instigated during the onset 
of tissue inflammation. The abundance and ratio of T reg cells in the CD4+ T cell 
population of the mesenteric lymph node were significantly increased in the GOF 
mice fed WD compared to WT mice (Figure 3.14A-C). A trend towards a decrease 
in the percentage of IFNγ -expressing CD4+ T cells was observed between the 
GOF and WT mice, although this was not significant (Figure 3.14D). These 
findings reflect the changes observed in VAT of GOF mice. The numbers of 
immune populations in the inguinal non-draining lymph nodes were not 
significantly altered between the GOF and WT mice during inflammation (Figure 
3.15A & B). 
 
Immune cells originate from the bone marrow and circulate and mature in the 
blood, before migrating to peripheral tissues. Analysing immune populations in 
the blood indicates the systemic modulation of immune responses and 
inflammatory state. Interestingly, there was a significant decrease in total number 
of CD45+ leukocytes, CD3+ and CD8+ T cell populations and neutrophils in the 
blood of the GOF mice fed WD compared to WT (Figure 3.16A-C), indicating a 
reduction in systemic inflammation by constitutive β-catenin activation in cDCs.  
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Figure 3.14 Immune phenotype of the draining lymph nodes in the GOF model in 
inflammation 
Mesenteric draining lymph nodes from GOF and WT mice fed WD, were digested. (A) 
Total numbers of immune populations in the draining lymph nodes were quantified by 
flow cytometry, mean  SEM (n=4). Representative dot plots of CD3+ T cell population 
with gates on CD8+ and CD4+ T cells (B) and T reg cells (C), from draining lymph nodes 
of GOF and WT mice. (D) Percentage of IFNγ, IL-17A, TNFα -expressing CD4+ T cells 
were quantified by flow cytometry, mean  SEM (n=4). Statistical significance was 
determined by Student’s two-tailed t-test, results not significant unless otherwise 
denoted as *p<0.05, **p<0.01.  
 
A 
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Figure 3.15 Immune phenotype of the non-draining lymph nodes in the GOF 
model in inflammation 
Inguinal non-draining lymph nodes from GOF and WT mice fed ND, were digested. (A) 
Total numbers of immune populations in the non-draining lymph nodes were quantified 
by flow cytometry, mean  SEM (n=4). (B) Percentage of IFNγ, IL-17A, TNFα -expressing 
CD4+ T cells were quantified by flow cytometry, mean  SEM (n=3). Statistical 
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Figure 3.16 Immune phenotype of the blood in the GOF model in inflammation 
(A) Total numbers of immune populations in the blood were quantified by flow cytometry, 
mean  SEM (n=4). Representative dot plots of Ly6G+ neutrophils (B) and CD3+ T cell 
population with gates on CD8+ and CD4+ T cells (C) from the blood of GOF and WT mice. 
Statistical significance was determined by Student’s two-tailed t-test, results not 
significant unless otherwise denoted as *p<0.05, **p<0.01. 
 
 
3.2.8 VAT-cDCs function and phenotype are modulated by 
constitutive β-catenin activation 
 
cDCs orchestrate the immune system, with a central role in initiating T cell 
immune responses. The maturation state of cDCs further shapes the T cell 
response. We proposed previously that cDCs in VAT of the GOF mice have a 
less activated phenotype, through the reduction in pro-inflammatory cytokine 
production. Thus, the antigen presenting capacity of cDCs was measured ex vivo 
with mixed leukocyte reactions (MLR) and in vivo with ovalbumin (OVA) 
immunisation. The ability of cDCs to initiate CD4+ T cell responses, was directly 
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assessed by analysing CD4+ T cell proliferation. In these assays CD4+ T cells 
were labelled with CFSE, a stable fluorescent cell dye which covalently binds to 
intracellular lysine residues. The CFSE signal dilutes during cell division, enabling 
easy tracking of cell proliferation. MLR use allogenic populations to initiate 
mismatch polyclonal T cell responses, while OT-II CD4+ T cells, which express 
transgenic OVA-specific αβ-TCRs, were utilised to observe antigen specific T cell 
activation after OVA immunisation.  
 
As expected, VAT-cDCs purified from GOF mice fed WD showed a decreased 
allo-stimulatory capacity indicated by a reduction in CFSE dilution, thus 
decreased CD4+ T cell proliferation (Figure 3.17A&B). This difference was not 
observed between spleen cDCs from GOF and WT mice (Figure 3.17A&B). 
Cytokines measured from the harvested supernatant of the MLR cultures, 
indicate a modulation in the CD4+ T cell helper subsets activated by the cDCs. 
IFNγ, produced by Th1 cells was significantly decreased and IL-4, produced by 
Th2 cells was significantly increased in the MLR cultures of VAT-cDCs from the 
GOF mice compared to the WT (Figure 3.17C). There was no difference in IL-
17A, produced by Th17 cells. This confirms the previous results that constitutive 
β-catenin activation in cDCs promotes an altered T cell phenotype in vivo, with 
moderate decreases in IFNγ, but not IL-17A. Furthermore, VAT-cDCs displayed 
reduced antigen specific T cell activation in vivo in response to OVA 
immunisation, shown by a decrease in CFSE dilution of OT-II CD4+ TCR Vα2+ 
cells (Figure 3.17D&E). This difference was not observed in the spleen (Figure 
3.17D&E). These findings suggest VAT-cDCs in GOF mice exhibit reduced 
antigen-presenting capacity, suggesting a less immunogenic phenotype and 
improved tolerogenic responses. 
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Figure 3.17 Decreased antigen presenting capacity of VAT-DC in the GOF model 
in inflammation 
(A) Ex vivo antigen presentation capacity of cDCs from VAT and spleen of WT and GOF 
mice were evaluated by mixed leukocyte reaction (MLR). CD4+ T cell proliferation was 
assessed by CFSE dilution. Histogram and dot plots were gated on the CD4+ T cell 
population and are representative of three independent experiments. (B) Percentage of 
proliferated CD4+ T cells in MLR cultures with cDCs from VAT and spleen of WT and 
GOF mice, mean  SEM (n=3). (C) Levels of IFNγ, IL-17A and IL-4 secreted from MLR 
cultures, were measured in the supernatant by ELISA, mean  SEM (n=6). (D) For in 
vivo antigen presentation, CFSE labelled OT-II cells were transferred intravenously 1 
day before immunisation with 200 μg OVA intraperitoneally. Three days later, cell 
division of proliferating OT-II T cells were analysed in VAT and spleen from GOF and 
WT mice by flow cytometry. CFSE dilution was analysed on gated CD45+ CD3+ CD4+ 
TCR Vα2+ cells. Histogram and dot plots are representative of three independent 
experiments. (E) Percentage of proliferated CD4+ TCR Vα2+ cells from VAT and spleen 
of immunised WT and GOF mice, mean  SEM (n=3). Statistical significance was 
determined by Student’s two-tailed t-test, results not significant unless otherwise 
denoted as *p<0.05.  
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To further assess the VAT-cDC phenotype, cell surface activation markers and 
production of cytokines were measured. Interestingly, the levels of secreted 
CCL17 from VAT-cDCs cultured ex vivo was significantly decreased in the GOF 
mice, while the levels of IL-6 and IL-10 only showed minimal changes (Figure 
3.18A-C). As CCL17 is associated with the recruitment of CCR4+ inflammatory T 
cell recruitment, this suggest that modulation of cDC activation and CCL17 
production by constitutive activation of β-catenin may not necessarily alter the 
total number of CD4+ T cells but may modulate the phenotype of the recruited 
CD4+ T cells. In response to inflammation, cDCs upregulate costimulatory 
molecules including CD40, CD80 and CD86 on their surface to enable antigen 
presentation. The VAT-cDC in vivo from GOF mice displayed a trend towards a 
decreased expression of CD40 compared to VAT-cDCs from WT mice (Figure 
3.18D). However, there was no overall significant differences in co-stimulatory 
molecules, as the expression of CD80 and CD86 remained unchanged. 
Combined, these findings suggest that constitutive activation of β-catenin 
improves tolerogenic responses of VAT-cDCs by influencing the T cell immune 
phenotype in diet-induced tissue inflammation.  
 
Figure 3.18 VAT-DC phenotype of the GOF model in inflammation 
VAT-DCs were isolated from GOF and WT mice fed 16 weeks of WD. CD11c+ DCs were 
isolated from VAT of GOF and WT mice and cultured overnight. (A) CCL17, (B) IL-6 and 
(C) IL-10 were measured in supernatant by ELISA, mean  SEM (n=4). (D) Percentage 
of CD40+, CD80+, CD86+ -expressing DCs were quantified by flow cytometry, mean  
SEM (n=3). Statistical significance was determined by Student’s two-tailed t-test, results 
not significant unless otherwise denoted as *p<0.05.  
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3.2.9 Constitutive β-catenin activation in cDCs modulates 
the systemic adiponectin levels in Western diet-
induced tissue inflammation   
 
Obesity is a prominent cause of metabolic dysfunction, including the 
dysregulation of systemic lipid metabolism. Excess energy is stored as TG in 
adipocytes and mobilised through lipolysis to be released as FFA when required. 
However during adipocyte dysfunction in obesity, levels of FFA and TG are 
increased in the plasma as lipid are redirected in the body. Despite a significant 
decrease in systemic levels of TNFα in the plasma of the GOF mice fed WD 
compared to WT, there was no difference in levels of FFA or TG measured in the 
plasma (Figure 3.19A-C). This implies that although constitutive β-catenin 
activation in cDC modulates the systemic inflammatory state, it has no 
observable effect on lipid regulation during tissue inflammation.  
 
Mature adipocytes secrete adipokines, such as leptin and adiponectin, to regulate 
tissue homeostasis and energy metabolism (76) (57). The dysregulation of 
adipokines has been recognised in obesity; excess adiposity and adipocyte 
dysfunction causes an increase in adipokine release, often which possess pro-
inflammatory properties (203). The systemic levels of leptin in the plasma of GOF 
and WT mice fed WD were not different (Figure 3.19D), in agreement with no 
change in mRNA expression of leptin measured by qRT-PCR in VAT (Figure 
3.11B). Adiponectin levels are important biomarkers for metabolic syndrome, low 
levels of adiponectin are inversely correlated with body mass index in patient 
populations (204). As previously reported, the concentration of adiponectin 
decreases during obesity, as observed in WT mice (Figure 3.19E) (205). 
However in concordance with increased mRNA levels in VAT (Figure 3.11B), the 
systemic plasma concentration of adiponectin was significantly increased in the 
GOF mice fed WD compared to WT (Figure 3.19E). 
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Figure 3.19 Metabolic measures of the GOF model in inflammation 
Plasma was harvested from the GOF and WT mice fed 16 weeks of WD. (A) TNFα was 
measured in the plasma collected from terminal cardiac bleed by ELISA, mean  SEM 
(n=7). Mice were fasted overnight and plasma was collected from tail bleeds. (B) Levels 
of free fatty acid and (C) triglycerides were quantified in the fasted plasma using 
commercial kits, mean  SEM (n=10). (D) Leptin was measured in the fasted plasma by 
ELISA, mean  SEM (n=8). (E) Adiponectin was measured in the fasted plasma by 
ELISA, from GOF and WT mice fed ND or WD, mean  SEM (n=10). Statistical 
significance was determined by Student’s two-tailed t-test, results not significant unless 
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The observed increase in adiponectin indicates an improved adipocyte function 
in VAT of the GOF mice fed WD. This can be the result of decreased adipocyte 
hypertrophy, which is known to occur during chronic over-nutrition. However, 
there was no difference in adipocyte size between the GOF and WT mice fed WD 
(Figure 3.20A&B). In addition, during metabolic overload adipocyte dysfunction 
results in ectopic fat deposits in the liver and other tissues. Fat deposition was 
observed in the liver of WD fed mice and visually appears not to be altered 
between the GOF and WT mice (Figure 3.20C), however further analysis and 
quantification would be required to determine if there was a difference. 
 
Figure 3.20 Tissue structure of the GOF model in inflammation 
(A) Representative images of H&E stained sections of adipose tissue from GOF and WT 
mice fed 16 weeks of WD. (B) Frequency distribution of adipocyte area in GOF and WT 
mice fed WD. Frequency of cell area is expressed in number of cells per area bin, from 
measurements using ImageJ Adiposoft software. Statistical significance was determined 
by Student’s two-tailed t-test, results not significant (C) Representative images of H&E 
stained sections of liver from GOF and WT mice fed WD.  
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3.2.10 Constitutive β-catenin activation in cDCs in High fat 
diet-induced tissue inflammation   
 
Majority of mouse models of obesity rely on high fat diet (HFD) to induce chronic 
tissue inflammation, which has further elevated levels of saturated fat, more than 
60% energy from fat compared to 40% in WD and no extra sugars (Table 2.1). 
Consequently, the inflammatory response in VAT from HFD fed mice is instigated 
predominately by tissue infiltrating inflammatory macrophages due to the 
increase in lipid content (86). Therefore, it was of interest to investigate if the 
effects of immune modulation by constitutive β-catenin activation in cDC were 
also observed in an alternative inflammatory setting, such as HFD fed mice. GOF 
and WT mice were fed HFD for 16 weeks and body weight increased at the same 
rate over time (Figure 3.21A). Immune modulation in VAT of the GOF mice fed 
HFD demonstrated similar results to WD fed GOF mice, specifically significant 
increases in the mRNA expression of adiponectin and IL-10 and the ratio of T reg 
cells in CD4+ T cell population was significantly increased (Figure 3.21B&C). This 
suggests that constitutive activation of β-catenin in cDCs enables a T cell driven 
immunosuppressive phenotype in HFD fed mice, therefore also possess the 
potential to revert tissue inflammation. Furthermore, the increase in the cDC1 
population in the spleen of GOF mice was also observed, although no differences 
in numbers of neutrophils or T reg cells (Figure 3.21D). The numbers of immune 
populations in the mesenteric draining lymph nodes and inguinal non-draining 
lymph nodes were not significantly altered between the GOF and WT mice fed 
HFD (Figure 3.21E&F).  
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Figure 3.21 Immune phenotype in the GOF model in High fat diet-induced 
inflammation 
GOF and WT mice were fed HFD to induce chronic low-grade tissue inflammation. (A) 
Body weight was measured over the duration of 16 weeks. (B) qRT-PCR analysis for 
mRNA expression in VAT of GOF and WT mice fed HFD. Expression levels of all mRNA 
were normalised to GAPDH expression. Bars represent ΔΔCT data values, the 
expression in GOF mice compared to WT, set at 1 indicated by the dotted line. Error 
bars show the geometric mean of six biological replicates. Statistical significance of ΔCT 
data values was determined by Student’s two-tailed t-test, results not significant unless 
otherwise denoted as *p<0.05. Total numbers of immune populations in the (C) VAT, (D) 
spleen, (E) mesenteric draining lymph nodes and (F) inguinal non-draining lymph nodes 
were quantified by flow cytometry, mean  SEM (n=4). Statistical significance was 
determined by Student’s two-tailed t-test, results not significant unless otherwise 
denoted as *p<0.05. 
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3.2.11 Constitutive β-catenin activation in cDCs improves the 
glucose homeostasis in Western diet-induced tissue 
inflammation 
 
The previous data suggests that constitutive activation of β-catenin pathway in 
cDCs plays a role in reverting the development of VAT inflammation during 
obesity. Modulation of tissue inflammation has long been proposed to restore 
insulin sensitivity. Studies have demonstrated that neutralisation of pro-
inflammatory adipose cytokines and ablation of inflammatory cells in VAT, 
promotes the recovery of glucose homeostasis in obese mice (10) (132). Thus, 
we hypothesised that constitutive β-catenin activation in cDCs would prevent the 
development of IR during WD-induced tissue inflammation.  
 
To assess the effects on whole-body glucose sensitivity and the response to 
insulin, mice were fasted to remove the effects of nutritional glucose. 
Intraperitoneal glucose tolerance tests (GTT) and insulin tolerance tests (ITT) 
were used to evaluate the glucose homeostasis in GOF and WT mice. The 
clearance of intraperitoneally (i.p) injected glucose load was measured in the 
GTT, whereby the ability of pancreatic β-cells to release insulin, was assessed in 
response to high blood glucose levels. The ITT determined the insulin sensitivity; 
an insulin bolus was injected i.p. to induce hypoglycaemia and blood glucose 
concentrations were measured over time to detect insulin resistance in the 
peripheral tissues, as blood glucose levels were restored to normal. There were 
no differences in the ITT response between the GOF and WT mice fed ND and 
WD (Figure 3.22). This absence of effect suggests that although constitutive β-
catenin activation in cDCs was able to revert the development of tissue 
inflammation in part, this was not sufficient to improve insulin sensitivity in obesity.  
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Figure 3.22 Insulin sensitivity of the GOF model in inflammation is not altered 
Systemic insulin sensitivity was measured by insulin tolerance test (ITT) in GOF and WT 
mice fed ND (A), 4 weeks of WD (B), 8 weeks of WD (C) or 16 weeks of WD (D), mean 
 SEM (n=10). Statistical significance at different time points was analysed by two-way 
ANOVA with Bonferroni’s post-test, results not significant unless otherwise denoted as 
*p<0.05, **p<0.01, ***p<0.001. 
 
As expected there was no observable difference in GTT response between GOF 
and WT mice fed ND (Figure 3.23A). However, as diet-induced tissue 
inflammation developed over time, the response to glucose deteriorated in WT 
mice (Figure 3.23B-D). There was no differential response between the GOF and 
WT mice fed 4 or 8 weeks of WD (Figure 3.23B&C). Although, by 16 weeks of 
diet-induced tissue inflammation, the GTT response of the GOF mice was 
significantly different than the response by WT mice demonstrating improved 
whole-body glucose sensitivity (Figure 3.23D). The basal levels of blood glucose 
were lower in the GOF mice fed 16 weeks of WD after fasting, indicating prior to 
glucose challenge the GOF mice have not developed the diet-induced 
hyperglycaemia to the same extent as the WT mice (Figure 3.23D). This 
metabolic modulation represents a key observation for the GOF model, 
specifically that constitutive β-catenin activation in cDCs has the ability to alter 
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insulin secretion. Interestingly, systemic insulin levels measured from the plasma 
of fasted mice demonstrated a significant increase in GOF mice fed WD for 12 
weeks, although no change was observed in mice fed ND (Figure 3.24A). In 
addition to the increased basal level of insulin in the plasma of the GOF mice, 
these levels remained significantly higher 15 min post administration of glucose 
i.p. compared to the WT mice (Figure 3.24B). Thus, as constitutive activation of 
β-catenin in cDCs improved whole-body glucose response but not insulin 
sensitivity, this suggested that the elevation in insulin was due to a modulation in 




Figure 3.23 Improved glucose sensitivity of the GOF model in inflammation 
Systemic glucose homeostasis was measured by glucose tolerance test (GTT) in GOF 
and WT mice fed ND (A), 4 weeks of WD (B), 8 weeks of WD (C) or 16 weeks of WD 
(D), mean  SEM (n=10). Statistical significance at different time points was analysed by 
two-way ANOVA with Bonferroni’s post-test, results not significant unless otherwise 
denoted as *p<0.05, **p<0.01, ***p<0.001.  
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Figure 3.24 Systemic insulin production increased in the GOF model 
(A) Insulin was measured by ELISA in the plasma of fasted GOF and WT mice fed either 
ND or WD, mean  SEM (n=10). Statistical significance was determined by Student’s 
two-tailed t-test, results not significant unless otherwise denoted as *p<0.05. (B) Insulin 
was measured by ELISA in the plasma collected after fast and 15 min post intraperitoneal 
injection with 1.5 mg glucose /g of body weight of GOF and WT mice, mean  SEM 
(n=10). Statistical significance was analysed by two-way ANOVA with Bonferroni’s post-





Studies have demonstrated a clear link between the Wnt/β-catenin pathway and 
the immune function of cDCs, contributing to the switch in phenotype to promote 
tolerogenic responses. This chapter has evaluated the role of β-catenin in cDCs 
in the context of VAT homeostasis and obesity-induced tissue inflammation.  
 
In VAT, cDCs acquire a tolerogenic phenotype during homeostatic conditions by 
upregulating adipocyte related pathways to maintain tissue homeostasis. 
Activation of Wnt/β-catenin pathway in cDC1 subset promoted an anti-
inflammatory milieu in the tissue through enhanced IL-10 production (Figure 
3.1D). This highlights that tissue microenvironment influences cDC phenotype. 
Wnt ligands are produced by preadipocytes to regulate adipogenesis. 
Preadipocytes are predominately located adjacent to adipose vasculature where 
they also differentiate to mature adipocytes (140) (141). Interestingly, cDCs are 
also found in close proximity to AT vessels (138) (Figure 3.1A), suggesting a 
possible crosstalk with pre-adipocytes to activate Wnt/β-catenin pathway in VAT-
cDCs. The depletion of β-catenin pathway in cDCs exacerbates VAT 
inflammatory response in vivo through the loss of a tolerogenic phenotype (Figure 
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3.2), further detailed in Table 3.1 (193). The alteration of T cell responses in the 
inflamed VAT of β-catenin knockdown mice, align with previous observations that 
abrogation of β-catenin expression promotes Th17 T cell responses and inhibits 
T reg cell induction (185) (178) (186). Due to the high specificity of the Zbtb46 
promoter used for generating β-catenin knockdown mice, the contribution of this 
T-cell mediated phenotype in modulating VAT inflammation is likely to be due to 
the action of β-catenin on cDC, rather than through an effect on macrophage 
populations, which reportedly modulates the innate pro-inflammatory profile in 
VAT. These findings confirm the importance of cDCs in controlling T cell 
responses in vivo and identify a novel mechanism by which cDCs maintain tissue 
immune homeostasis during steady state and obesity-induced inflammation.  
 
Chronic inflammation promotes cDC recruitment in VAT, where they adopt an 
activated pro-inflammatory state. In addition to obesity-induced tissue 
inflammation overriding suppressive pathways, inhibition of the β-catenin 
pathway in cDCs also plays a role in promoting the switch to immunogenic 
phenotype in VAT. In line with previous reports, Wnt ligand availability was 
diminished in obese VAT, specifically the levels of Wnt10b, which resulted in 
impaired Wnt/β-catenin pathway activation in VAT-cDCs (Figure 3.3). Thus, we 
investigated if constitutive activation of β-catenin in cDCs in obese VAT could 
revert the development of tissue inflammation and associated IR. 
 
In homeostatic conditions with mice fed ND, constitutive activation of β-catenin in 
cDCs exhibited minimal changes in the immune phenotype however there were 
indications of a possible T cell driven immunosuppressive phenotype in VAT. 
Increased T reg cell infiltration and reduction in the T cell chemoattractant CCL17 
expression suggests that constitutive activation of β-catenin in cDCs played a 
role in steady state conditions to promote anti-inflammatory T cell responses in 
VAT (Figure 3.9). Despite this, there was no increase of IL-10 production in VAT, 
which several studies have shown activation of β-catenin in DCs produces high 
levels of IL-10 (206) (182) (179). However, it is important to note that Wnt/β-
catenin pathway is active in steady-state VAT-DCs (Figure 3.4A) and the GOF 
model only increases the level of activation which may account for only marginal 
changes observed under ND, in the absence of VAT inflammation. Modulation of 
T reg cell induction was also observed in the spleen in homeostatic conditions, 
  119 
indicating a wider systemic change in T reg cell homeostasis by constitutive 
active β-catenin in cDCs (Figure 3.6A). Although β-catenin is not normally active 
in splenic cDCs, in the GOF model constitutive activation is induced in all cDCs 
in every tissue having a systemic effect and not just restrained to VAT, where 
expression is normally observed. However, this caveat of systemic β-catenin 
activation in cDCs, more accurately represents a therapeutic drug strategy, for 
example GSK3β inhibitors, where similar systemic effects may be observed. 
Surprisingly the number of splenic NK cells increased with active β-catenin in 
cDCs (Figure 3.6A), despite no change in other tissues in homeostatic conditions. 
This could suggest β-catenin may affect cDC activation of innate effector 
functions, however further characterisation would be required. 
 
Restoring β-catenin activation in cDCs demonstrated signs of reduced local 
obesity-induced inflammation. VAT-cDCs were modulated to induce a tolerogenic 
phenotype by constitutive β-catenin activation in concordance with previous 
reports, where similar phenotypes of DCs were exhibited in other tissues such as 
the gut. This change in cDC function is responsible for the altered T cell 
phenotype in VAT of GOF mice. Although only limited differences were observed 
in the abundance of T cells in VAT, the modulation of mRNA expression and 
increased numbers of naïve T cells suggested there was a change in phenotype 
of recruited T cells (Figure 3.11 & 3.12A). This was further confirmed by ex vivo 
analysis of VAT-cDCs from GOF mice, where reduced T cell responses were 
observed (Figure 3.17). Thus, the subtle but important change in T cell phenotype 
affects local inflammation by modulating the VAT immune network. However, the 
distribution of immune populations in VAT is heterogenous. It is widely reported 
that perinodal AT (PAT) is enriched with immune cells and lymphocytes 
especially, locate in FALCs which suggests that inflammatory responses are in 
very localised parts of the tissue. In these in vivo experiments, immune cell 
populations were analysed in total VAT from pooled depots in each mouse and 
consequently the effects by constitutive β-catenin activation in cDCs on 
inflammatory responses may have been diluted. This explains why potentially 
only minimal differences were observed in VAT of the GOF model and therefore 
localised responses in PAT may have revealed more striking effects by 
constitutive β-catenin activation in cDCs. While indications suggested local 
inflammation was in part reduced, the level of systemic inflammation was also 
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affected in GOF mice fed WD. Effects on the systemic immune populations may 
have arisen as a consequence of local changes in VAT immune populations or 
resulting from the systemic nature of the GOF model, where constitutive β-
catenin activation is induced in all cDCs from every tissue including the spleen 
and lymph nodes. The exact mechanism by which β-catenin in cDCs modulates 
systemic inflammation will be difficult to decipher. However local and systemic 
inflammation was not completely restrained, suggesting that constitutive β-
catenin activation in cDCs was not sufficient to fully overcome established 
inflammatory processes. As detailed in Table 3.1, the GOF model did not 
completely restore the results observed in the β-catenin knockdown mice (193). 
A maximal tolerogenic effect of β-catenin activity in cDCs may have been 
reached, which could not limit the development of tissue inflammation. 
Furthermore, residual β-catenin expression was still detectable in VAT-cDCs 
from obese control mice indicating that activation of the Wnt/β-catenin was not 
entirely impaired (Figure 3.4A). Thus, this may explain why constitutive β-catenin 
activation in cDCs does not induce highly significant changes, if activity however 
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β-catenin knockdown mice β-catenin gain-of-function mice 
In ND fed mice, reduction of IL-10 
mRNA expression and T reg infiltrate 
in VAT. Antigen-specific T cell 
activation increased in VAT with and 
without inflammatory stimulus. No 
change in metabolic parameters- 
including body and VAT weight, 
glucose and insulin sensitivity. 
Decreased anti-inflammatory state 
of VAT in homeostatic conditions 
In ND fed mice, increase in CD4+ T cells 
and T regs and mRNA expression of IL-
17A, FOXP3 in VAT. Reduction in 
CCL17 and no change in IL-10 mRNA 
expression. No change in metabolic 
parameters- including body and VAT 
weight, glucose and insulin sensitivity. 
 
Anti-inflammatory state of VAT 
maintained in homeostatic conditions 
In WD fed mice, reduction of IL-10 
and adiponectin mRNA expression 
and increase in CCL17, IL17, IL6 
mRNA expression in VAT and SVF. 
Decrease in T reg infiltrate in VAT. 
Elevated antigen-specific T cell 
activation and cDC stimulatory 
capacity. 
 
Exacerbated obesity-induced VAT 
inflammation 
In WD fed mice, elevation of IL-10, 
FOXP3 and adiponectin mRNA 
expression and decrease in CCL17 and 
IFNγ mRNA expression in VAT and 
SVF. No change in T reg numbers in 
VAT although possible change in T cell 
phenotype. Reduction in antigen-specific 
T cell activation and cDC stimulatory 
capacity. 
Reduced diet-induced VAT 
inflammation in part 
In WD fed mice, decreased glucose 
and insulin sensitivity and reduction of 
insulin-stimulated AKT 
phosphorylation in VAT and liver. 
Increased obesity-induced IR 
In WD fed mice, increased glucose 
sensitivity and elevated systemic insulin 
secretion.  
Improved control of obesity-induced 
hyperglycaemia 
 
Table 3.1 Comparison of phenotypes in β-catenin knockdown and GOF mice 
Summary of data in this thesis and published in Macdougall et al. (193) 
 
The results of the GOF model mimic the effect of pharmacological inhibition of 
upstream GSK3β which renders β-catenin active. GSK3β inhibitors result in DC 
maturation and acquisition of tolerogenic potential (182). In view of this, other 
signalling pathways that inactivate GSK3β could supply Wnt-independent 
mechanisms to promote tolerance. Interestingly, activation of TLRs which 
  122 
respond to pathogenic antigens, may simultaneously activate genes controlled 
by GSK3β while also stimulating the production of immunogenic DCs. This poses 
a feedback mechanism that could attenuate T cell activation by DCs. Hence 
pathways that β-catenin interacts with, need to be further investigated to 
understand the complete functional effect of constitutive β-catenin activation in 
cDCs. 
 
Obesity-induced inflammation plays a crucial role in the development of insulin 
resistance and consequently T2DM (207). A decrease in insulin sensitivity 
initiates in VAT, where modulation of adipokines promotes chronic systemic 
exposure of pro-inflammatory mediators. These mediators disrupt insulin 
signalling in peripheral tissues, promoting insulin resistance and resulting in 
reduced glucose uptake from the blood and subsequently hyperglycaemia 
develops. In this context, β-cells increase the production of insulin in an attempt 
to counteract high glucose levels. Thus, elevated systemic insulin levels are 
ordinarily associated with the development of IR. Interestingly, constitutive β-
catenin activation in cDCs induced an improvement in whole-body glucose 
homeostasis, although this was not caused by an improvement in peripheral 
insulin sensitivity (Figure 3.22 & 3.23). Rather increased levels of circulating 
insulin were observed paradoxically (Figure 3.24), not as an indication of 
increased IR but as a result of enhanced insulin secretion and an improved ability 
to control hyperglycaemia. Consequently, the effect of constitutive β-catenin 
activation in cDCs on metabolic control is further investigated in Chapter 4, 
specifically examining the impact on β-cells in the islets. Thus, in the GOF model 
where all cDCs are systemically targeted for sustained β-catenin activation, cDCs 
may have varying tissue-dependent effects including in the pancreas. Therefore 
β-catenin activity in cDCs may not be confined to VAT and could regulate other 
metabolic processes.  
 
In summary, this chapter has demonstrated a novel mechanism to induce a 
tolerogenic phenotype of cDCs in VAT through activation of Wnt/β-catenin 
pathway, which was responsible for reverting, in part, systemic and local adipose 
tissue inflammation in a model of diet-induced obesity.  
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 Metabolic changes induced by 
constitutive β-catenin pathway 






In obesity, the inability of adipocytes to store excess lipids causes dysregulation 
of lipid and glucose metabolism leading to ectopic fat deposition, hyperglycaemia, 
insulin resistance (IR) and dyslipidaemia (66). The pancreas responds to obesity 
through the expansion of β-cell mass, in order to compensate for the increased 
IR of the peripheral tissues and to restrain hyperglycaemia, by increasing insulin 
production (31). Understanding what regulates β-cell proliferation in obesity is a 
complex picture with many factors playing a role, including nutrients, insulin, 
incretins and growth factors (208). During the development of T2DM, β-cell mass 
and function are dramatically reduced and thus stimulating β-cell proliferation 
could provide therapeutic potential to revert β-cell failure.  
 
The dysregulation of Wnt/β-catenin pathway has been associated with IR and the 
development of T2DM in mouse and man (172). Loss of Wnt5b function and 
variants of Tcf7l2 confer increased T2DM susceptibility in humans (173) (175). In 
mice, overexpression of Wnt10b in adipocytes prevented the development of 
HFD induced insulin resistance (176). Interestingly, Wnt/β-catenin pathway has 
been shown to have a direct effect on β-cells. Tcf7l2-deficient mice exhibit 
reduced β-cell mass and decreased insulin secretion (209). In addition, a recent 
study detailed further that during pre-diabetic state, β-catenin was activated in 
islets during compensatory β-cell hyperplasia in mice (210). The low-density 
lipoprotein receptor-related proteins (LRP) are co-receptors critical for 
transducing Wnt signals for canonical β-catenin signalling. Loss of LRP5 
modulates systemic cholesterol and glucose metabolism, specifically impairing 
the glucose-induced insulin secretion of islets (211). Wnt ligands have also been 
shown to stimulate insulin secretion and induce β-cell proliferation in vitro (212), 
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while SFRP5, a secreted Wnt inhibitor blocks rat β-cell proliferation (213). 
Furthermore in primary mouse islets and in vivo, increasing β-catenin expression 
expands β-cell mass (214). However the source of Wnt ligands to induce β-
catenin activation for β-cell expansion remains unknown. 
 
Modulation of tissue inflammation has long been proposed to restore peripheral 
insulin sensitivity. However results from Chapter 3 indicated that despite 
restraining obesity-induced systemic and local inflammation, constitutive 
activation of β-catenin in cDCs was not sufficient to improve peripheral insulin 
sensitivity. Interestingly, constitutive β-catenin activation in cDCs improved 
whole-body glucose homeostasis as a result of enhanced insulin production. 
Combined, these results indicated that constitutive activation of β-catenin in cDCs 
could have the potential to modulate islet biology and β-cell secretory responses 
through reverting inflammatory responses in the pancreas, although the 
mechanisms remain unclear. 
 
In this chapter the role of Wnt/β-catenin signalling in cDCs is investigated to 
evaluate the metabolic effect on insulin secretion and islet inflammation in the 





4.2.1 Constitutive β-catenin activation in cDCs induces the 
expansion of islet size 
 
Islets are distributed through the pancreas and contain endocrine cells that 
secrete hormones, predominately comprised of insulin secreting β-cells. Using 
H&E and insulin counterstained sections (Figure 4.1C&D), the islet size was 
assessed in the pancreas of the GOF and WT mice. There was a trend towards 
an increase in mean size of the islets in the GOF mice compared to WT fed ND, 
however in mice fed WD there was a significant expansion of islet size (Figure 
4.1A). In addition the distribution of islet size was modulated, indicating a 
significant decrease of smaller islets in the GOF model (Figure 4.1B). To confirm 
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that the increased insulin production observed in the plasma of GOF mice (Figure 
3.24) was a result of the increased islet size, sized-matched islets from mice fed 
WD were cultured overnight. A significant increase in insulin secretion could be 
detected from cultured islets from GOF mice compared to WT (Figure 4.1E). This 
suggests that, despite changes in VAT inflammation, the improved whole-body 
glucose metabolism observed in GOF mice was due to a modulation of insulin 
secretion in the pancreas.  
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Figure 4.1 Increased size of islets in the GOF model 
(A) Quantification of islet size from levelled sections of pancreas tissues from GOF and 
WT mice fed ND or WD was determined using ImageJ software, mean  SEM (n= 4/5). 
(B) Frequency distribution of islets size in pancreas sections of GOF and WT mice. 
Frequency of cell area is expressed in number of cells per area bin, mean  SEM (n= 5). 
Representative images of (C) H&E and (D) insulin counter-stained sections of pancreas 
from GOF and WT mice fed WD. (E) Sized-matched islets isolated from GOF and WT 
mice fed ND or WD, were cultured overnight and insulin was measured by ELISA from 
the supernatant harvested the next day to measure basal secretion, mean  SEM 
(n=9/12). Statistical significance was determined by Student’s two-tailed t-test, results 
not significant unless otherwise denoted as *p<0.05. 
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Insulin regulation of blood glucose concentration, is correlated with β-cell mass. 
The processes that regulate β-cell mass are highly complex and balanced 
between β-cell differentiation, replication and death. To understand the 
mechanism of islet expansion in the GOF model, cell proliferation was 
investigated. To do so, islets from donor B6 mice were co-cultured with Flt3L-
bone marrow derived cDCs from GOF or WT mice (Figure 2.5). After 5 days of 
culture, a clear increase in Ki67+ cells could be observed in the islets incubated 
with GOF cDCs (Figure 4.2A). Ki67 is a widely used marker for cell proliferation. 
When cells undergo mitosis, levels of Ki67 increase which can be easily detected 
by antibody staining. Proliferation markers at the mRNA level showed a trend 
towards an increase in cMyc and CyclinD1 expression in the islets from GOF 
mice fed WD (Figure 4.2B), confirming previous reports in vitro (214). 
Furthermore, immunohistochemistry staining demonstrated a significant increase 
in Ki67+ cells in the islets of the GOF mice compared to WT (Figure 4.2C&D). No 
changes in apoptosis in the islets visually appears between the GOF and WT 
mice as measured by cleaved caspase-3 immunohistochemistry staining (Figure 
4.2E), however further analysis and quantification would be required to determine 
if there was a difference. These results indicate that constitutive activation of β-
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Figure 4.2 Increased proliferation in the islets of the GOF model 
(A) cDCs isolated from GOF and WT mice fed WD were co-cultured with islets from 
donor mice for 5 days. Proliferation in the islets was analysed by flow cytometry to 
measure the Ki67+ cells, represented as a percentage of CD45- population, mean  SEM 
(n=3). (B) qRT-PCR analysis for mRNA expression of proliferation markers in islets of 
GOF and WT mice. Expression levels of all mRNA were normalised to GAPDH 
expression. Bars represent ΔΔCT data values, the expression in GOF mice compared 
to WT, set at 1 indicated by the dotted line. Error bars show the geometric mean of five 
biological replicates. Statistical significance of ΔCT data values was determined by 
Student’s two-tailed t-test, results not significant. (C) Representative images of Ki67-
stained sections of pancreas from GOF and WT mice. Islets are indicated by the dotted 
line, arrows indicate Ki67+ cells. (D) Ki67+ cells in islets counted and number per islet per 
section determined, mean  SEM (n=15). (E) Representative images of cleaved 
caspase-3 -stained sections of pancreas from GOF and WT mice, islets are indicated by 
the dotted line. Statistical significance was determined by Student’s two-tailed t-test, 
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Islets are comprised of five main endocrine cell types, which produce specific 
hormones. To investigate the proliferating cell type, islets were analysed by 
immunofluorescence staining which revealed a significant increase in the 
proliferation of Nkx6.1+ β-cells (Figure 4.3A&B). This was supported by an 
increase in the number of Nkx6.1+ β-cells in the islets co-cultured with GOF cDCs 
for 5 days (Figure 4.3C). The primary source of new pancreatic β-cells in adult 
mice is through replication of existing β-cells (215). Therefore harnessing 
mechanisms that regulate β-cell proliferation has the potential to restore insulin 
secretion in diabetes.  
 
The processes that trigger endogenous β-cell proliferation have been widely 
studied, with several pathways implicated. Wnt signalling in the pancreas has 
been reported to be necessary and sufficient for β-cell proliferation (214) (212). 
Wnt proteins are known to affect cell growth, the expression of these are tightly 
regulated during development. Interestingly, in the GOF mice there was an 
increase, though not significant, in islet Wnt3a expression by RT-PCR analysis 
(Figure 4.3D), which supports previous observations (214). Furthermore, the 
production of Wnt ligands from Flt3L-bone marrow derived cDCs was altered in 
the GOF mice, with elevated mRNA expression certain Wnt ligands (Figure 4.4). 
Collectively from these results we hypothesise that the constitutive activation of 
β-catenin in cDCs produces an increase in Wnt ligand expression and availability, 
which enables the expansion of islet size by increasing β-cell proliferation. 
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Figure 4.3 β-cell proliferation is increased in the islets of the GOF model 
(A) Representative images of immunofluorescence stained sections of pancreas from 
GOF and WT mice. Arrows indicate Ki67+ Nkx6.1+ β-cells. (B) Ki67+ Nkx6.1+ β-cells in 
islets counted and number per islet per section determined, mean  SEM (n=12). 
Statistical significance was determined by Student’s t-test with two-tailed P values, 
results not significant unless otherwise denoted as *p<0.05. (C) cDCs isolated from GOF 
and WT mice fed WD were co-cultured with islets from donor mice for 5 days. Number 
of Nkx6.1+ β-cells was determined in these islets by flow cytometry, mean  SEM (n=3). 
(D) qRT-PCR analysis for mRNA expression of Wnt ligands in islets of GOF and WT 
mice. Expression levels of all mRNA were normalised to GAPDH expression. Bars 
represent ΔΔCT data values, the expression in GOF mice compared to WT, set at 1 
indicated by the dotted line. Error bars show the geometric mean of five biological 
replicates. Statistical significance of ΔCT data values was determined by Student’s two-
tailed t-test, results not significant. 
 
Dysregulation of Wnt/β-catenin pathway has been implicated with T2DM 
susceptibility, for example variants of Tcf7l2 gene are strongly associated with 
T2DM (175). In addition, single nucleotide polymorphisms in Wnt5b gene are 
associated with the risk of T2DM in the absence of obesity (173) (174). 
Interestingly, levels of Wnt5b were elevated in cDCs from the GOF mice 
compared to WT (Figure 4.4). Expression of Wnt7a and Fzd1, which is a Wnt 
signalling receptor, were also significantly increased in cDCs from the GOF mice, 
while production of Wnt10a expression was reduced compared to WT (Figure 
4.4).  
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Figure 4.4 Wnt profile in the GOF model 
qRT-PCR analysis for mRNA expression of Wnt ligands in Flt3L-bone marrow derived 
cDCs from GOF and WT mice. Expression levels of all mRNA were normalised to 
GAPDH expression. Bars represent ΔΔCT data values, the expression in GOF mice 
compared to WT, set at 1 indicated by the dotted line. Error bars show the geometric 
mean of six biological replicates. Statistical significance of ΔCT data values was 
determined by Student’s t-test with two-tailed P values, results not significant unless 
otherwise denoted as *p<0.05, **p<0.01. 
 
4.2.2 Modulation of islet immune phenotype by constitutive 
β-catenin activation in cDCs 
 
The link between the development of T2DM and chronic low-grade inflammation 
is well reported (207). It has been shown that infiltrating CD68+ macrophages are 
present in islets of T2DM human tissue (37), producing high levels of IL-1β which 
plays a role in the early pathology of T2DM through inflammasome activation in 
islets (50) (38). However, there remains a limited understanding of if and how 
cDCs can directly affect β-cell insulin secretion in T2DM.  
 
To evaluate if differences in the activated cDC phenotype of GOF and WT mice 
could directly influence insulin release by β-cells, co-cultures were set up with 
islets from donor B6 mice and Flt3L-bone marrow derived cDCs from GOF or WT 
mice (Figure 2.5). The acute overnight incubation was designed to analyse the 
effects on insulin release in a size independent manner, separate from the 
previous observations on β-cell proliferation. To note, manipulation of cDCs by 
pipetting or co-culturing is known to induce a certain level of cell activation which 
consequently is expected to affect β-cell function. Insulin measured from GOF 
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cDC co-cultures was increased compared to WT cDC co-cultures (Figure 4.5A), 
suggesting that WT cDC exhibit a more activated phenotype than GOF cDC and 
subsequently inhibit insulin release. Furthermore, when neutralising IL-10 in the 
co-cultures, insulin secretion was significantly decreased in the GOF co-cultures 
(Figure 4.5B). This effect on insulin release can be in part explained by the 
increase in IL-10 produced from GOF cDC (Figure 4.5C), which could contribute 
towards a generating an immunosuppressive environment in the islets preventing 




Figure 4.5 GOF cDCs alter the insulin release from islets independent of size 
(A) cDCs isolated from GOF and WT mice fed WD were co-cultured overnight with and 
without islets from donor mice. Insulin was measured by ELISA from the supernatant 
harvested the next day to measure secretion, mean  SEM (n=4) representative of three 
independent experiments. (B) IL-10 was neutralised in the co-cultures with 1 µg/ml anti- 
IL-10 and insulin was measured by ELISA from the supernatant harvested the next day, 
mean  SEM (n=3/4) representative of three independent experiments. (C) 
Concentration of IL-10 measured by ELISA from supernatant of WT and GOF cDC 
cultured overnight, mean  SEM (n=6). Statistical significance was determined by 
Student’s two-tailed t-test, results not significant unless otherwise denoted as *p<0.05. 
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The phenotype of cDCs in the pancreas during chronic inflammation and T2DM 
has yet to be fully characterised, in contrast to the well-studied autoimmune 
T1DM where subsets of cDCs have been identified in islets (163). Indeed, using 
Zbtb46GFP mice the presence of cDCs were confirmed in both the pancreas and 
islets (Figure 4.6A&B). Increased expression of β-catenin in cDCs from the 
pancreas was observed in the GOF mice by western blot and densitometry 
analysis (Figure 4.6C). To assess the pancreas cDC phenotype and abundance, 
expression of co-stimulatory molecules  was analysed by flow cytometry. There 
were no differences in the percentage of cDCs or subsets in the pancreas 
between the GOF and WT mice fed WD (Figure 4.6D). In addition, the expression 
of costimulatory molecules CD40, CD80 and CD86 remain unchanged on the 
pancreas cDC surface, indicating no effect on co-stimulation of pancreas cDC in 
mice with diet-induced tissue inflammation (Figure 4.6E). These findings suggest 
that the observed effect by of constitutive β-catenin activation in cDCs on insulin 
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Figure 4.6 Pancreas DC phenotype in the GOF model 
(A) Representative images of immunofluorescence stained sections of pancreas from 
Zbtb46GFP mice. Islet is indicated by the dotted line, arrows indicate cDCs in pancreas 
tissue and (B) in islet. (C) CD11c+ DCs were isolated from pancreas of WT and GOF 
mice. Expression of β-catenin was detected by western blot, shown as a representative 
of three independent experiments. Expression of β-catenin was normalised to β-actin 
expression by densitometry analysis, mean ± SEM (n=3). (D) Islets from GOF and WT 
mice fed WD were digested and cDC populations were analysed by flow cytometry, 
presented as percentage of parent population, mean  SEM (n=3). (E) Percentage of 
CD40+, CD80+, CD86+ -expressing cDCs were quantified by flow cytometry, mean  SEM 
(n=3). Statistical significance was determined by Student’s two-tailed t-test, results not 
significant. 
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The previous results suggest that modulation of in vivo insulin secretion in the 
GOF mice can be controlled by local inflammation. To investigate this possibility, 
immune cell responses in the islets of GOF and WT mice fed WD were assessed. 
Immune cell populations in the islets were analysed by flow cytometry. The gating 
strategy detailed previously was used to analyse the immune populations (Figure 
2.4). A trend towards a reduction in the percentage of CD3+ T cells and a 
significant increase in the percentage of T reg cells was observed in the GOF 
mice compared to WT (Figure 4.7A&B). The percentage of T cell memory subsets 
were unchanged, however in the GOF mice there was a significant reduction in 
the percentage of IFNγ-producing CD4+ T cells (Figure 4.7C). The overall 
reduction in CD3+ T cells suggests less lymphocytes infiltrate into the islets of the 
GOF mice fed WD, which was also confirmed by immunohistochemistry staining 
of CD3+ T cells (Figure 4.7D). Furthermore, the expression of T cell 
chemoattractant CCL17 was significantly decreased in the islets of GOF mice fed 
WD compared to WT, as measured by qRT-PCR analysis (Figure 4.7E). This 
corroborates previous findings in Chapter 3, that constitutive β-catenin activation 
in cDCs modulates T cell recruitment and promotes a T cell driven 
immunosuppressive phenotype. Despite this, the CCR4 expression in the islets 
of the GOF mice was not decreased, which is the cognate chemokine receptor 
for CCL17. In addition, the mRNA expression of IL-10 in the islets was not 
significantly increased in the GOF mice fed WD. Although unexpected, the 
absence of difference in IL-10 expression could be the result of low cDC 
abundance in the islet or rather a localised effect which was diluted in whole islet 
mRNA expression analysis. However, a significant reduction was observed in the 
expression of NFkB p65 subunit as measured by western blot, suggesting a 
decrease in activation of immune cells and consequently as an indicator of less 
inflammation in the islets of the GOF mice (Figure 4.7F). Therefore, constitutive 
β-catenin activation in cDCs promotes a healthier immune phenotype in the islets 
which in combination with an increased islet size, enables the islets to provide a 
greater insulin reserve in response to diet-induced inflammation. 
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Figure 4.7 Modulation of the T cell phenotype in the islets of the GOF model  
(A) Immune cell populations from islets of GOF and WT mice fed WD were analysed by 
flow cytometry, presented as percentage of parent population, as determined in gating 
strategy (Figure 2.4), mean  SEM (n=5). (B) Representative dot plots of T reg cells from 
the islets of GOF and WT mice. (C) Intracellular cytokine expression of islet infiltrated 
CD4+ T cells was analysed by flow cytometry, presented as percentage of CD4+ 
population, mean  SEM (n=5/6). (D) Representative images of CD3-stained sections of 
pancreas from GOF and WT mice, islets are indicated by the dotted line. (E) qRT-PCR 
analysis for mRNA expression in islets of GOF and WT mice. Expression levels of all 
mRNA were normalised to GAPDH expression. Bars represent ΔΔCT data values, the 
expression in GOF mice compared to WT, set at 1 indicated by the dotted line. Error 
bars show the geometric mean of five biological replicates. Statistical significance of ΔCT 
data values was determined by Student’s two-tailed t-test, results not significant unless 
otherwise denoted as *p<0.05. (F) Expression of p65 RelA protein in islets from GOF 
and WT mice fed WD, measured by western blot, mean  SEM (n=4). Statistical 
significance was determined by Student’s two-tailed t-test, results not significant unless 
otherwise denoted as *p<0.05. 
A 
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4.3 Discussion 
 
Metabolic control is tightly entwined with the immune system. Studies are 
beginning to explore the effect of immune cells in the development of T2DM. This 
chapter has discovered a novel role of β-catenin activation in cDCs to enhance 
β-cell insulin secretion and modulate islet inflammation, thus generating a greater 
insulin reserve in response to diet-induced obesity and providing an increased 
ability to control hyperglycaemia. 
 
While investigating the pancreas function, an unexpected observation was 
uncovered in relation to islet size (Figure 4.1). Constitutive activation of β-catenin 
in cDCs induced the expansion of islets, which was attributed to increased β-cell 
proliferation (Figure 4.3). The number of functional β-cells is the main factor that 
contributes to the amount of insulin secreted in response to metabolic demand. 
A decrease in β-cell number and function contributes to the pathophysiology of 
T2DM. Interestingly, a modulation of Wnt ligands was observed in the islets of 
GOF mice. The Wnt/β-catenin pathway has been previously linked to expansion 
of β-cell mass and improved insulin secretory function (211) (209). Specifically 
Wnt3a signalling in the pancreas has been shown to induce β-cell proliferation 
(214). Wnt3a is an activator of the canonical Wnt/β-catenin pathway and is 
present in the developing pancreas and in adult human islets (216). Wnt3a 
stimulates the expression of multiple β-cell cycle regulators including c-Myc, 
cyclin D1 and CDK4, to promote cell proliferation (214). It has also been proposed 
that Wnt signalling may crosstalk with other pathways within the β-cell to induce 
proliferation, for example with the incretin, glucagon-like peptide-1 (GLP-1) 
signalling (172). As well as stimulating insulin secretion, GLP-1 is also known to 
promote β-cell proliferation (217). Thus, Wnt ligands may act directly or indirectly 
to initiate β-cell proliferation. An increase, although not significant, of Wnt3a, 
cMyc and Cyclin D1 expression was observed in the islets of GOF mice (Figure 
4.2 & 4.3), suggesting constitutive β-catenin activation in cDCs may contribute 
locally to an increase β-cell proliferation. Additionally, the Wnt ligand profile 
produced by Flt3L-bone marrow derived cDCs was significantly altered in the 
GOF mice (Figure 4.4), indicating a potential local increase in ligand availability. 
It has been observed previously that cDCs produce Wnt ligands in the gut (185). 
Thus, we propose that constitutive activation of β-catenin may directly induce a 
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feedforward loop for initiating and producing Wnt ligands from cDCs, which could 
act in a paracrine manner on β-cells to induce proliferation. Indeed, Wnt ligands 
have poor solubility implying this interaction may happen locally in the islets, in 
close proximity. Therefore, cDCs with constitutive β-catenin activation, which are 
present in the pancreas and islets, may potentially act as a source for tissue-
specific Wnt ligands. This increase in Wnt ligand expression and availability in 
the pancreas, may act as a local system promoting β-cell proliferation and 
increasing β-cell mass. However, the exact mechanism requires further 
investigation. Interestingly, the proliferative potential of human β-cells has been 
shown to rely on Wnt ligand receptor activation, through crosstalk of multiple 
signalling pathways (218). Thus, activation of Wnt/β-catenin pathway in cDCs, 
may have the potential to translate in humans as a possible strategy to restore 
the loss of β-cell mass in T2DM, as well as in T1DM. 
 
Although β-cell proliferation from pre-existing β-cells is increased in the GOF 
islets, this may not entirely account for the expansion of β-cell population in the 
islets. β-cell neogenesis also occurs in the pancreas, through activation of β-cell 
progenitor cells or transdifferentiation, which may additionally increase the 
number of β-cells. Transdifferentiation is a process whereby a differentiated cell 
is converted into another cell type. It has been shown that functional insulin 
secreting β-cells have arisen from pre-existing α-cells in the islet and exocrine 
cells including acinar ductal cells (219). The Wnt/β-catenin pathway is known to 
be important for regulating cell differentiation. Interestingly, the pathway is 
activated during the differentiation of adipose-derived stem cells into functional 
β-cells (220), suggesting another possible mechanism by which the β-cell 
population expands in response to increased Wnt ligand exposure. Although 
prolonged activation of Wnt/β-catenin pathway has also shown to affect the 
differentiation state of β-cells (221). Consequently the local levels of Wnt 
expression in the islets may be critical to determine their beneficial effect on β-
cell population. Thus, further investigation of alternative mechanisms by which β-
cell expansion can occur in the islet, in response to constitutive β-catenin 
activation in cDCs, will be required. 
 
Islet inflammation has been associated with T2DM and is known to contribute to 
the onset and progression of β-cell failure (39). Increased numbers of leukocytes 
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and pro-inflammatory mediators have been observed in the islets of individuals 
with T2DM, specifically an elevation of CD68+ macrophages, increased B 
lymphocyte infiltration and greater absolute numbers of T cells and CD11b+ 
CD11c+ myeloid cells (37) (36). However less is known about the infiltration and 
pathological consequence of cDCs in the islets in T2DM. A size-independent 
effect was observed by cDCs with constitutively active β-catenin, to generate an 
immunosuppressive environment in the islet through increased IL-10 production 
and infiltration of T reg cells (Figure 4.5 & 4.7). IL-10 has well characterised anti-
inflammatory properties, and emerging evidence suggests the cytokine can exert 
direct effects on β-cell function and viability (222) (223). In addition T reg cells 
are known to promote systemic insulin sensitivity, demonstrated in the  inhibition 
of diabetes induced through the adoptive transfer of diabetogenic T cells in 
immunocompromised NOD mice (224). At an islet-specific level the action of T 
reg cells are yet to be explored in T2DM but it is known their numbers and function 
are decreased in the inflamed islets of T1DM patients (225). Interestingly, islet 
antigen-specific T reg cells, expanded in vitro by cDCs, were able to expand the 
endogenous T reg population in vivo, restoring insulin secretion and further 
reverting diabetes in the NOD mouse (226). Therefore, the reduction of islet 
inflammation by constitutive activation of β-catenin in cDCs may provide a 
potential mechanism to prevent the deleterious effects on β-cell insulin secretion. 
Despite the beneficial effects on β-cell health, the immunosuppressive 
environment generated by constitutively active β-catenin in cDCs should be 
cautious to consider the development of pancreatic cancer. Tumour development 
favours immune suppression, including the recruitment of T reg cells and 
tolerogenic DCs. Furthermore overexpression of β-catenin promotes pancreatic 
cancer (227). 
 
In summary, this chapter has demonstrated a novel mechanism by which cDCs 
promote a healthier immune phenotype in the islets, which in combination with 
an increased islet size, enables the islets to provide a greater insulin reserve in 
response to diet-induced inflammation. Furthermore, this work suggests a 
possible new compensatory mechanism to prevent hyperglycaemia in the 
development of T2DM. Although we have shown the Wnt/β-catenin signalling as 
a novel pathway in cDCs to modulate islet inflammation, investigations of other 
immunosuppressive pathways in cDCs may also provide beneficial effects on 
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islet immune health during T2DM. Ultimately, these findings highlight the potential 
of immune modulation to improve β-cell mass and function and opens up the 
possibility of targeting cDCs for the treatment of T2DM. 
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 Translational impact of Wnt/β-catenin 






Adiponectin is known to regulate a number of metabolic processes including 
glucose regulation and fatty acid oxidation, thus suppressing the metabolic 
derangements that result in the development of T2DM and obesity (205). 
Adiponectin has also been shown to have a beneficial role in cardiovascular 
disease, specifically anti-inflammatory and anti-atherogenic effects in the 
development of atherosclerosis (228). Results in Chapter 3 demonstrated 
significant increases in adiponectin mRNA expression in VAT, as measured by 
qRT-PCR and elevated levels of adiponectin protein in the plasma of the GOF 
model in diet-induced tissue inflammation (Figure 3.11B & 3.19E). Additionally, it 
has been shown that CCL17-expressing cDCs drive atherosclerosis by 
restraining T reg cell recruitment into the aortic vessel (198). In line with this, 
results in Chapter 3 also showed a significant decrease in CCL17 mRNA 
expression in VAT, as well as reduced protein level produced by VAT-cDCs from 
the GOF mice during diet-induced tissue inflammation (Figure 3.11B & 3.18A). 
Furthermore, the T reg cell phenotype is modulated in the GOF model, 
suggesting a decrease in CCL17 may enable an expansion of the T reg 
population in the aorta. Combined, these results indicated that constitutive 
activation of β-catenin in cDCs may have the potential to reduce 
atheroprogression by reverting inflammatory responses in the aortic vessel. 
 
Atherogenesis is a process of atheroma plaque formation in the intima layer of 
arteries, causing vessel remodelling. The luminal of the artery becomes narrowed 
and arterial walls stiffen as the plaque develops over time, which results in an 
increased risk of cardiovascular complications including coronary artery disease, 
stroke and kidney disorders. A number of contributory factors that exacerbate 
atheroprogression include obesity and T2DM. The progressive development of 
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atherosclerosis occurs predominately due to endothelial dysfunction, lipid 
accumulation and chronic inflammation (229). Macrophages and oxidised low-
density lipoprotein (LDL) are well-established players in the initiation of atheroma 
development (230). Cholesterol lipids are required for cell membranes and are 
transported in the blood by lipoproteins, which are categorised by their density 
including LDL, high-density lipoprotein (HDL) and very low-density lipoprotein 
(VLDL). HDL is responsible for scavenging cholesterol from peripheral tissues to 
the liver for their removal, while LDL exerts opposite functions carrying 
cholesterol from towards cells where it binds to LDL receptors (LDL-R) for 
cholesterol absorption. However, during chronic overnutrition when cells reach 
their limit of cholesterol uptake from the blood, the synthesis of LDL-R is blocked 
resulting in elevated blood cholesterol levels (hypocholesterolaemia) (229). Free 
LDL is oxidised in the blood and phagocytosed by macrophages, which are 
recruited to the arterial wall and transform into high-lipid carrying “foam cells” 
(231). These cells are a hallmark of the early atherosclerotic plaque and secrete 
pro-inflammatory cytokines to amplify local inflammatory responses at the arterial 
site (232). Recruitment of other inflammatory immune cells, increased ROS 
generation and production of matrix metalloproteinases (MMP) and growth 
factors contribute to the atherosclerotic plaque formation, where smooth muscle 
cell deposition of extracellular matrix accumulates, increasing the plaque size 
(233). Inflammation is key in the pathophysiology of atherosclerosis and has been 
the focus of therapeutic interventions to ameliorate disease progression. 
Although macrophages are well characterised in atherogenesis, adaptive 
immune responses also contribute to the regulation of aortic inflammation (232). 
T cells are present in atherosclerotic plaques and depending on the balance of T 
helper cell subsets, exacerbate or limit inflammation to influence atheroma 
formation (234). cDCs have also been identified in atherosclerosis, participating 
in lipid uptake and inflammation resolution (235). Thus, we proposed that cDCs 
with constitutive β-catenin activation may have the potential to attenuate the 
systemic inflammation developed in VAT as a result of dyslipidaemia and/or 
directly affect local inflammation in the plaque. Therefore we hypothesised that 
GOF mice could have a potential cardio-protective phenotype, reducing plaque 
development in an atherosclerosis model. 
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In this chapter the role of Wnt/β-catenin signalling in cDCs is investigated, to 
assess the effect on the development of atherosclerosis and explore the 





5.2.1 Constitutive β-catenin activation in cDCs reduces free 
fatty acids in an atherosclerosis model 
 
To investigate the effect of constitutive β-catenin activation in cDCs on 
atherogenic development, bone marrow chimeric mice were generated using the 
Ldlr -/- mouse model. The Ldlr -/- mouse model is commonly used for 
atherosclerotic studies due to the deficiency of functional LDL-R, consequently 
cholesterol cannot be efficiently cleared from the blood accelerating the 
development of atherosclerotic plaques during WD feeding. Bone marrow cells 
from β-cateninFl/+ Zbtb46-Cre+ (GOF) or β-catenin+/+ Zbtb46-Cre+ (WT) were 
transferred into irradiated B6.129S7-Ldlrtm1Her/J (Ldlr-/-) recipient mice, hence 
forth referred to as Ldlr -/- GOF mice or Ldlr -/- WT mice respectively (Figure 2.3). 
In the Ldlr -/- GOF model, only cDCs express Zbtb46 and hence, exclusively 
express constitutively active β-catenin. Mice were fed 12 weeks of WD to induce 
atherogenic development. There was no difference in body weight between Ldlr 
-/- GOF and Ldlr -/- WT mice fed WD (Figure 5.1A). Free fatty acids (FFA) are 
elevated in the plasma during obesity and contribute to the development of 
atherosclerotic plaques. Encouragingly, there was a significant decrease of 
plasma FFA levels in Ldlr -/- GOF mice compared to Ldlr -/- WT mice (Figure 5.1B), 
suggesting that constitutive β-catenin activation in cDCs may limit FFA 
generation from inflamed VAT and thus promote a beneficial effect on lipid 
regulation. Despite this, there was no difference in total cholesterol, HDL or 
LDL/VLDL levels in the plasma between Ldlr -/- GOF and Ldlr -/- WT mice (Figure 
5.1C-E). Furthermore the adipokine leptin, which has a well-established role in 
the metabolic control of lipids, was unchanged in the plasma of Ldlr -/- GOF mice 
(Figure 5.1F). Unexpectedly, the level of circulating adiponectin in the plasma of 
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Ldlr -/- GOF mice was not significantly increased compared to Ldlr -/- WT mice 




Figure 5.1 Metabolic phenotype of the Ldlr -/- GOF model 
(A) Body weight was measured pre-diet and after 12 weeks of WD of Ldlr -/- GOF and 
Ldlr -/- WT mice, mean ± SEM (n=20). (B) Levels of free fatty acid and (C) total 
cholesterol, (D) HDL, (E) VLDL /LDL, (F) leptin and (G) adiponectin were quantified in 
the fasted plasma of Ldlr -/- GOF and Ldlr -/- WT mice, using ELISA and commercial kits, 
mean  SEM B. (n=9) F. (n=8) C-E, G. (n=20). Statistical significance was determined 
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5.2.2 Constitutive activation of β-catenin in cDCs affects the 
immune phenotype in an atherosclerosis model 
 
To explore the impact of constitutive β-catenin activation in cDCs on the immune 
phenotype in the Ldlr -/- model, flow cytometry staining was used to quantify 
immune cell numbers in the spleen, mediastinal draining lymph nodes and 
inguinal non-draining lymph nodes of Ldlr -/- GOF and Ldlr -/- WT mice. The gating 
strategy detailed previously, was used to analyse the immune populations (Figure 
2.4). Constitutive activation of β-catenin in cDCs did not impact the numbers of 
immune cells in the spleen (Figure 5.2). Interestingly, however when analysing 
the immune populations in the mediastinal draining lymph nodes and inguinal 
non-draining lymph nodes, the neutrophil populations were observed to be 
significantly reduced in the Ldlr -/- GOF mice compared to Ldlr -/- WT (Figure 5.3 
& 5.4). A decrease in the number of neutrophils suggests a decrease in systemic 
inflammation, although this effect was not detected in the spleen. Constitutive 
activation of β-catenin in cDCs did not significantly affect the numbers of other 
immune cell populations in the mediastinal draining lymph nodes and inguinal 
non-draining lymph nodes (Figure 5.3 & 5.4). However there was an indication 
that migratory cDCs were increased in the draining lymph nodes of the Ldlr -/- 
GOF mice, while a trend towards a decrease in numbers of migratory cDCs was 
observed in the non-draining lymph nodes. This distribution infers that 
constitutively activated β-catenin in cDCs may preferentially locate to the site of 
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Figure 5.2 Immune phenotype in the spleen of the Ldlr -/- GOF model 
Spleen from Ldlr -/- GOF and Ldlr -/- WT mice were digested. Total numbers of immune 
populations were quantified by flow cytometry, mean  SEM (n=10). Statistical 
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Figure 5.3 Immune phenotype in the draining lymph nodes of the Ldlr -/- GOF 
model 
Mediastinal draining lymph nodes from Ldlr -/- GOF and Ldlr -/- WT mice were digested. 
Total numbers of immune populations were quantified by flow cytometry, mean  SEM 
(n=8). Statistical significance was determined by Student’s two-tailed t-test, results not 
significant. 
  148 
 
Figure 5.4 Immune phenotype in the non-draining lymph nodes of the Ldlr -/- GOF 
model 
Inguinal non-draining lymph nodes from Ldlr -/- GOF and Ldlr -/- WT mice were digested. 
Total numbers of immune populations were quantified by flow cytometry, mean  SEM 
(n=7). Statistical significance was determined by Student’s two-tailed t-test, results not 
significant. 
 
Immune populations could not be analysed in the aorta of Ldlr -/- GOF and Ldlr -/- 
WT mice as the whole aortas were required for plaque density measurements. 
However in previous experiments, immune cells in the aorta of WT and GOF mice 
fed WD to induce inflammation, were analysed to indicate potential changes in 
the Ldlr -/- model. There were no differences in the percentage of total leukocytes 
in the aorta, neither in the percentage of the CD3+, CD8+, CD4+ T cell or T reg 
cell populations (Figure 5.5). This indicates there was no change of immune cell 
recruitment in the aorta of GOF and WT mice suggesting that constitutive β-
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catenin activation in cDCs may not have affected the aortic inflammation in the 
Ldlr-/- atherosclerosis model. 
 
 
Figure 5.5 Immune populations in the aorta of the GOF model in inflammation 
Aortic cells were isolated from GOF and WT mice and immune cell populations were 
analysed by flow cytometry. Presented as percentage of parent population, as 
determined in gating strategy (Figure 2.4), mean  SEM (n=5). Statistical significance 
was determined by Student’s two-tailed t-test, results not significant. 
 
5.2.3 Constitutive activation of β-catenin in cDCs improves 
the immune phenotype of the adipose tissue in an 
atherosclerosis model 
 
To further assess the immune phenotype of Ldlr -/- GOF mice, mRNA expression 
of cytokines, chemokines and adipokines was measured in the SVF and 
pericardial AT by qRT-PCR. Similarly to previous observations in a model of diet-
induced obesity (Figure 3.11), the expression of T cell chemoattractant CCL17 
was significantly reduced in SVF of Ldlr -/- GOF compared to Ldlr -/- WT mice 
(Figure 5.6A). This suggests that constitutive activation of β-catenin in cDCs may 
have modulated the T cell recruitment in VAT to reduce inflammation. Although 
there was no change in expression of T cell immunosuppressive cytokines such 
as IL-10 and TGFβ between Ldlr -/- GOF and Ldlr -/- WT mice, there was a trend 
towards an increase in FOXP3 expression suggesting a potential expansion of T 
reg cell population in VAT of Ldlr -/- GOF mice. Additionally the production of pro-
inflammatory TNFα was significantly reduced, indicating a potential reduction in 
TNFα -expressing CD4+ T cells (Figure 5.6A). Furthermore in pericardial AT 
located around the aorta vessel, there was also a significant reduction in CCL17 
and TNFα and an increase in FOXP3 expression in Ldlr -/- GOF mice (Figure 
5.6B). This suggests a local modulation of T cell phenotype near the vessel, 
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potentially promoting an immunosuppressive environment. IL-6 was significantly 
decreased in the pericardial AT of Ldlr -/- GOF mice indicating there was a 
possible reduction in inflammation (Figure 5.6B). Despite previous results 
showing no change in circulating adiponectin levels (Figure 5.1G), there was a 
significant increase in the adiponectin expression locally in the pericardial AT of 
Ldlr -/- GOF mice (Figure 5.6B). This suggests an improved local adipocyte 
function, although local production was not sufficient to affect systemic 
concentrations. Therefore, the beneficial effects of adiponectin on supressing 
inflammation may have occurred locally and not systemically in the Ldlr-/- GOF 
atherosclerosis model.  
 
Figure 5.6 Immune phenotype in the VAT and pericardial AT of the Ldlr -/- GOF 
model 
qRT-PCR analysis for mRNA expression in SVF (A) and pericardial AT (B) of Ldlr -/- GOF 
and Ldlr -/- WT mice. Expression levels of all mRNA were normalised to GAPDH 
expression. Bars represent ΔΔCT data values, the expression in GOF mice compared 
to WT, set at 1 indicated by the dotted line. Error bars show the geometric mean of eight 
biological replicates. Statistical significance of ΔCT data values was determined by 
Student’s two-tailed t-test, results not significant unless otherwise denoted as *p<0.05.  
  151 
5.2.4 Constitutive β-catenin activation in cDCs does not 
revert the development of atherosclerosis 
 
Atherogenic development can be assessed in mouse models by measuring 
atherosclerotic plaque size in the aorta. Oil Red O solution is fat soluble, staining 
TG, cholesteryl esters and lipoproteins but not biological membranes. Oil Red O 
is commonly used to stain lipid-rich regions such as plaques, in aortic vessels. 
Whole mount en face aortas from Ldlr -/- GOF and Ldlr -/- WT mice were stained 
with Oil Red O (Figure 5.7A). The Oil Red O+ stained plaque area was analysed 
blindly to determine the lesion density as a percentage of total aorta area. The 
percentage aortic lesion density was not significantly different between Ldlr -/- 
GOF and Ldlr -/- WT mice (Figure 5.7B), demonstrating that constitutive activation 
of β-catenin in cDCs could not revert the development of atherosclerosis. 
Furthermore, there was no improvement in collagen deposition in the aortic sinus 
of Ldlr -/- GOF mice compared to the Ldlr -/- WT mice (Figure 5.8), suggesting that 
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Figure 5.7 Lesion density in the aorta of the Ldlr -/- GOF model 
(A) Whole mount en face aortas stained with Oil Red O from Ldlr -/- GOF and Ldlr -/- WT 
mice. (B) Lesion density calculated as Oil Red O+ stained plaque area as a percentage 
of total aorta area, mean  SEM (n=20). Statistical significance was determined by 
Student’s two-tailed t-test, results not significant. 
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Figure 5.8 Histopathology of the aortic sinus of the Ldlr -/- GOF model 
Representative images of sirus red stained aortic sinus sections of the heart from Ldlr -/- 
GOF and Ldlr -/- WT mice. 
 
5.2.5 Translation of constitutive β-catenin activation in cDCs 
for therapeutic use 
 
Despite not ameliorating atherogenic development in the Ldlr -/- model, 
constitutive β-catenin activation in cDCs has demonstrated beneficial effects in 
reducing VAT inflammation and improving whole-body glucose metabolism in 
Chapters 3 and 4. Thus we proposed that activation of Wnt/β-catenin pathway in 
cDCs could hold therapeutic potential. Since the Wnt/β-catenin pathway 
modulates many biological processes, non-specific activation of the pathway has 
significant wide-ranging effects. Pharmacological inhibitors of GSK3β have failed 
to have successful clinical use due to the lack of selectivity, high toxicity and 
adverse side effects (236). Additionally the stabilisation and nuclear translocation 
of β-catenin, induced by GSK3β inhibitors also holds oncogenic potential (237). 
Therefore a targeted method of activating the Wnt/β-catenin pathway in cDCs 
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could provide increased specificity, while requiring lower dosage, avoiding 
unwanted responses and reducing toxicity. Furthermore, targeting cDCs in 
vaccinations is widely accepted as a successful concept for protective immunity 
(238).  
 
To investigate the specificity and affinity of such targeted delivery, multi-polymer 
micelle structures were kindly generated by Dr. Remzi Becer (School of 
Engineering and Materials Science, QMUL). The micelles encapsulate drugs for 
intracellular delivery, such as Wnt/β-catenin pathway agonist SB216763 (SB) and 
are formed of polymers which have high affinity to lectins. Lectins are 
glycoproteins, highly expressed on the surface of cDCs and macrophages. To 
measure the selectivity of micelles to cDCs, FITC conjugated micelles were 
utilised to determine their binding by flow cytometry. The gating strategy detailed 
previously was used to analyse the immune populations (Figure 2.4). A mixed 
splenocyte single cell population was treated with FITC conjugated micelles and 
the number of FITC labelled cells of immune populations were determined. The 
cDC population showed the greatest number of FITC labelled cells compared to 
other immune cells, suggesting the lectin binding provided specificity for targeted 
delivery (Figure 5.9A&B). An advantage of targeted delivery is the reduced drug 
dosage required, therefore micelles containing SB were titrated and IL-10 
production from cDCs was analysed as a functional response. The dose 
response curve demonstrated that treatment of 1 µg/ml of micelle containing SB 
was the concentration which had maximal effect on β-catenin activity (Figure 
5.9C). This concentration of micelle containing SB was used to compare with SB 
alone, as a measure of targeted versus untargeted β-catenin activation in cDCs. 
The concentration of SB used previously in initial experiments (20 µM, 7.42 
µg/ml), was used in these experiments to ensure cDC response was achieved. 
The IL-10 response was significantly increased in VAT-cDCs treated with micelle 
containing SB compared to untreated (Figure 5.9D). Interestingly, this response 
was greater than the treatment of VAT-cDCs with SB alone, suggesting the 
micelle enhanced delivery for β-catenin activity while requiring a lower 
concentration of SB. Control treatment with micelle alone in the absence of SB 
showed an unexpected level of IL-10 production from VAT-cDCs, indicating that 
micelles alone may have a non-specific effect on β-catenin activity. Thus, this 
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method of delivery will need to be further investigated to understand how micelles 
affect pathways in cDCs.  
 
 
Figure 5.9 Targeted micelle delivery of Wnt/β-catenin pathway agonists to cDCs 
(A) Spleen from C57BL/6 mice were digested and single cell mixed splenocyte 
population was treated with 1 µg/ml FITC conjugated micelles for 1 hour. After washing, 
immune cell populations were permeabilised and stained to analyse micelle binding by 
flow cytometry, mean  SEM (n=3). (B) Representative dot plots of micelle binding from 
cDC population treated and untreated. (C) VAT-cDCs were isolated from C57BL/6 mice 
and treated with increasing concentrations of micelle containing β-catenin pathway 
agonist (SB) overnight. IL-10 was measured in the supernatant by ELISA, mean  SD 
(n=2). (D) VAT-cDCs were treated with 1 µg/ml Micelle with or without SB, 20 µM (7.42 
µg/ml) SB alone or untreated overnight. IL-10 was measured in the supernatant by 
ELISA, mean  SEM (n=3). Statistical significance was determined by Student’s two-




Chronic inflammation underlies many metabolic-related diseases including 
atherogenesis. As cDCs play a critical role in the initiation of inflammatory 
responses, modulating their function has been proposed as a mechanism to 
ameliorate chronic inflammation and the development of cardiovascular disease. 
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In this chapter, we have shown that constitutive β-catenin activation in cDCs was 
not sufficient to revert the atherogenic process. Nevertheless, activation of Wnt/β-
catenin pathway contributes to the regulation of inflammatory responses by for 
example, improving whole-body glucose metabolism. Thus, initial findings 
suggest that targeted delivery to activate Wnt/β-catenin pathway in cDCs could 
hold therapeutic potential. 
 
Chemokines are crucial regulators of leukocyte trafficking during immune 
surveillance and inflammation. CCL17 has been previously reported to play a role 
in the recruitment of DCs to atherosclerotic plaques (198). DCs which express 
CCL17, accumulate in the arterial intima of atherosclerotic-susceptible regions of 
mice and recruitment of cDCs is also observed in advanced human plaques (239) 
(240). CCL17-expressing DCs have been shown to exacerbate inflammation 
during atheroma formation, recruiting circulating T cells and limiting T reg 
population expansion (198). Despite constitutive activation of β-catenin in cDCs 
resulting in the reduction of CCL17 expression, the numbers of T cell populations, 
specifically T reg cells, were not changed systemically in the Ldlr -/- GOF model 
(Figure 5.2). Thus the local mechanism in the aorta proposed by Weber et al. 
may not correlate in other tissues or systemically as observed in the spleen. 
Although there was a suggestion that T cell phenotype was modulated in the 
mesenteric AT and pericardial AT of Ldlr -/- GOF mice, this may imply that the 
decreased CCL17 induced by constitutive β-catenin activation in cDCs promotes 
local T cell changes in the tissue (Figure 5.6). Yet there were no differences in T 
cell populations in the aorta of GOF mice fed WD (Figure 5.5), however due to 
experimental constraints, immune cells could not be analysed in the aorta of the 
Ldlr -/- chimera mice. Thus, the aortic immune populations measured in previous 
experiments of diet-induced obesity, may not have been exposed to the same 
level of inflammation in the aorta as in the Ldlr -/- model, caused by the higher lipid 
conditions in the absence of LDL-R.  
 
Despite previous observations in Chapter 3 that constitutive β-catenin activation 
in cDCs, in part, reverted systemic inflammation, there was less of an indication 
that systemic inflammation was controlled in the Ldlr-/- GOF mice. The immune 
cell populations remained unchanged in the spleen (Figure 5.2), in contrast to 
previous observations in Chapter 3 in diet-induced obesity model, where there 
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was an increased number of cDC1 and reduced neutrophil count in the GOF mice 
(Figure 3.13). The absence of these differences in the spleen of Ldlr -/- GOF mice 
could be due to changes in the stroma environment in Ldlr -/- model and/or the 
high lipid conditions in the absence of LDL-R. Indeed, it has been observed that 
the capacity of tolerogenic cDCs is altered by high cholesterol, in respect to the 
lipid droplet (LD) content (154). However there was a significant decrease in the 
number of neutrophils in the lymph nodes (Figure 5.3 & 5.4). Neutrophils are the 
first immune cells recruited to the site of inflammation, hence the reduction 
suggests a decrease of inflammation in the peripheral tissues. Additionally, it is 
known that neutrophils participate in atherogenesis (241), thus it is possible that 
if there are less neutrophils present in the aorta-draining lymph nodes of the Ldlr 
-/- GOF mice, constitutive β-catenin activation in cDCs may decrease aortic 
inflammatory responses. Although neutrophils are also important for the 
resolution of inflammation, suggesting that with less neutrophils, there may be 
greater inflammation-induced damage. Despite this, a reduction of pro-
inflammatory cytokines and an increase in FOXP3 was observed in the 
pericardial AT of the Ldlr -/- GOF mice indicating a possible immunosuppressive 
phenotype in the tissue (Figure 5.6). As pericardial AT is in close contact with the 
aorta, restraining the local tissue inflammation could revert inflammatory 
responses in the vessel.  
 
In addition to inflammation, dyslipidaemia plays a key role in the pathophysiology 
of atherosclerosis. The total cholesterol and lipoprotein plasma concentrations 
remained unchanged in the GOF mice. However the circulating levels of FFA 
were decreased in the Ldlr -/- GOF mice (Figure 5.1), which could suggest that 
adipocytes have a reduced capacity to buffer the excess of lipids, although the 
exact mechanism is unclear. The dyslipidaemia associated with the Ldlr -/- model, 
is known to activate skin murine DCs, paradoxically inhibiting their migration to 
lymph nodes and suppressing immunological priming (242). Interestingly, the 
migratory cDC population was increased in the mediastinal draining lymph nodes 
of the Ldlr -/- GOF mice (Figure 5.3), suggesting that the cDCs with constitutive β-
catenin activation were less affected by the high lipid inhibition on their migration. 
Improved VAT function was further suggested by a local increase in adiponectin 
in the pericardial AT (Figure 5.6). Yet this elevated adiponectin was not observed 
in circulating levels in the Ldlr-/- GOF mice, as previously demonstrated in GOF 
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mice in diet-induced obesity model (Figure 3.19E). Despite constitutive β-catenin 
activation in cDCs promoting local improvement of adiponectin expression, 
systemic differences may have been lost in Ldlr -/- GOF mice due to the 
contribution of bone marrow AT (BMAT) to circulating levels of adiponectin. 
BMAT is a rich source of adiponectin (243), thus in the higher lipid Ldlr -/- model 
BMAT production of adiponectin may have disguised the local changes in white 
AT depots. Further investigation will be required to assess VAT and pericardial 
AT function in this model, however these results indicate that constitutive β-
catenin activation in cDCs improves adipocyte function during tissue 
inflammation sufficiently to improve local adiponectin levels and decrease 
systemic FFA levels. 
 
Additionally these results suggest that constitutive β-catenin activation in cDCs 
may induce less inflammatory responses locally in the aorta during 
atheroprogression. Although there was a reduction of CCL17-expressing cDCs 
and possible modulation of systemic and local inflammation in the Ldlr -/- GOF 
mice, constitutive β-catenin activation in cDCs did not affect the plaque 
development. Weber et al. investigated the role of CCL17-expressing DCs in 
ApoE-/- model of atherosclerosis using a knockout of CCL17 (198). While 
expression of CCL17 in our model was significantly reduced, it was not totally 
abrogated thus expression of CCL17, albeit at low levels still permits the 
development of atherosclerosis. 
 
The translational impact of modulating the Wnt/β-catenin pathway has been 
highlighted by the generation of GSK3β inhibitors. However due to off-target 
effects, progress in the pharmaceutical modulation of the Wnt/β-catenin pathway 
has been hampered. By targeting β-catenin agonists to cDCs, these issues could 
be bypassed. Initial results suggest that multi-polymer micelle structures 
demonstrate specificity and affinity for cDCs and can activate β-catenin activity 
as measured by IL-10 production. Thus, delivery of β-catenin pathway agonist 
through micelle structures has demonstrated a potential route for therapeutic use. 
Further investigations are required to evaluate the selectivity and efficacy of 
micelle-drug delivery in vivo.  
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In summary, this chapter has demonstrated that constitutive β-catenin activation 
in cDCs does not confer a cardio-protective phenotype in this model. Activation 
of Wnt/β-catenin pathway in cDCs in the Ldlr -/- atherosclerotic model did not 
reduce systemic or local inflammation enough to ameliorate plaque development. 
Interestingly, initial findings indicate the delivery of β-catenin pathway agonists 
through micelle structures could hold a potential route for therapeutic use. 
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 General discussion 
 
 
This thesis has examined the role of the Wnt/β-catenin pathway in cDCs, 
particularly in the context of VAT inflammation and obesity-associated T2DM. 
Activation of the Wnt/β-catenin pathway has recently been described to influence 
cDC function and limit inflammatory responses (167), however this had yet to be 
explored in VAT, where β-catenin plays a critical role in adipogenesis (65). 
Therefore, we aimed to evaluate the effect of Wnt/β-catenin pathway activation 
on VAT-cDC phenotype and on VAT immune and metabolic homeostasis, under 
steady-state conditions and during diet-induced tissue inflammation. 
 
From transcriptome data, we initially discovered that the Wnt/β-catenin pathway 
was selectively upregulated in VAT-cDC1 subset. This was expected since β-
catenin is known to target the Irf8 promoter specific for cDC1 differentiation (202). 
Although stabilisation of β-catenin was not observed in splenic cDCs, active β-
catenin was demonstrated in cDCs in the pancreas as well as in VAT. This 
revealed that activation of Wnt/β-catenin pathway in cDCs potentially had 
pleiotropic effects dependent on tissue. In VAT, we proposed that activation of β-
catenin in cDCs is due to a possible crosstalk with pre-adipocytes in order to 
maintain tissue homeostasis. However, how this pathway is activated in pancreas 
cDCs and not in splenic cDCs remains unclear. It may be due to tissue specificity 
of Wnt ligand expression, which are key extracellular regulators of β-catenin 
stabilisation. Regulation of Wnt ligands in adult tissue is complex and varies 
dependent on tissue in a temporal and spatially restricted manner. Wnt ligands 
are also key signalling molecules for maintaining stem cell niches in tissues (244), 
hence similar to in VAT, crosstalk of stem cell populations with cDCs in tissues 
such as the pancreas, may offer a possible means of how β-catenin activation in 
cDCs occurs. Independent of Wnt, β-catenin can also become activated in cDCs 
through various other signalling pathways including TLR (179), TGF-β (184) and 
inflammatory cytokines such as TNFα and IFNγ. Therefore the stromal 
environment in tissues may also indirectly regulate activation of β-catenin in 
cDCs.  
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A number of studies have reported that activation of Wnt/β-catenin pathway 
induces tolerogenic responses by cDCs (185) (178). Results from our β-catenin 
knockdown mice supports this, demonstrating that β-catenin in VAT-cDCs plays 
a role in modulating T cell responses and tissue homeostasis. Furthermore 
abrogation of Wnt/β-catenin pathway in VAT-cDCs exposed the potential for 
manipulating cDC function in VAT, to control the initiation of tissue inflammation 
and obesity-associated IR. This highlights the concept of immunomodulation in 
VAT, which can have significant impact locally in the tissue and systemically in 
whole body glucose metabolism. Indeed, systemic immunotherapy targeting T or 
B cells for depletion, suppresses VAT inflammation and reverses IR in diet-
induced obesity mice models (105) (107). In addition, cytotoxic T lymphocyte 
antigen (CTLA)-4Ig immunotherapy exploits ATM polarisation to ameliorate 
inflammation and IR in HFD fed mice (245). In our GOF mouse model, we have 
shown that constitutive β-catenin activation in cDCs offers a novel mechanism to 
induce tolerogenic VAT-cDCs, which promotes an immunosuppressive VAT 
phenotype in steady-state and reverts in part, systemic and local tissue 
inflammation in diet-induced obesity. These findings open up the possibility that 
VAT immune homeostasis could be modulated by other adipocyte-related 
pathways regulating cDC function, including the Xbp1 and HIF1α pathways.  
 
We have shown that β-catenin activity in cDCs is not exclusive to VAT and in 
addition, plays a non-redundant role in the pancreas. Constitutive activation of 
the Wnt/β-catenin pathway in cDCs demonstrated an improvement of whole-body 
glucose homeostasis, as a result of enhanced β-cell insulin secretion and 
modulation of islet inflammation in response to diet-induced obesity. Our data 
revealed an increase in islet size in GOF mice, which we propose is due to 
increased Wnt ligands produced by cDCs with constitutively active β-catenin. It 
has been observed previously that cDCs produce Wnt ligands in the gut (185). β-
catenin or associated proteins may directly regulate Wnt ligand expression, 
inducing a feedforward circuit of the Wnt/β-catenin pathway by cDCs. 
Interestingly, it has emerged that components of the Wnt/β-catenin pathway, 
such as FZD receptors, Axin, LRP6, TCF/LEF and pathway agonist R-spondin 
(Rspo) are regulated by β-catenin (170), suggesting that self-regulatory loops of 
the pathway do exist. Indeed, induction of Rspo and TCF/LEF gene transcription 
by Wnt/β-catenin pathway activation has shown to reinforce Wnt signalling, 
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driving a feedforward mechanism (246) (247). However, whether Wnt gene 
transcription is self-regulated directly or indirectly by β-catenin remains to be 
explored. Wnt biogenesis and secretion is a highly regulated process, involving 
several post-translational modifications (170) (248). A multitude of proteins are 
required to glycosylate, palmitoylate and escort the synthesised Wnt ligands from 
the ER to membrane. Thus, active β-catenin may play a role in promoting these 
processes to enhance Wnt production in cDCs. 
 
Aberrant Wnt/β-catenin pathway activation occurs in disease (249). Interestingly, 
modulation of Wnt ligand expression has been identified in pathological 
conditions. High expression of Wnt ligands are reported in cancers and 
inflammatory diseases, such as arthritis (250), psoriasis (251) and 
neuroinflammation (252). Furthermore, in the intestine, Wnt ligand expression 
increases with the development of inflammation (253) (185). On the contrary, in 
VAT inflammation, we have shown that chronic overnutrition decreases the 
availability of Wnt ligands in obese VAT, in order to promote adipocyte 
hyperplasia. These results support previous findings that loss of Wnt10b function 
is associated with obesity (196) (176), while loss of Wnt5b function confers 
susceptibility to T2DM (173). Wnt5b represses the canonical Wnt/β-catenin 
pathway, thus suggesting pathway activation occurs in T2DM. Indeed it has been 
shown that activation of Wnt/β-catenin pathway in the islet is important for the β-
cell adaptive stage early in the pre-diabetic state (254) (214). During the initial 
stages of hyperglycaemia in obesity or pre-diabetes, compensatory β-cell 
expansion occurs to fulfil the insulin requirement of peripheral tissues. Wnt/β-
catenin pathway has been suggested to regulate this β-cell adaption, supporting 
cell growth and proliferation (214) (172) (255). β-catenin is activated in islets 
during compensatory β-cell hyperplasia in pre-diabetic mice (210). However the 
transition from pre-diabetes to the onset of T2DM, when β-cells can no longer 
compensate and their mass and function declines, correlates with reduced 
canonical Wnt expression and loss of Wnt/β-catenin pathway activation. In a 
recent study, modulation of Wnt expression was demonstrated during the 
progression of HFD-induced T2DM, specifically canonical Wnt activator Wnt3a 
and canonical Wnt suppressor Wnt4 (254). In pre-diabetic rats Wnt3 increased 
in VAT, skeletal muscle and plasma, while expression reduced later on in the 
development of T2DM as Wnt4 levels elevated, resulting in dysfunctional 
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pancreatic islet function (256). Similarly, the expression of Wnt4 has shown to be 
significantly upregulated in IR mouse models particularly in the islets, and 
furthermore in the islets of T2DM patients (257) (254). Since Wnt4 suppresses 
canonical β-catenin pathway activation, exogenous Wnt4 antagonises Wnt3a 
action in islets, inhibiting the Wnt3a stimulated β-cell proliferation and insulin 
secretion (255). What controls this modulation of Wnt expression in the islets, 
during the transition from pre-diabetes to the onset of T2DM remains unknown. 
Wnt ligand expression can be regulated in response to nutritional and metabolic 
changes, thus potentially as hyperglycaemia increases and β-cell adaption can 
no longer compensate, high glucose or low insulin levels could trigger a change 
in Wnt ligand expression. Another possible mechanism may involve epigenetic 
changes in the promoter regions of Wnt genes. As changes occur in lipid 
metabolism in obesity and subsequently T2DM, it has been reported that 
palmitate metabolism modulates DNA methylation and hence altering gene 
expression (258). Wnt crosstalk may also occur between IR tissues and the 
pancreas (256). However we have shown that constitutive β-catenin activation in 
cDCs appears to elevate Wnt3a expression in the islets of a diet-induced obesity 
model, suggesting a potential mechanism to induce sustained expression of 
Wnt3a in order to revert the decrease observed during the onset of T2DM. Wnt4 
expression was not examined in the islets of the GOF mice, although it would be 
of interest to understand how constitutive β-catenin activation in cDCs affects 
Wnt4 levels in particular during T2DM. Thus, these findings reveal a previously 
unreported role for cDCs in the pancreas and opens up the possibility that cDCs, 
and potentially other Wnt-producing immune cells, could restore Wnt/β-catenin 
pathway activation in β-cells.  
 
β-cell adaption involves the expansion of β-cell mass, by increasing proliferation, 
replication and hypertrophy to compensate for the increased demand of insulin 
secretion (259). This occurs in obesity and in pre-diabetes when IR of peripheral 
tissues initiates, in order to conserve glucose homeostasis. β-cell adaption can 
successfully prevent the development of T2DM in many obese individuals, 
however in a fraction of the obese population β-cell function and mass cannot 
sufficiently compensate resulting in hyperglycaemia and β-cell failure (260). 
Many factors are thought to contribute to this loss of β-cell adaption, including 
ageing, genetic variants, metabolic insults such as glucotoxicity, lipotoxicity and 
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ER stress and inflammation, and in addition changes in Wnt ligand exposure as 
discussed above (32) (34) (35). These contributors are not mutually exclusive 
and it is widely accepted that multiple signalling systems and pathways act 
synergistically to exacerbate β-cell dysfunction. Our findings have demonstrated 
that modulating cDC function has had multifaceted effects on β-cell mass and 
function, to potentially prevent islet failure. However it is unclear how these 
compensatory effects would maintain long-term health of β-cells and prevent the 
development of T2DM. It is possible that other factors and signalling events may 
override the potential beneficial effects that constitutive β-catenin activation in 
cDC may serve in the islet.  
 
Interestingly, we have observed different responses in different tissues in the 
GOF model. Constitutively active β-catenin was induced systemically in cDCs, 
not exclusively to VAT where it was initially observed to maintain tissue 
inflammation. While our results suggest that inflammation was, in part, reverted 
in VAT and in the islets of the GOF mice in a diet-induced obesity model, there 
was less of an indication that inflammation was controlled in the atherosclerosis 
model. An anatomical reason that could explain this, is the lack of epicardial AT 
in mice, which sits in close contact with the heart and aortic vessel in humans 
and is considered a potential regulator of vessel inflammation. Therefore in the 
Ldlr-/- mice, constitutively active β-catenin in cDCs may not have had the 
opportunity to influence aortic inflammation due to the absence of epicardial AT, 
although in humans there may be a greater effect on atherosclerosis. Despite 
constitutively active β-catenin in cDCs revealing an increase in β-cell proliferation 
in the pancreas to elevate insulin secretion, it was not sufficient to revert the 
atherogenic process. The differences in tissue responses may have been due to 
the abundance of cDCs in these tissues, hence varying the tolerogenic effect on 
tissue inflammation. In addition, the influence of cDCs is likely to be tissue-
specific and differ in pathological processes. Other immune cells such as 
macrophages predominate in atherosclerotic inflammation, thus cDCs may have 
had less impact. These findings in the GOF mice indicate that modulating cDC 
function in the pancreas has a notable consequence, greater than in the aorta. 
As we have suggested, Wnt ligands produced by cDCs control β-cell proliferation, 
thus it is also possible that Wnt ligands were produced by cDCs in the aorta of 
the GOF mice. However in vessels these Wnt ligands may play a detrimental role, 
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promoting plaque growth. Indeed, the Wnt/β-catenin pathway is known to control 
the expression of several extracellular matrix components and assist in the 
proliferation and survival of smooth muscle cells (261). Thus our proposed 
mechanism of Wnt production by cDCs with constitutively active β-catenin, may 
provide differing effects dependent on tissue. Furthermore, this study reveals that 
immune modulation does not promote consistent responses systemically, tissues 
have varied stromal environments and hence different outcomes are observed. 
 
The GOF model represents a therapeutic drug strategy, whereby systemically all 
cDCs are targeted for Wnt/β-catenin pathway activation. Targeted delivery by for 
example, micelles could be an effective method with the advantages of a lower 
drug dosage, reduced side effects and toxicity, but with greater specificity 
compared to current options of β-catenin activation such as GSK3β inhibitors. 
cDCs have been successfully targeted for therapeutic vaccination strategies, to 
deliver antigens for the priming of T cell and B cell responses for protective and 
anti-tumour immunity. Multiple delivery systems to cDCs have been explored 
including ligand based, antibody based and nanoparticles such as liposomes, to 
offer the potential for co-delivery (262). Hence targeting cDCs with Wnt/β-catenin 
pathway agonist could promote tolerogenic responses to reduce inflammation 
and provide beneficial effects on β-cell health. However, the immunosuppressive 
environment generated by constitutively active β-catenin in cDCs, should be 
considered in respect to the development of cancer. Tumour development 
favours immune suppression, including the recruitment of T reg cells and 
tolerogenic DCs. Furthermore overexpression of β-catenin holds oncogenic 
potential and promotes tumour development.  
 
Research limitations of this study include power for statistical tests. Improved 
power calculations and increased sample sizes would have generated more 
robust data conclusions. Although irradiated chimeras were used to analyse the 
effects of solely donor bone marrow immune cells, resident irradiation-resistant 
immune cells in recipient tissue may not have been fully eradicated and hence 
could have interfered with immune responses. Sampling of VAT in mice as 
discussed previously, did not consider the distribution of immune cells and thus 
may have diluted the effect of localised immune responses.  
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6.1 Future work 
 
Although we have established that constitutive Wnt/β-catenin pathway activation 
in cDCs has the potential to revert VAT inflammation, co-activation of other 
complementary suppressive pathways in VAT-cDCs such as PPARγ would be of 
interest, since PPARγ signalling is also impaired in obesity (263) (264). Similarly 
restoring PPARγ activity in cDCs could also revert VAT inflammation. In addition, 
gender and age are factors which will need to be considered in the effects on 
inflammatory immune response in VAT. Sex differences are known to exist in 
VAT deposition and influence inflammatory and metabolic status of the tissue 
(265).  
 
Our findings in the pancreas will require further characterisation to determine the 
mechanisms by which constitutive activation of β-catenin in cDCs can enhance 
insulin secretion. It will be critical to understand the production of Wnt ligands 
from pancreas cDCs and how this can be altered during the development of diet-
induced obesity and T2DM. As the GOF model systemically affects cDCs, the 
Wnt-specific effects in other tissues such as the liver, should also be further 
explored. Although innate immune cells have been well established in islet 
inflammation in T2DM, the contribution of adaptive immune responses are less 
clear. It would be of interest to further investigate the action of cDCs and T cells 
in the islets during pre-diabetes and progression of T2DM, specifically focusing 
on the tolerogenic effects beneficial for islet immune health.  
 
The interaction between cDC chemokine CCL17 and CCR4+ T cells has been 
discussed in this thesis, however the exact mechanisms of homing in the VAT 
and how this affects VAT homeostasis are still yet to be explored. Specifically, 
how activation of β-catenin in cDCs modifies CCL17 expression remains to be 
clarified. In addition, CCR4 has another cognate chemokine, CCL22 which is also 
expressed by cDCs. It would be interesting to understand the effect of constitutive 
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6.2 Conclusion 
 
This thesis has demonstrated the significance of modulating the Wnt/β-catenin 
pathway in cDCs, with the potential to control VAT inflammation and metabolic 
dysfunction in obesity and in the development of T2DM. While depletion of β-
catenin in cDCs exacerbated diet-induced tissue inflammation, constitutive 
activation of β-catenin pathway in cDCs was able to revert, in part, the 
development of systemic and local tissue inflammation in a model diet-induced 
obesity. By inducing a tolerogenic phenotype in VAT-cDCs, constitutive β-catenin 
activation modulates T cell responses generating an immunosuppressive 
phenotype in VAT. However activation of Wnt/β-catenin pathway in cDCs did not 
reduce systemic or local inflammation enough to ameliorate plaque development 
in the Ldlr -/- atherosclerotic model. Interestingly, despite no change in peripheral 
insulin sensitivity, whole-body glucose homeostasis was improved due to 
enhanced β-cell insulin secretion and reduction of islet inflammation. We 
demonstrated a novel finding by which cDCs with constitutive β-catenin activation 
induce β-cell proliferation and suggest a potential mechanism through the 
production of Wnt3a. Further investigation will be required to decipher if cDCs act 
as a source of Wnt ligands in the pancreas and if this holds the potential to restore 
β-cell mass and function in T2DM. This work proposes a unique compensatory 
mechanism driven by cDCs to generate a greater insulin reserve in response to 
obesity-induced IR, highlighting the potential of immune modulation in the 
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